<SEC-DOCUMENT>0001654954-18-001366.txt : 20180212
<SEC-HEADER>0001654954-18-001366.hdr.sgml : 20180212
<ACCEPTANCE-DATETIME>20180212171241
ACCESSION NUMBER:		0001654954-18-001366
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180212
DATE AS OF CHANGE:		20180212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11889
		FILM NUMBER:		18597522

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cvm_10q.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times\ New\ Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">UNITED
STATES</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">SECURITIES
AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Washington,
D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
FORM 10-Q</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;(Mark
One)</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font>
&#x2612;</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">THE
SECURITIES EXCHANGE ACT OF 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For the
quarterly period ended December 31, 2017</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">OR</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font>
&#x2610;</font> &#xA0; &#xA0; &#xA0; &#xA0;&#xA0; TRANSITION REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">THE
SECURITIES EXCHANGE ACT OF 1934</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For the
transition period from _______________ to
______________.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Commission
File Number 001-11889</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI CORPORATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: middle; width: 33%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font><font style="font-size: 13px">Colorado</font></font></div>
</td>
<td style="vertical-align: middle; width: 34%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 34%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font> <font style="font-size: 13px">&#xA0;</font><font style="font-size: 13px">&#xA0;</font><font style="font-size: 13px">84-0916344</font><font style="font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font><font style="font-size: 13px">State or other
jurisdiction</font><font style="font-size: 13px">&#xA0;</font><font style="font-size: 13px">incorporation</font></font></div>
</td>
<td style="vertical-align: middle; width: 34%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 34%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font><font style="font-size: 13px">(IRS)
Employer</font><font style="font-size: 13px">&#xA0;</font><font style="font-size: 13px">Identification Number</font></font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: middle; width: 100%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font><font style="font-size: 13px">8229 Boone Boulevard,
Suite 802</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 100%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font><font style="font-size: 13px">Vienna, Virginia
22182</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 100%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font><font style="font-size: 13px">Address of principal
executive offices</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 100%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font><font style="font-size: 13px">(703)
506-9460</font></font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 100%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font><font style="font-size: 13px">Registrant's telephone
number, including area code</font></font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the Registrant was required to file such
reports) and (2) had been subject to such filing requirements for
the past 90 days.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Yes
<font>&#x2612;</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
No <font>&#x2610;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant has submitted electronically
and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405
of Regulation S-T (&#xA7;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant
was required to submit and post such files). Yes <font>&#x2612;</font> No <font>&#x2610;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the Registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#x201C;large accelerated
filer,&#x201D; &#x201C;accelerated filer&#x201D; and &#x201C;smaller
reporting company&#x201D; and &#x201C;emerging growth company&#x201D;
in Rule 12b-2 of the Exchange Act. (Check One):</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Large&#xA0;accelerated&#xA0;filer</font></div>
</td>
<td style="vertical-align: bottom; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px">&#x2610;</font></div>
</td>
<td style="vertical-align: bottom; width: 28%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Accelerated&#xA0;filer</font></div>
</td>
<td style="vertical-align: bottom; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px">&#x2610;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 20%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Non-accelerated
filer</font></div>
</td>
<td style="vertical-align: bottom; width: 49%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font>
&#x2610;</font> (Do not check if a smaller reporting
company)</font></div>
</td>
<td style="vertical-align: bottom; width: 28%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Smaller&#xA0;reporting&#xA0;company</font></div>
</td>
<td style="vertical-align: bottom; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px">&#x2612;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 20%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 28%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Emerging
growth company</font></div>
</td>
<td style="vertical-align: bottom; width: 3%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px">&#x2610;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. <font>&#x2610;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the Registrant is a shell company (as defined
in Exchange Act Rule 12b-2 of the Exchange Act).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Yes
<font>&#x2610;</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
No <font>&#x2612;</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: middle; width: 33%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Class
of Stock</font></div>
</td>
<td style="vertical-align: middle; width: 33%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font><font style="font-size: 13px">No. Shares
Outstanding</font></font></div>
</td>
<td style="vertical-align: middle; width: 33%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Common</font></div>
</td>
<td style="vertical-align: middle; width: 33%">
<div style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;13,993,957</font></div>
</td>
<td style="vertical-align: middle; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">February
4, 2018</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: rgb(255, 255, 255);">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<font style="font-weight: bold">TABLE
OF CONTENTS</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
PART I FINANCIAL INFORMATION</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Item 1.</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Page</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Condensed Balance Sheets at December 31, 2017 and</font>
<font style="color: #000000">September 30, 2017
(unaudited)</font></font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Condensed Statements of Operations for the three months</font>
<font style="color: #000000">ended December 31, 2017 and 2016
(unaudited)</font></font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
4</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Condensed Statements of Cash Flows for the three months</font>
<font style="color: #000000">ended December 31, 2017 and 2016
(unaudited)</font></font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
5</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
&#xA0;</font> <font style="color: #000000">&#xA0;</font></font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Notes to Condensed Financial Statements</font><font style="font-weight: bold; color: #000000">&#xA0;</font><font style="color: #000000">(unaudited)</font></font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
7</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Item 2.</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">
Management's Discussion and Analysis of Financial Condition</font>
<font style="color: #000000">and Results of
Operations</font></font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
23</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Item 3.</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Quantitative and Qualitative Disclosures about Market
Risks</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
25</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Item 4.</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Controls and Procedures</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
25</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
PART II</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Item 2.</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Unregistered Sales of Equity Securities and Use of
Proceeds</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
26</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Item 6.</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Exhibits</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
26</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 9%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 81%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Signatures</font></div>
</td>
<td style="vertical-align: top; width: 10%;">
<div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
29<br></font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">2</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td colspan="3" rowspan="1" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CEL-SCI CORPORATION</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CONDENSED BALANCE SHEETS</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">(UNAUDITED)</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 80%; font-size: 11px; font-weight: bold;">DECEMBER 31,</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 80%; font-size: 11px; font-weight: bold;">SEPTEMBER 30,</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">ASSETS</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Current
Assets:</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;
Cash and cash equivalents</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,142,734</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,369,438</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;
Receivables</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">47,610</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">218,481</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;
Prepaid expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">805,729</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">826,429</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;
Deposits - current portion</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">150,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;
Inventory used for R&amp;D and manufacturing</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">644,749</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">672,522</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
current assets</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,640,822</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">4,236,870</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Plant,
property and equipment, net</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16,647,211</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">16,793,220</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Patent
costs, net</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">214,872</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">223,167</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Deposits</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,670,917</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,670,917</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
Assets</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">22,173,822</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">22,924,174</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">LIABILITIES
AND STOCKHOLDERS' DEFICIT</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CURRENT
LIABILITIES:</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Accounts payable</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,872,799</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,196,334</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Accrued expenses</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">970,042</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">936,698</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Due to employees&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">846,751</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">693,831</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Notes payable</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">874,593</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">994,258</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Derivative instruments, current portion&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">19,724</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,984</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Other current liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">11,815</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">12,449</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Total current liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,595,724</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,844,554</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Derivative instruments, net of current portion</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,991,908</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,042,418</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Lease liability</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,255,468</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,211,925</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Deferred revenue</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">126,550</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">125,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Other liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">38,212</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">37,254</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27,007,862</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">26,261,151</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Commitments
and Contingencies</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">STOCKHOLDERS'
DEFICIT</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Preferred stock, $.01 par value-200,000 shares
authorized;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;
-0- shares issued and outstanding</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Common stock, $.01 par value - 600,000,000 shares
authorized;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;
13,258,051 and 11,903,133 shares issued and
outstanding</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;
at December 31, 2017 and September 30, 2017,
respectively</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">132,581</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">119,031</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Additional paid-in capital</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">300,975,618</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">296,298,401</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Accumulated deficit</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(305,942,239</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(299,754,409</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
stockholders' deficit</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(4,834,040</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(3,336,977</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">TOTAL
LIABILITIES AND STOCKHOLDERS' DEFICIT</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">22,173,822</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">22,924,174</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">See notes to condensed financial
statements.</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">3</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CEL-SCI CORPORATION</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CONDENSED STATEMENTS OF
OPERATIONS</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">THREE MONTHS ENDED DECEMBER 31, 2017 and
2016</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">(UNAUDITED)</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Grant
and other income</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">113,897</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,258</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
Expenses:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Research and development</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,326,014</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,548,257</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
General &amp; administrative</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,699,313</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,407,009</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total
operating expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">5,025,327</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">4,955,266</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Operating
loss</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,911,430</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(4,938,008</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">(Loss)
gain on derivative instruments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(958,230</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,928,312</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Interest
expense, net</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(318,170</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(469,151</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
(loss) income available to common shareholders</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(6,187,830</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">3,521,153</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">NET
(LOSS) INCOME PER COMMON SHARE</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
BASIC</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.53</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.59</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
DILUTED</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(0.53</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.32</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">WEIGHTED
AVERAGE COMMON SHARES</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
OUTSTANDING</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
BASIC</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,636,730</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,994,431</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
DILUTED</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,636,730</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,084,708</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">See notes to condensed financial
statements.</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">4</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CEL-SCI CORPORATION</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CONDENSED STATEMENTS OF CASH
FLOWS</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">THREE MONTHS ENDED DECEMBER 31, 2017 and
2016</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">(UNAUDITED)</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
(loss) Income</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(6,187,830</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,521,153</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Adjustments to reconcile net (loss) income to</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;
net cash used in operating activities:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Depreciation and amortization</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">155,417</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">159,173</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Share-based payments for services</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">42,342</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">78,553</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Equity based compensation</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,448,098</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">312,375</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Common stock contributed to 401(k) plan</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">35,880</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">38,372</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Loss on retired equipment</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,187</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Loss (gain) on derivative instruments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">958,230</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(8,928,312</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Amortization of debt discount</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">611,717</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Capitalized lease interest</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">43,543</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">51,213</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
(Increase)/decrease in assets:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Receivables</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">195,871</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">85,046</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Prepaid expenses&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,765</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">96,507</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Inventory used for R&amp;D and manufacturing</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">27,773</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">314,138</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Deposits</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">150,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">150,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Increase/(decrease) in liabilities:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Accounts payable</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(286,984</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(75,029</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Accrued expenses</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">33,344</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(59,196</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Deferred revenue</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,550</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Due to employees</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">152,920</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">17,110</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Deferred rent liability</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,506</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(1,496</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash used in operating activities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,612,858</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(4,239,206</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM INVESTING ACTIVITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
Expenditures for patent costs</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(959</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash used in investing activities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(959</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
FLOWS FROM FINANCING ACTIVITIES:</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;
Proceeds from issuance of common stock and warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,389,395</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,709,931</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;&#xA0;
Payments on obligations under capital lease</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,282</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(2,048</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Net
cash provided by financing activities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,387,113</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">3,707,883</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;NET
DECREASE IN CASH AND CASH EQUIVALENTS</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(226,704</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(531,323</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
AND CASH EQUIVALENTS, BEGINNING OF PERIOD</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,369,438</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,917,996</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">CASH
AND CASH EQUIVALENTS, END OF PERIOD</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,142,734</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">2,386,673</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td colspan="3" style="vertical-align:bottom;width:100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">See notes to condensed financial
statements.</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">5</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td colspan="3" rowspan="1" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CEL-SCI CORPORATION</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">CONDENSED STATEMENTS OF CASH
FLOWS</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">THREE MONTHS ENDED DECEMBER 31, 2017 and
2016</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">SUPPLEMENTAL
SCHEDULE OF NON-CASH INVESTING AND FINANCING
ACTIVITIES:</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px; font-weight: bold;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px; font-weight: bold;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Decrease
in receivable due under the litigation funding arrangement
offset</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
by the same amount payable to the legal firm providing the
services</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">305,341</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Capitalizable
patent costs included in accounts payable</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,967</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,813</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Capital
lease obligation included in accounts payable&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">790</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">372</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Property
and equip acquired through capital lease</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">26,104</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Fair
value of warrants issued in connection with public
offering</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,316,084</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Financing
costs included in accounts payable</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">77,987</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Prepaid
consulting services paid with issuance of common stock</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(16,935</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(18,183</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Notes
payable converted into common shares</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">75,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">&#xA0;
Cash paid for interest expense</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">433,707</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">469,366</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td colspan="3" style="vertical-align: bottom; width: 100%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font><font style="text-align: center; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:94%;font-size:13px;">See notes to condensed financial
statements.</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:3%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">6</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
CEL-SCI CORPORATION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
NOTES TO CONDENSED FINANCIAL STATEMENTS</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
THREE MONTHS ENDED DECEMBER 31, 2017 AND 2016
(UNAUDITED)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">A.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 24px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Basis of Presentation</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
accompanying condensed financial statements of CEL-SCI Corporation
(the Company) are unaudited and certain information and footnote
disclosures normally included in the annual financial statements
prepared in accordance with accounting principles generally
accepted in the United States of America have been omitted pursuant
to the rules and regulations of the Securities and Exchange
Commission. While management of the Company believes that the
disclosures presented are adequate to make the information
presented not misleading, these interim condensed financial
statements should be read in conjunction with the financial
statements and notes included in the Company&#x2019;s annual report
on Form 10-K for the year ended September 30, 2017.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In the
opinion of management, the accompanying unaudited condensed
financial statements contain all accruals and adjustments (each of
which is of a normal recurring nature) necessary for a fair
presentation of the Company&#x2019;s financial position as of
December 31, 2017 and the results of its operations for the three
months then ended. The condensed balance sheet as of September 30,
2017 is derived from the September 30, 2017 audited financial
statements. Significant accounting policies have been consistently
applied in the interim financial statements and the annual
financial statements. The results of operations for the three
months ended December 31, 2017 and 2016 are not necessarily
indicative of the results to be expected for the entire
year.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
financial statements have been prepared assuming that the Company
will continue as a going concern, but due to recurring losses from
operations and future liquidity needs, there is substantial doubt
about the Company&#x2019;s ability to continue as a going concern.
The financial statements do not include any adjustments that might
result from the outcome of this uncertainty. Refer to discussion in
Note B.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Summary of Significant Accounting Policies:</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Research and Office Equipment and Leasehold
Improvements</font> - Research and office equipment is recorded at
cost and depreciated using the straight-line method over estimated
useful lives of five to seven years. Leasehold improvements are
depreciated over the shorter of the estimated useful life of the
asset or the term of the lease. Repairs and maintenance which do
not extend the life of the asset are expensed when incurred. The
fixed assets are reviewed on a quarterly basis to determine if any
of the assets are impaired.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Patents</font> - Patent expenditures are
capitalized and amortized using the straight-line method over the
shorter of the expected useful life or the legal life of the patent
(17 years). In the event changes in technology or other
circumstances impair the value or life of the patent, appropriate
adjustment in the asset value and period of amortization is made.
An impairment loss is recognized when estimated future undiscounted
cash flows expected to result from the use of the asset, and from
its disposition, is less than the carrying value of the asset. The
amount of the impairment loss would be the difference between the
estimated fair value of the asset and its carrying
value.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Research and Development Costs</font> -
Research and development costs are expensed as incurred. Management
accrues CRO expenses and clinical trial study expenses based on
services performed and relies on the CROs to provide estimates of
those costs applicable to the completion stage of a study.
Estimated accrued CRO costs are subject to revisions as such
studies progress to completion. The Company charges revisions to
estimated expense in the period in which the facts that give rise
to the revision become known.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">7</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Income Taxes</font> - The Company uses the
asset and liability method of accounting for income taxes. Under
the asset and liability method, deferred tax assets and liabilities
are recognized for future tax consequences attributable to
differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases and
operating and tax loss carryforwards. Deferred tax assets and
liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences
are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in
income in the period that includes the enactment date. The Company
records a valuation allowance to reduce the deferred tax assets to
the amount that is more likely than not to be recognized.
<font style="color: #000000">&#xA0;</font>A full valuation
allowance was recorded against the deferred tax assets as of
December 31, 2017 and September 30, 2017.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">On
December 22, 2017, the "Tax Cuts and Jobs Act" (the "Tax Act"), was
signed into law by the President of the United States (U.S.). The
Tax Act includes significant changes to corporate taxation,
including reduction of the U.S. corporate tax rate from 35% to 21%,
effective January 1, 2018, limitation of the tax deduction for
interest expense to 30% of earnings (except for certain small
businesses), limitation of the deduction for net operating losses
to 80% of current year taxable income and elimination of net
operating loss carrybacks. The Company has accounted for certain
income tax effects of the Act in applying FASB ASC 740 to the
current reporting period. Because the Company records a valuation
allowance for its entire deferred income tax asset, there was no
impact to the amounts reported in the Company's financial
statements resulting from the Tax Act.<br></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">Derivative Instruments</font>
<font style="color: #000000">&#x2013; The Company has entered into
financing arrangements that consist of freestanding derivative
instruments that contain embedded derivative features. The Company
accounts for these arrangements in accordance with</font>
Accounting Standards Codification (<font style="color: #000000">ASC) 815, &#x201C;Accounting for Derivative
Instruments and Hedging Activities.&#x201D;</font> In accordance
with accounting principles generally accepted in the United States
(U.S. GAAP), derivative instruments and hybrid instruments are
recognized as either assets or liabilities in the balance sheet and
are measured at fair value with gains or losses recognized in
earnings or other comprehensive income depending on the nature of
the derivative or hybrid instruments. The Company determines the
fair value of derivative instruments and hybrid instruments based
on available market data using appropriate valuation models giving
consideration to all of the rights and obligations of each
instrument. The derivative liabilities are re-measured at fair
value at the end of each interim period.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">Deferred
Rent</font><font style="color: #000000">&#x2013; Certain of the
Company&#x2019;s operating leases provide for minimum annual
payments that adjust over the life of the lease.&#xA0; The
aggregate minimum annual payments are expensed on a straight-line
basis over the minimum lease term. The Company recognizes a
deferred rent liability for rent escalations when the amount of
straight-line rent exceeds the lease payments, and reduces the
deferred rent liability when the lease payments exceed the
straight-line rent expense.&#xA0; For tenant improvement allowances
and rent holidays, the Company records a deferred rent liability
and amortizes the deferred rent over the lease term as a reduction
to rent expense.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic; color: #000000">Leases &#x2013;</font>
<font style="color: #000000">Leases are categorized as either
operating or capital leases at inception. Operating lease costs are
recognized on a straight-line basis over the term of the lease. An
asset and a corresponding liability for the capital lease
obligation are established for the cost of capital leases. The
capital lease obligation is amortized over the life of the lease.
For build-to-suit leases, the Company establishes an asset and
liability for the estimated construction costs incurred to the
extent that it is involved in the construction of structural
improvements or takes construction risk prior to the commencement
of the lease. Upon occupancy of facilities under build-to-suit
leases, the Company assesses whether these arrangements qualify for
sales recognition under the sale-leaseback accounting guidance. If
a lease does not meet the criteria to qualify for a sale-leaseback
transaction, the established asset and liability remain on the
Company's balance sheet.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Stock-Based Compensation</font> &#x2013;
Compensation cost for all stock-based awards is measured at fair
value as of the grant date in accordance with the provisions of ASC
718 &#x201C;Compensation &#x2013; Stock Compensation.&#x201D; The fair
value of stock options is calculated using the Black-Scholes option
pricing model. The Black-Scholes model requires various judgmental
assumptions including volatility and expected option life. The
stock-based compensation cost is recognized on the straight line
allocation method as expense over the requisite service or vesting
period.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Equity
instruments issued to non-employees are accounted for in accordance
with ASC 505-50, &#x201C;Equity-Based Payments to Non
Employees.&#x201D; Accordingly, compensation is recognized when
goods or services are received and is measured using the
Black-Scholes valuation model. The Black-Scholes model requires
various judgmental assumptions regarding the fair value of the
equity instruments at the measurement date and the expected life of
the options.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company has Incentive Stock Option Plans, Non-Qualified Stock
Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an
Incentive Stock Bonus Plan. In some cases, these Plans are
collectively referred to as the "Plans". All Plans have been
approved by the stockholders.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">8</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s stock options are not transferable, and the actual
value of the stock options that an employee may realize, if any,
will depend on the excess of the market price on the date of
exercise over the exercise price. The Company has based its
assumption for stock price volatility on the variance of daily
closing prices of the Company&#x2019;s stock. The risk-free interest
rate assumption was based on the U.S. Treasury rate at date of the
grant with term equal to the expected life of the option.
Forfeitures are accounted for when they occur. The expected term of
options represents the period that options granted are expected to
be outstanding and has been determined based on an analysis of
historical exercise behavior. If any of the assumptions used in the
Black-Scholes model change significantly, stock-based compensation
expense for new awards may differ materially in the future from
that recorded in the current period.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Vesting
of restricted stock granted under the Incentive Stock Bonus Plan is
subject to service, performance and market conditions and meets the
classification of equity awards. These awards were measured at
market value on the grant-dates for issuances where the attainment
of performance criteria is likely and at fair value on the
grant-dates, using a Monte Carlo simulation for issuances where the
attainment of performance criteria is uncertain. The total
compensation cost will be expensed over the estimated requisite
service period.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
New Accounting Pronouncements</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In May 2017, the FASB issued ASU
2017-09,&#xA0;</font><font style="font-style: italic; color: #000000">Compensation &#x2013; Stock
Compensation (Topic 718)</font><font style="color: #000000">, which
affects any entity that changes the terms or conditions of a
share-based payment award.&#xA0; This Update amends the definition
of modification by qualifying that modification accounting does not
apply to changes to outstanding share-based payment awards that do
not affect the total fair value, vesting requirements, or
equity/liability classification of the awards.&#xA0; The amendments
in this Update are effective for all entities for annual periods,
and interim periods within those annual periods, beginning after
December 15, 2017. Early adoption is permitted, including adoption
in any interim period, for (1) public business entities for
reporting periods for which financial statements have not yet been
issued and (2) all other entities for reporting periods for which
financial statements have not yet been made available for issuance.
The amendments in this Update should be applied prospectively to an
award modified on or after the adoption date. The Company is
currently evaluating the impact the adoption of the standard will
have on the Company&#x2019;s financial position or results of
operations.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In July 2017, the FASB issued ASU
2017-11,&#xA0;</font><font style="font-style: italic; color: #000000">Earnings Per Share (Topic
260), Distinguishing Liabilities from Equity (Topic 480), and
Derivative and Hedging (Topic 815)</font><font style="color: #000000">. The amendments in Part I of this Update change
the classification analysis of certain equity-linked financial
instruments (or embedded features) with down-round features. When
determining whether certain financial instruments should be
classified as liabilities or equity instruments, a down-round
feature no longer precludes equity classification when assessing
whether the instrument is indexed to an entity&#x2019;s own stock.
The amendments also clarify existing disclosure requirements for
equity-classified instruments. As a result, a freestanding
equity-linked financial instrument (or embedded conversion option)
no longer would be accounted for as a derivative liability at fair
value as a result of the existence of a down-round feature. For
freestanding equity classified financial instruments, the
amendments require entities that present earnings per share
(&#x201C;EPS&#x201D;) in accordance with Topic 260 to recognize the
effect of the down-round feature when it is triggered. That effect
is treated as a dividend and as a reduction of income available to
common shareholders in basic EPS. Convertible instruments with
embedded conversion options that have down-round features are now
subject to the specialized guidance for contingent beneficial
conversion features (in Subtopic 470-20,&#xA0;</font><font style="font-style: italic; color: #000000">Debt&#x2014;Debt with
Conversion and Other Options</font><font style="color: #000000">),
including related EPS guidance (in Topic 260). The amendments in
Part II of this Update re-characterize the indefinite deferral of
certain provisions of Topic 480 that now are presented as pending
content in the Accounting Standards Codification, to a scope
exception. Those amendments do not have an accounting effect. For
public business entities, the amendments in Part I of this Update
are effective for fiscal years, and interim periods within those
fiscal years, beginning after December 15, 2018. Early adoption is
permitted, including adoption in an interim period. If an entity
early adopts the amendments in an interim period, any adjustments
should be reflected as of the beginning of the fiscal year that
includes that interim period. The amendments in Part I of this
Update should be applied either retrospectively to outstanding
financial instruments with a down-round feature by means of a
cumulative-effect adjustment to the statement of financial position
as of the beginning of the first fiscal year and interim period(s)
in which the pending content that links to this paragraph is
effective or retrospectively to outstanding financial instruments
with a down-round feature for each prior reporting period presented
in accordance with the guidance on accounting changes in paragraphs
250-10-45-5 through 45-10. The amendments in Part II of this Update
do not require any transition guidance because those amendments do
not have an accounting effect.&#xA0;The Company does not expect the
adoption of this standard to have a significant impact on its EPS
calculations, as it does not have any free-standing equity based
financial instruments with down-round
provisions.&#xA0;</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">9</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In August 2017, the FASB issued ASU
2017-12,&#xA0;</font><font style="font-style: italic; color: #000000">Derivatives and Hedging (Topic
850)</font><font style="color: #000000">, the objective of which is
to improve the financial reporting of hedging relationships to
better portray the economic results of an entity&#x2019;s risk
management activities in its financial statements. In addition, the
amendments in this Update make certain targeted improvements to
simplify the application and disclosure of the hedge accounting
guidance in current general accepted accounting
principles.&#xA0;&#xA0;For public business entities, the amendments
in&#xA0;this Update are effective for fiscal years beginning after
December 15, 2018, and interim periods within those fiscal years.
For all other entities, the amendments are effective for fiscal
years beginning after December 15, 2019, and interim periods
beginning after December 15, 2020. Early adoption is permitted in
any period after issuance.&#xA0;&#xA0;For cash flow and net
investment hedges existing at the date of adoption, an entity
should apply a cumulative-effect adjustment related to eliminating
the separate&#xA0;measurement of ineffectiveness to accumulated
other comprehensive income with a corresponding adjustment to the
opening balance of retained earnings as of the beginning of the
fiscal year that an entity adopts the amendments in this Update.
The amended presentation and disclosure guidance is required only
prospectively.&#xA0;&#xA0;The Company is currently evaluating the
impact the adoption of the standard will have on the
Company&#x2019;s financial position or results of
operations.</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In February 2016, the FASB issued</font> ASU
<font style="color: #000000">2016-02,&#xA0;</font><font style="font-style: italic; color: #000000">Leases</font><font style="color: #000000">, which will require most long-term leases to be
recognized on the balance sheet as an asset and a lease liability.
Leases will be classified as an operating lease or a financing
lease. Operating leases are expensed using the straight-line method
whereas financing leases will be treated similarly to a capital
lease under the current standard. The new standard will be
effective for annual and interim periods, within those fiscal
years, beginning after December 15, 2018, but early adoption is
permitted. The new standard must be presented using the modified
retrospective method beginning with the earliest comparative period
presented. The Company is currently evaluating the effect of the
new standard on its financial statements and related
disclosures.</font> The Company is currently evaluating the impact
the adoption of the standard will have on the Company's financial
position or results of operations.<br></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
March 2016, the FASB issued ASU<a name="jump_exp_1"><!--anchor--></a> 2016-09 <font style="font-style: italic">Compensation&#x2014;Stock Compensation (Topic
718): Improvements to Employee Share-Based Payment
Accounting</font>. The guidance simplified the accounting and
financial reporting of the income tax impact of share-based
compensation arrangements. This guidance requires excess tax
benefits to be recorded as a discrete item within income tax
expense rather than additional paid-in-capital. In addition, excess
tax benefits are required to be classified as cash from operating
activities rather than cash from financing activities. The Company
adopted the provisions of ASU 2016-09 effective October&#xA0;1,
2017. The Company elected to apply the cash flow guidance of ASU
2016-09 retrospectively to all prior periods with no impact to
historical periods. The Company also adopted a change in accounting
policy to recognize forfeitures of awards as they occur instead of
estimating potential forfeitures with no material impact on
historical periods.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-size: 13px; font-family: Times New Roman">The
Company has considered all other recently issued accounting
pronouncements and does not believe the adoption of such
pronouncements will have a material impact on its financial
statements.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">B.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
OPERATIONS AND FINANCING</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company has incurred significant costs since its inception for the
acquisition of certain patented and unpatented proprietary
technology and know-how relating to the human immunological defense
system, patent applications, research and development,
administrative costs, construction of laboratory facilities, and
clinical trials.&#xA0; The Company has funded such costs with
proceeds from loans and the public and private sale of its common
stock.&#xA0; The Company will be required to raise additional
capital or find additional long-term financing in order to continue
with its research efforts.&#xA0; To date, the Company has not
generated any revenue from product sales. As a result, the Company
has been dependent upon the proceeds from the sale of its
securities to meet all of its liquidity and capital requirements
and anticipates having to do so in the future.&#xA0; The ability of
the Company to complete the necessary clinical trials and obtain US
Food &amp; Drug Administration (FDA) approval for the sale of
products to be developed on a commercial basis is uncertain.
Ultimately, the Company must complete the development of its
products, obtain the appropriate regulatory approvals and obtain
sufficient revenues to support its cost structure.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">10</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company is currently running a large multi-national Phase 3
clinical trial for head and neck cancer with its partners TEVA
Pharmaceuticals and Orient Europharma. During the three months
ended December 31, 2017, the Company raised approximately $2.45
million net proceeds from a public offering. To finance the study
beyond the next twelve months, the Company plans to raise
additional capital in the form of corporate partnerships, debt
and/or equity financings. The Company believes that it will be able
to obtain additional financing because it has done so consistently
in the past and because Multikine is a product in the Phase 3
clinical trial stage. However, there can be no assurance that the
Company will be successful in raising additional funds on a timely
basis or that the funds will be available to the Company on
acceptable terms or at all.&#xA0; If the Company does not raise the
necessary amounts of money, it may have to curtail its operations
until such time as it is able to raise the required funding. The
financial statements have been prepared assuming the Company will
continue as a going concern, but due to the Company&#x2019;s
negative working capital, stockholders&#x2019; deficit, recurring
losses from operations and future liquidity needs, there is
substantial doubt about the Company&#x2019;s ability to continue as
a going concern. The financial statements do not include any
adjustments that might result from the outcome of this
uncertainty.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Since the Company launched its Phase 3 clinical
trial for Multikine, the Company has incurred expenses of
approximately $47.0 million as of December 31, 2017 on direct costs
for the Phase 3 clinical trial. the Company estimates it will incur
additional expenses of approximately $12.2 million for the
remainder of the Phase 3 clinical trial. It should be noted that
this estimate is based only on the information currently available
in the Company&#x2019;s contracts with the Clinical Research
Organizations responsible for managing the Phase 3 clinical trial
and does not include other related costs, e.g., the manufacturing
of the drug. This number may be affected by the rate of death
accumulation in the study, foreign currency exchange rates, and
many other factors, some of which cannot be foreseen today. It is
therefore possible that the cost of the Phase 3 clinical trial will
be higher than currently estimated.</font><font style="color: #000000; font-family: Times New Roman">&#xA0;</font>Nine
hundred twenty-eight (928) head and neck cancer patients have been
enrolled and have completed treatment in the Phase 3 study. The
study end point is a 10% increase in overall survival of patients
between the two main comparator groups in favor of the group
receiving the Multikine treatment regimen. The determination if the
study end point is met will occur when there are a total of 298
deaths in those two groups.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s shareholders approved a reverse split of the
Company&#x2019;s common stock which became effective on the NYSE
American on June 15, 2017. On that date, every twenty-five issued
and outstanding shares of the Company&#x2019;s common stock
automatically converted into one outstanding share of common stock.
As a result of the reverse stock split, the number of outstanding
shares of common stock decreased from 230,127,331 (pre-split)
shares to 9,201,645 (post-split) shares. By reducing the number of
outstanding shares, the Company&#x2019;s loss per share in all prior
periods increased by a factor of twenty-five. The reverse stock
split affected all stockholders of the Company&#x2019;s common stock
uniformly, and did not affect any stockholder&#x2019;s percentage of
ownership interest. The par value of the Company&#x2019;s stock
remained unchanged at $0.01 per share<font style="font-size: 13px">&#xA0;</font>and the number of authorized shares
of common stock remained the same after the reverse stock
split.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; display: table;">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">C.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
STOCKHOLDERS&#x2019; EQUITY</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Stock
options, stock bonuses and compensation granted by the Company as
of December 31, 2017 are as follows:</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 44%;">
<div style="text-align: left; border-bottom: 2px solid rgb(0, 0, 0); margin-left: 0px; text-indent: 0px; margin-right: 0px;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times\ New\ Roman;">Name of
Plan</font></font></div>
</div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-size: 11px"><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman;">Total Shares Reserved Under Plans</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-size: 11px"><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman;">Shares Reserved for Outstanding
Options</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-size: 11px"><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman;">Shares Issued</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-size: 11px"><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman;">Remaining Options/Shares Under
Plans</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times\ New\ Roman; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Incentive Stock
Options Plans</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">138,400</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">124,758</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">454</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Non-Qualified Stock
Option Plans</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,187,200</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,107,054</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">46,798</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Stock Bonus
Plans</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">383,760</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">222,574</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">161,153</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Stock Compensation
Plan</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">134,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">115,590</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">18,410</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Incentive Stock
Bonus Plan</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">640,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">624,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">16,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">11</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Stock
options, stock bonuses and compensation granted by the Company as
of September 30, 2017 are as follows:</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px;">
<table cellpadding="0" cellspacing="0" style="text-align: left; margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-size: 11px"><font style="font-weight: bold; font-family: Times\ New\ Roman;">Name of
Plan</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-size: 11px"><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman;">Total Shares Reserved Under Plans</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-size: 11px"><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman;">Shares Reserved for Outstanding
Options</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-size: 11px"><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman;">Shares Issued</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="font-size: 11px"><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman;">Remaining Options/Shares Under
Plans</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%;">&#xA0;</font></font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-left:0px;margin-right:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Incentive Stock
Option Plans</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">138,400</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">124,758</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">454</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Non-Qualified Stock
Option Plans</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,187,200</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,115,086</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">42,830</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Bonus
Plans</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">383,760</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">206,390</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">177,337</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Stock Compensation
Plan</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">134,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">115,590</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">18,410</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Incentive Stock
Bonus Plan</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">640,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">N/A</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">624,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">16,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Stock option
activity</font>:</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:28%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; font-weight: bold; vertical-align: bottom; display: inline-block; width: 5%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; font-weight: bold; vertical-align: bottom; display: inline-block; width: 90%; font-size: 11px;">Three Months Ended December 31,</font><font style="text-align: left; font-family: Times\ New\ Roman; font-weight: bold; vertical-align: bottom; display: inline-block; width: 5%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; margin-left: 0px; padding-bottom: 2px; text-indent: 0px; margin-right: 0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px;">2017</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px;">2016</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Granted</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">10,300</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Expired</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">17,523</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">15,081</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Forfeited</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">809</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Stock-Based Compensation Expense</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:28%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; font-weight: bold; vertical-align: bottom; display: inline-block; width: 5%; font-size: 11px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; font-weight: bold; vertical-align: bottom; display: inline-block; width: 90%; font-size: 11px; border-bottom: 2px solid rgb(0, 0, 0);">Three months Ended December 31,</font><font style="text-align: left; font-family: Times\ New\ Roman; font-weight: bold; vertical-align: bottom; display: inline-block; width: 5%; font-size: 11px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px;">2017</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px;">2016</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Employees</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,448,098</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">312,375</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Non-employees</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">42,342</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">78,553</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Employee
compensation expense includes the expense related to options issued
or vested and restricted stock. The increase in employee's expense
in 2017 is primarily due to an increase of approximately $1.1
million in equity based compensation related to the Company's
shareholder approved 2014 Incentive Stock Bonus Plan. Non-employee
expense includes the expense related to options and stock issued to
consultants expensed over the period of their service contracts.
Stock based compensation expense is included in general and
administrative expenses on the statements of
operations.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">12</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Warrants and Non-employee Options</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
following chart presents the outstanding warrants and non-employee
options, listed by expiration date at December 31,
2017:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: bottom; width: 15%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="color: rgb(0, 0, 0); font-family: Times\ New\ Roman; font-weight: bold;">
Warrant</font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 25%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 25px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="color: rgb(0, 0, 0); font-family: Times\ New\ Roman; font-weight: bold;">
Issue Date</font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 17%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 10px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times\ New\ Roman; font-weight: bold;"><font style="color: rgb(0, 0, 0); font-weight: bold;">Shares Issuable upon
Exercise of</font> <font style="color: rgb(0, 0, 0); font-weight: bold;">Warrants</font></font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 13%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="font-family: Times\ New\ Roman; font-weight: bold;"><font style="color: rgb(0, 0, 0); font-weight: bold;">Exercise</font>
<font style="color: rgb(0, 0, 0); font-weight: bold;">Price</font></font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 19%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="color: rgb(0, 0, 0); font-family: Times\ New\ Roman; font-weight: bold;">
Expiration Date</font></font></font></font></div>
</td>
<td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 11px"><font style="font-weight: bold;"><font style="font-weight: bold;"><font style="color: rgb(0, 0, 0); font-family: Times\ New\ Roman; font-weight: bold;">
Reference</font></font></font></font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
DD</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/8/2016</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1,360,960</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$4.50</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3/1/2018</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
EE</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/8/2016</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1,360,960</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$4.50</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3/1/2018</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
N</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8/18/2008</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">85,339</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.00</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8/18/2018</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">-<br></font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
S</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">10/11/13-
10/24/14</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1,037,120</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$31.25</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10/11/2018</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
V</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">5/28/2015</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">810,127</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$19.75</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
5/28/2020</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
W</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">10/28/2015</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">688,930</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$16.75</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10/28/2020</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
X</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1/13/2016</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">120,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$9.25</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
1/13/2021</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">-<br></font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
Y</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2/15/2016</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">26,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$12.00</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2/15/2021</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">-<br></font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
ZZ</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">5/23/2016</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">20,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$13.75</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
5/18/2021</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
BB</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8/26/2016</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">16,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$13.75</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8/22/2021</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
Z</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">5/23/2016</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">264,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$13.75</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
11/23/2021</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
FF</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/8/2016</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">68,048</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.91</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
12/1/2021</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
CC</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/8/2016</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">680,480</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$5.00</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
12/8/2021</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
HH</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2/23/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">20,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.13</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2/16/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
AA</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8/26/2016</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">200,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$13.75</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2/22/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
JJ</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">3/14/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">30,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.13</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3/8/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
LL</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">4/30/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">26,398</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.59</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
4/30/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
MM</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">6/22/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">893,491</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$1.86</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
6/22/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">-<br>
</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
NN</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">7/24/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">539,300</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$2.52</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
7/24/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">-<br>
</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
OO</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">7/31/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">60,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$2.52</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
7/31/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">-<br>
</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
QQ</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8/22/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">87,500</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$2.50</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8/22/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">-<br>
</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
GG</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2/23/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">400,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.00</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
8/23/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
II</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">3/14/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">600,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.00</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
9/14/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
RR</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">10/30/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">583,057</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$1.65</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
10/30/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
KK</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">5/3/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">395,970</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$3.04</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
11/3/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
SS</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">12/19/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1,289,478</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$2.09</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
12/18/2022</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">2</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Series
PP</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">8/28/2017</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">1,750,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$2.30</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
2/28/2023</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">-<br>
</font></div>
</td>
</tr><tr>
<td style="vertical-align: middle; width: 15%;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">Consultants</font></div>
</td>
<td style="vertical-align: middle; width: 25%;">
<div style="text-align: right; margin-left: 24px; margin-right: 25px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">3/30/15-
7/28/17</font></div>
</td>
<td style="vertical-align: middle; width: 17%;">
<div style="text-align: right; margin-left: 24px; margin-right: 10px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">40,000</font></div>
</td>
<td style="vertical-align: middle; width: 13%;">
<div style="text-align: center; margin-left: 0px; margin-right: -6px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">$2.18-
$25.50</font></div>
</td>
<td style="vertical-align: middle; width: 19%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3/29/18- 7/27/27</font></div>
</td>
<td style="vertical-align: middle; width: 11%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
3</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">13</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">1.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Derivative Liabilities</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
table below presents the warrant liabilities and their respective
balances at the balance sheet dates:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px;">December 31, 2017</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px;">September 30, 2017</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series S
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">19,705</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">32,773</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series V
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">171,225</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">72,912</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series W
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">213,221</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">83,754</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series Z
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">132,751</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">77,216</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series ZZ
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">8,096</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,753</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series AA
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">112,447</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">65,087</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series BB
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">6,953</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,322</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series CC
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">591,041</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">394,220</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series DD
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,492</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series EE
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">9</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,492</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series FF
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">65,201</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">47,154</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series GG
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">457,305</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">342,173</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series HH
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">21,676</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">16,014</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series II
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">690,442</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">511,636</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series JJ
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">32,745</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">24,203</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series KK
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">460,747</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">345,720</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series LL
warrants</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">28,059</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">20,481</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: bottom; width: 72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total warrant
liabilities</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,011,632</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">2,053,402</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
table below presents the gains and (losses) on the warrant
liabilities for the three months ended December 31:</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2017</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; vertical-align: bottom; font-size: 11px; display: inline-block; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold;">2016</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; width: 10%; padding-bottom: 2px; font-size: 11px; font-weight: bold;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series S
Warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times\ New\ Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-size: 13px; font-family: Times\ New\ Roman; display: inline-block;">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-size: 13px; font-family: Times\ New\ Roman; display: inline-block;">13,068</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times\ New\ Roman; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times\ New\ Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 5%; font-size: 13px; font-family: Times\ New\ Roman; display: inline-block;">$</font><font style="text-align: right; vertical-align: bottom; width: 75%; font-size: 13px; font-family: Times\ New\ Roman; display: inline-block;">2,621,321</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times\ New\ Roman; display: inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series V
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(98,313</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,417,721</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series W
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(129,467</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,667,604</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series Z
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(55,535</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">868,787</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series ZZ
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(3,343</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">63,884</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series AA
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(47,360</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">679,569</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series BB
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(2,631</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">52,672</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series CC
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(196,821</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">604,492</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series DD
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,483</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">370,919</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series EE
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,483</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">514,603</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series FF
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(18,047</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">66,740</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series GG
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(115,132</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series HH
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(5,662</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series II
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(178,806</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series JJ
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(8,542</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series KK
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(115,027</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Series LL
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(7,578</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">-</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Net (loss) gain on
warrant liabilities</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(958,230</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">8,928,312</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: right; margin-left: 24px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">&#xA0;</font>&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">14</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company reviews all outstanding warrants in accordance with the
requirements of ASC 815. This topic provides that an entity should
use a two-step approach to evaluate whether an equity-linked
financial instrument (or embedded feature) is indexed to its own
stock, including evaluating the instrument&#x2019;s contingent
exercise and settlement provisions. The warrant agreements provide
for adjustments to the exercise price for certain dilutive events.
Under the provisions of ASC 815, the warrants are not considered
indexed to the Company&#x2019;s stock because future equity
offerings or sales of the Company&#x2019;s stock are not an input to
the fair value of a &#x201C;fixed-for-fixed&#x201D; option on equity
shares, and equity classification is therefore
precluded.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
accordance with ASC 815, derivative liabilities must be measured at
fair value upon issuance and re-valued at the end of each reporting
period through expiration. Any change in fair value between the
respective reporting dates is recognized as a gain or
loss.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<font style="color: #000000">&#xA0;</font></font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">2.&#xA0;&#xA0;&#xA0;
<font style="text-decoration: underline">Issuance of Equity
Warrants</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Series SS Warrants</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
December 19, 2017 the Company received subscription agreements for
the purchase of 1,289,478 shares of CEL-SCI common stock at a price
of $1.90 in the principal amount of $2.45 million.&#xA0; The
purchasers of the common stock also received Series SS warrants
which entitle the purchasers to acquire up to 1,289,478 shares of
the Company&#x2019;s common stock.&#xA0;&#xA0;The warrants are
exercisable at a fixed price of $2.09 per share, are exercisable on
June 20, 2018 and will expire on December 18, 2022. Shares issuable
upon the exercise of the warrants will be restricted securities
unless registered. The Company allocated the proceeds received to
the shares and the Series SS warrants on a relative fair value
basis. As a result of such allocation, the Company determined the
initial carrying value of the Series SS warrants to be
approximately $1.0 million. The Series SS warrants qualify for
equity treatment in accordance with ASC 815.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-style: italic">Series RR Warrants</font><font style="color: #000000">&#xA0;&#xA0;</font></font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">On
October 30, 2017, holders of convertible notes in the principal
amount of $1.1 million issued in June 2017 and holders of
convertible notes in the principal amount of $1.2 million issued in
July 2017 agreed to extend the maturity date of these notes to
September 21, 2018.&#xA0;&#xA0;In consideration for the extension
of the maturity date of the convertible notes, the Company issued a
total of 583,057 Series RR warrants to the convertible note holders
that agreed to the extension.&#xA0;&#xA0;Each Series RR warrant
entitles the holder to purchase one share of the Company&#x2019;s
common stock.&#xA0;&#xA0;The Series RR warrants may be exercised at
any time on or before October 30, 2022 at an exercise price of
$1.65 per share. The Series RR warrants were recorded at the fair
value on the date of issuance of approximately $0.7 million, as
described in Note F.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Expiration of Warrants</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
October 17, 2017, 17,821 Series U warrants, with an exercise price
of $43.75 expired. The fair value of the Series U warrants was $0
on the date of expiration.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
December 6, 2016, 105,000 Series R warrants, with an exercise price
of $100.00, expired. The fair value of the Series R warrants was $0
on the date of expiration.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">15</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">3.&#xA0;</font></div>
<div style="text-align: left; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Options and shares issued to Consultants</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company typically enters into consulting arrangements in exchange
for common stock or stock options. During the three months ended
December 31, 2017, the Company issued 13,705 shares of common
stock, of which 13,705 were restricted shares. During the three
months ended December 31, 2016, the Company issued 14,900 shares of
common stock, of which 10,800 were restricted shares. The weighted
average grant value of the shares issued to consultants was $1.85
and $4.98 during the three months ended December 31, 2017 and 2016,
respectively. The aggregate values of the issuances of restricted
common stock and common stock options are recorded as prepaid
expenses and are charged to general and administrative expenses
over the periods of service.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended December 31, 2017 and 2016, the Company
recorded total expense of approximately $42,000 and $79,000,
respectively, relating to these consulting agreements. At December
31, 2017 and September 30, 2017, approximately $28,000 and $45,000,
respectively, are included in prepaid expenses. As of December 31,
2017, the Company had 40,000 options outstanding, which were issued
to consultants as payment for services. All off these options were
vested and all were issued from the Non-Qualified Stock Option
plans.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Other Equity Transactions</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
August 15, 2017, the Company entered into a Securities Purchase
Agreement with Ergomed plc, the Company&#x2019;s Clinical Research
Provider, to facilitate a partial payment of the accounts payable
balances due Ergomed. Under the Agreement, the Company issued
Ergomed 480,000 shares, with a fair market value of approximately
$1.3 million, as a forbearance fee in exchange for Ergomed&#x2019;s
agreement to provisionally forbear collection of the payables in an
amount equal to the net proceeds from the resales of the shares
issued to Ergomed. During the year ended September 30, 2017, the
Company recorded the full amount of the expense upon issuance,
offset by amounts realized through the resale of 64,792 shares and
the corresponding reduction of the payables, for a net expense of
$1.2 million. During the quarter ended December 31, 2017, the
Company realized approximately $0.7 million through the resale of
the remaining 415,208 shares and reduced the payables and interest
expense by that amount.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
</div>
<div style="margin-left: 0px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">D.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
FAIR VALUE MEASUREMENTS</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
accordance with ASC 820-10, <font style="font-style: italic">&#x201C;Fair Value Measurements,&#x201D;</font>
the Company determines fair value as the price that would be
received to sell an asset or paid to transfer a liability in an
orderly transaction between market participants at the measurement
date. The Company generally applies the income approach to
determine fair value. This method uses valuation techniques to
convert future amounts to a single present amount. The measurement
is based on the value indicated by current market expectations with
respect to those future amounts.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">ASC
820-10 establishes a fair value hierarchy that prioritizes the
inputs used to measure fair value. The hierarchy gives the highest
priority to active markets for identical assets and liabilities
(Level 1 measurement) and the lowest priority to unobservable
inputs (Level 3 measurement). The Company classifies fair value
balances based on the observability of those inputs. The three
levels of the fair value hierarchy are as follows:</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 36px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">&#x25CF;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Level 1 &#x2013;
Observable inputs such as quoted prices in active markets for
identical assets or liabilities</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 36px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">&#x25CF;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Level 2 &#x2013;
Inputs other than quoted prices that are observable for the asset
or liability, either directly or indirectly. These include quoted
prices for similar assets or liabilities in active markets, quoted
prices for identical or similar assets or liabilities in markets
that are not active and amounts derived from valuation models where
all significant inputs are observable in active
markets</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 36px">
<div style="display: table-row">
<div style="display: table-cell; width: 24px"><font style="font-family: Times New Roman; font-size: 13px">&#x25CF;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Level 3 &#x2013;
Unobservable inputs that reflect management&#x2019;s
assumptions</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 72px; margin-right: 0px; text-indent: -24px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">For
disclosure purposes, assets and liabilities are classified in their
entirety in the fair value hierarchy level based on the lowest
level of input that is significant to the overall fair value
measurement. The Company&#x2019;s assessment of the significance of
a particular input to the fair value measurement requires judgment
and may affect the placement within the fair value hierarchy
levels.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">16</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
table below sets forth the assets and liabilities measured at fair
value on a recurring basis, by input level, in the condensed
balance sheet at December 31, 2017:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:44%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times\ New\ Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times\ New\ Roman;font-size:11px;">Quoted Prices in Active Markets for Identical Assets
or Liabilities (Level 1)</font><font style="text-align: left; font-family:Times\ New\ Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times\ New\ Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times\ New\ Roman;font-size:11px;">Significant Other Observable Inputs (Level
2)</font><font style="text-align: left; font-family:Times\ New\ Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times\ New\ Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times\ New\ Roman;font-size:11px;">Significant Unobservable Inputs (Level
3)</font><font style="text-align: left; font-family:Times\ New\ Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times\ New\ Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font><font style="text-align: center; border-bottom:solid 2px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:80%;font-family:Times\ New\ Roman;font-size:11px;">Total</font><font style="text-align: left; font-family:Times\ New\ Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:2px;width:10%;font-size:11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Derivative
instruments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">19,705</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,991,927</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,011,632</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
table below sets forth the assets and liabilities measured at fair
value on a recurring basis, by input level, in the condensed
balance sheet at September 30, 2017:</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:44%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px;">Quoted Prices in Active Markets for Identical Assets
or Liabilities (Level 1)</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px;">Significant Other Observable Inputs (Level
2)</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px;">Significant Unobservable Inputs (Level
3)</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; border-bottom: 2px solid rgb(0, 0, 0); font-weight: bold; vertical-align: bottom; display: inline-block; width: 80%; font-family: Times\ New\ Roman; font-size: 11px;">Total</font><font style="text-align: left; font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:44%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:44%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Derivative
instruments</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">32,773</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,020,629</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,053,402</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<font style="font-size: 13px">&#xA0;</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
following sets forth the reconciliation of beginning and ending
balances related to fair value measurements using significant
unobservable inputs (Level 3) for the three months ended December
31, 2017 and the year ended September 30, 2017:</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">3 months ended</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">12 months ended</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">December 31, 2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">September 30, 2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Beginning
balance</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,020,629</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">5,283,573</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Issuances</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">-</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">4,665,683</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Realized and
unrealized losses and (gains)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">971,298</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">(7,928,627</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">)</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;"><font style="font-family: Times New Roman; font-size: 13px">Ending
balance</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,991,927</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,020,629</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
fair values of the Company&#x2019;s derivative instruments disclosed
above under Level 3 are primarily derived from valuation models
where significant inputs such as historical price and volatility of
the Company&#x2019;s stock, as well as U.S. Treasury Bill rates, are
observable in active markets.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; display: table;">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">E.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
RELATED PARTY TRANSACTIONS</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On July
24, 2017, the Company issued convertible notes (Series NN Notes) in
the aggregate principal amount of $1.2 million to 12 individual
investors. A trust in which Geert Kersten, the Company&#x2019;s
Chief Executive Officer, holds a beneficial interest participated
in the offering and purchased a note in the principal amount of
$250,000. Patricia B. Prichep, the Company&#x2019;s Senior Vice
President of Operations, participated in the offering and purchased
a note in the principal amount of $25,000. The terms of the
trust&#x2019;s note and Ms. Prichep&#x2019;s note were identical to
the other participants. The number of shares of the Company&#x2019;s
common stock issued upon conversion will be determined by dividing
the principal amount to be converted by $2.29, which would result
in the issuance of 109,170 shares to the trust and 10,917 shares to
Ms. Prichep upon conversion. Along with the other purchasers of the
convertible notes, the trust and Ms. Prichep also received Series
NN warrants to purchase up to 109,170 and 10,917 shares,
respectively, of the Company&#x2019;s common stock. The Series NN
warrants are exercisable at a fixed price of $2.52 per share and
expire on July 24, 2022. Shares issuable upon the exercise of the
notes and warrants were restricted securities unless registered.
The shares were registered effective September 1,
2017.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">17</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">On June 22, 2017, CEL-SCI issued convertible notes
(Series MM Notes) in the aggregate principal amount of $1.5 million
to six individual investors.</font> Geert Kersten, the
Company&#x2019;s Chief Executive Officer, participated in the
offering and purchased notes in the principal amount of $250,000.
The terms of Mr. Kersten&#x2019;s note were identical to the other
participants. The number of shares of the Company&#x2019;s common
stock issued upon conversion will be determined by dividing the
principal amount to be converted by $1.69, which would result in
the issuance of 147,929 shares to Mr. Kersten upon conversion.
Along with the other purchasers of the convertible notes, Mr.
Kersten also received Series MM warrants to purchase up to 147,929
shares of the Company&#x2019;s common stock. The Series MM warrants
are exercisable at a fixed price of $1.86 per share and expire on
June 22, 2022. Shares issuable upon the exercise of the notes and
warrants were restricted securities unless registered. The shares
were registered effective August 8, 2017.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">On
October 30, 2017, the due date of the Series NN and Series MM Notes
was extended from December 22, 2017 to September 21, 2018 in
exchange for Series RR warrants. Mr. Kersten, the Trust and Ms.
Prichep received 73,965, 54,585 and 5,459 Series RR warrants,
respectively.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Approximately
$6,000 in accrued interest was due the officers at December 31,
2017. No interest payments were made to officers during the three
months ended December 31, 2017.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="margin-left: 0px; display: table;">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">F.</font></div>
<div style="text-align: justify; display: table-cell"><font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
NOTES PAYABLE</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">On October 30, 2017, the Company</font> extended
the due dates of the Series MM and Series NN Notes (the
&#x201C;Notes&#x201D;) from December 22, 2017 to September 2l, 20l8,
and issued the note holders an additional 583,057 of Series RR
Warrants. The Series RR warrants expire on October 30, 2022 and are
priced at $ 1.65 per share, the closing price on October 27, 2017.
These Series RR warrants are classified as equity warrants and are
recorded at approximately $0.7 million, the fair value on the date
of issuance.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Because the Company is experiencing financial
difficulties and the creditors granted the Company a concession
they would not have otherwise considered in the form of a lower
effective interest rate, this modification was accounted for under
ASC 470-60, &#x201C;</font><font style="font-style: italic; color: #000000">Troubled Debt
Restructuring.</font><font style="color: #000000">&#x201D; The
Company calculated the future cash flows of the restructured debt
to be greater than the carrying value of the debt and accounted for
the change in debt prospectively, using the effective interest rate
that equated the carrying amount to the future cash flows</font>.
The carrying value of the debt on the date of restructuring was
approximately $0.7 million, which was net of a discount of
approximately $1.6 million. The discount is being amortized to
interest expense over the life of the Notes using the effective
interest method. The Company recorded approximately $0.6 million in
interest expense, relating to the amortization of the debt
discount. As of December 31, 2017, after conversions, the carrying
value of the Notes is approximately $0.9 million, net of a discount
of approximately $1.3 million. The Notes bear interest at 4% and
are convertible in shares of common stock. At the option of the
note holders, the Notes can be converted into shares of the
Company&#x2019;s common stock at a fixed conversion rate of $1.69
for the Series MM Notes and $2.29 for the Series NN
Notes.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">During
the quarter ended December 31, 2017, a note holder converted a
Series NN note, in the principal amount of $75,000, into 32,751
shares of common stock. The unamortized debt discount relating to
the converted Note was charged to interest expense.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Series MM and Series NN Notes are secured by a first lien on all of
the Company&#x2019;s assets.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 0px; display: table;">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 24px">
<font style="font-family: Times New Roman; font-size: 13px">G.</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">C<font style="text-decoration: underline">OMMITMENTS AND
CONTINGENCIES</font></font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;</font></div>
<div style="text-align: left; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; color: #292929; font-family: Times New Roman; font-size: 13px">
Clinical Research Agreements</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">In
March 2013, the Company entered into an agreement with Aptiv
Solutions, Inc. (which was subsequently acquired by ICON Inc.) to
provide certain clinical research services in accordance with a
master service agreement. The Company will reimburse ICON for costs
incurred. The agreement required the Company to make $600,000 in
advance payments which are being credited against future invoices
in $150,000 annual increments through December 2017. As of December
31, 2017, all advance payments have been expensed.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">18</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">In April 2013, the Company entered into a
co-development and revenue sharing agreement with Ergomed. Under
the agreement, Ergomed will contribute up to $10 million towards
the Company&#x2019;s Phase 3 Clinical Trial in the form of offering
discounted clinical services in exchange for a single digit
percentage of milestone and royalty payments, up to a specific
maximum amount</font>. In October 2015, the Company entered into a
second <font style="color: #292929">co-development and revenue
sharing agreement with Ergomed</font> for an additional $2 million,
for a total of $12 million. The Company accounted for the
co-development and revenue sharing agreement in accordance with ASC
808 &#x201C;Collaborative Arrangements&#x201D;. The Company
determined the payments to Ergomed are within the scope of ASC 730
&#x201C;Research and Development.&#x201D; Therefore, the Company
records the discount on the clinical services as a credit to
research and development expense on its Statements of Operations.
Since the Company entered into the co-development and revenue
sharing agreement with Ergomed, it has incurred research and
development expenses of approximately $25.9 million related to
Ergomed&#x2019;s services. This amount is net of Ergomed&#x2019;s
discount of approximately $8.6 million. During the three months
ended December 31, 2017 and 2016, the Company recorded, net of
Ergomed&#x2019;s discount, approximately $0.9 million and $1.3
million, respectively, as research and development expense related
to Ergomed&#x2019;s services.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company is currently involved in a pending arbitration proceeding,
CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a
PharmaNet LLC) and PharmaNet GmbH (f/k/a PharmaNet AG).
T<font style="color: #000000">he Company initiated the proceedings
against inVentiv Health Clinical, LLC, or inVentiv, the former
third-party CRO, and is seeking payment for damages related to
inVentiv&#x2019;s prior involvement in the Phase 3 clinical trial of
Multikine. The arbitration claim, initiated under the Commercial
Rules of the American Arbitration Association, alleges (i) breach
of contract, (ii) fraud in the inducement, and (iii) common law
fraud. Currently, the Company is seeking at least $50 million in
damages in its amended statement of claim.</font></font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In an
amended statement of claim, the Company asserted the claims set
forth above as well as an additional claim for professional
malpractice.&#xA0;&#xA0;The arbitrator subsequently granted
inVentiv&#x2019;s motion to dismiss the professional malpractice
claim based on the &#x201C;economic loss doctrine&#x201D; which,
under New Jersey law, is a legal doctrine that, under certain
circumstances, prohibits bringing a negligence-based claim
alongside a claim for breach of contract.&#xA0;&#xA0;The arbitrator
denied the remainder of inVentiv&#x2019;s motion, which had sought
to dismiss certain other aspects of the amended statement of
claim.&#xA0;&#xA0;In particular, the arbitrator rejected
inVentiv&#x2019;s argument that several aspects of the amended
statement of claim were beyond the arbitrator&#x2019;s
jurisdiction.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
connection with the pending arbitration proceedings, inVentiv has
asserted counterclaims against the Company for (i) breach of
contract, seeking at least $2 million in damages for services
allegedly performed by inVentiv; (ii) breach of contract, seeking
at least $1 million in damages for the alleged use of
inVentiv&#x2019;s name in connection with publications and
promotions in violation of the parties&#x2019; contract; (iii)
opportunistic breach, restitution and unjust enrichment, seeking at
least $20 million in disgorgement of alleged unjust profits
allegedly made by the Company as a result of the purported breaches
referenced in subsection (ii); and (iv) defamation, seeking at
least $1 million in damages for allegedly defamatory statements
made about inVentiv. The Company believes inVentiv&#x2019;s
counterclaims are meritless&#xA0;and has defended against them.
However, if such defense is unsuccessful, and inVentiv successfully
asserts any of its counterclaims, such an adverse determination
could have a material adverse effect on the Company&#x2019;s
business, results, financial condition and liquidity.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
October 2015 the Company signed an arbitration funding agreement
with a company established by Lake Whillans Litigation Finance,
LLC, a firm specializing in funding litigation expenses. Pursuant
to the agreement, an affiliate of Lake Whillans provided the
Company with up to $5 million in funding for litigation expenses to
support its arbitration claims against inVentiv. The funding was
available to the Company to fund the expenses of the ongoing
arbitration and will only be repaid if the Company receives
proceeds from the arbitration. All related legal fees are directly
billed to and paid by Lake Whillans. As part of the agreement with
Lake Whillans, the law firm agreed to cap its fees and expenses for
the arbitration at $5 million.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
hearing (the &#x201C;trial&#x201D;) started on September 26, 2016.
The last witness in the arbitration hearing testified on November
8, 2017, and no further witnesses or testimony are expected. With
that final witness, the testimony phase of the arbitration
concluded. All that remained after November 8, 2017 at the trial
level were closing statements and post-trial
submissions.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">19</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
Lease Agreements</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company leases a manufacturing facility near Baltimore, Maryland
(the San Tomas lease). The building was remodeled in accordance
with the Company&#x2019;s specifications so that it can be used by
the Company to manufacture Multikine for the Company&#x2019;s Phase
3 clinical trial and sales of the drug if approved by the FDA. The
lease is for a term of twenty years and requires annual base rent
to escalate each year at 3%. The Company is required to pay all
real estate and personal property taxes, insurance premiums,
maintenance expenses, repair costs and utilities. The lease allows
the Company, at its election, to extend the lease for two ten-year
periods or to purchase the building at the end of the 20-year
lease. The Company contributed approximately $9.3 million towards
the tenant-directed improvements, of which $3.2 million is being
refunded during years six through twenty through reduced rental
payments. The landlord paid approximately $11.9 million towards the
purchase of the building, land and the tenant-directed
improvements. The Company placed the building in service in October
2008.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">The
Company was deemed to be the owner of the building for accounting
purpose under the build-to-suit guidance in ASC 840-40-55. In
addition to tenant improvements the Company incurred, the Company
also recorded an asset for tenant-directed improvements and for the
costs paid by the lessor to purchase the building and to perform
improvements, as well as a corresponding liability for the landlord
costs. Upon completion of the improvements, the Company did not
meet the &#x201C;sale-leaseback&#x201D; criteria under ASC 840-40-25,
Accounting for Lease, Sale-Leaseback Transactions, and therefore,
treated the lease as a financing obligation. Thus, the asset and
corresponding liability were not de-recognized. As of December 31,
2017 and September 30, 2017, the leased building asset has a net
book value of approximately $16.5 and $16.6 million, respectively,
and the landlord liability has a balance of approximately $13.3 and
$13.2 million, respectively. The leased building is being
depreciated using a straight line method over the 20 year lease
term to a residual value. The landlord liability is being amortized
over the 20 years using the effective interest method. Lease
payments allocated to the landlord liability are accounted for as
debt service payments on that liability using the finance method of
accounting per ASC 840-40-55.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company was required to deposit the equivalent of one year of base
rent in accordance with the lease. When the Company meets the
minimum cash balance required by the lease, the deposit will be
returned to the Company. The approximate $1.7 million deposit is
included in non-current assets at December 31, 2016 and September
30, 2016.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;Approximate
future minimum lease payments under the San Tomas lease as of
December 31, 2017 are as follows:</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;Nine months
ending September 30, 2018&#xA0;&#xA0;&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,314,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;Year ending
September 30,</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;2019</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,808,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;2020</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,872,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;2021</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">1,937,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;2022</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,004,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;2023</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,073,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;Thereafter</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">11,685,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;Total future
minimum lease obligation</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">22,693,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;Less imputed
interest on financing obligation</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">(9,438,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">)</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;Net present
value of lease financing obligation</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">13,255,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company subleases a portion of its rental space on a month-to-month
term lease, which requires a 30 day notice for termination. The
Company receives approximately $6,000 per month in rent for the
sub-leased space.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company leases its research and development laboratory under a 60
month lease which expires February 28, 2022. The operating lease
includes escalating rental payments. The Company is recognizing the
related rent expense on a straight-line basis over the full 60
month term of the lease at the rate of approximately $13,000 per
month. As of December 31, 2017 and September 30, 2017, the Company
has recorded a deferred rent liability of approximately $8,000 and
$5,000, respectively.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">20</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company leases its office headquarters under a 60 month lease which
expires June 30, 2020. The operating lease includes escalating
rental payments. The Company is recognizing the related rent
expense on a straight line basis over the full 60 month term of the
lease at the rate approximately $8,000 per month. As of December
31, 2017 and September 30, 2017, the Company has recorded a
deferred rent liability of approximately $17,000 and $18,000,
respectively.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As of
December 31, 2017, material contractual obligations, excluding the
San Tomas lease, consisting of non-cancelable operating lease
payments are as follows:</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Nine months ending
September 30, 2018</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">189,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Year ending
September 30,</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2019</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">258,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2020</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">238,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2021</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">163,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2022</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">69,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">917,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company leases office equipment under a capital lease arrangement.
The term of the capital lease is 60 months and expires on October
31, 2021. The monthly lease payment is $505. The lease bears
interest at approximately 6.25% per annum.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">G.&#xA0;&#xA0;
<font style="text-decoration: underline">PATENTS</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended December 31, 2017 and 2016, no patent
impairment charges were recorded. For the three months ended
December 31, 2017 and 2016, amortization of patent costs totaled
approximately $9,000. Approximate estimated future amortization
expense is as follows:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr style="background-color:#cceeff;">
<td rowspan="1" style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Nine months ending
September 30, 2018</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">27,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Year ending
September 30,</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2019</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">35,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2020</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">32,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2021</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">29,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2022</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">25,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">2023</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">15,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Thereafter</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">52,000</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:86%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">Total</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">215,000</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">H.
&#xA0; <font style="text-decoration: underline">EARNINGS (LOSS) PER
COMMON SHARE</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">The
following table provides the details of the basic and diluted
earnings (loss) per-share computations:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 58%;">
<div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;&#xA0;&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:42%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 3%; font-size: 11px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 94%; font-size: 11px; border-bottom: 2px solid rgb(0, 0, 0);">Three Months Ended December 31,
2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 3%; font-size: 11px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Net loss</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Weighted Average Shares</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">LPS</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block;">&#xA0;</font><font style="text-align: center; vertical-align: bottom; width: 80%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block;">&#xA0;</font><font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 11px; font-family: Times\ New\ Roman; display: inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Basic
and diluted loss per share</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(6,187,830</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">11,636,730</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">$</font><font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">(0.53</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">)</font></div>
</td>
</tr></table>
</div>
<div style="null"><font>&#xA0;</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 58%;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="3" rowspan="1" style="vertical-align:bottom;width:42%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 3%; font-size: 11px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 94%; font-size: 11px; border-bottom: 2px solid rgb(0, 0, 0);">Three Months Ended December 31,
2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 3%; font-size: 11px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Net Income</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">Weighted Average Shares</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">EPS</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Basic
earnings per share</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">3,521,153</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">5,994,431</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.59</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px"><font style="color: #000000">Gain on derivatives</font> <font style="color: #000000; font-size: 13px">(1)</font></font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">(1,556,754</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">)</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">90,277</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:58%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:58%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Dilutive
earnings per share</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">1,964,399</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,084,708</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">$</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">0.32</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td colspan="2" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="text-align: left; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">(1</font><font style="text-align: left; vertical-align:bottom;color:#000000;font-size:13px;font-family:Times New Roman;display:inline-block;">) Includes certain Series CC, DD, EE and FF
warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">21</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">The
gain on derivatives priced lower than the average market price
during the period is excluded from the numerator and the related
shares are excluded from the denominator in calculating diluted
loss per share.</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">In
accordance with the contingently issuable shares guidance of FASB
ASC Topic 260, <font style="font-style: italic">Earnings Per
Share</font>, the calculation of diluted net earnings (loss) per
share excludes the following securities because their inclusion
would have been anti-dilutive as of December 31:</font></div>
<div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px;">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div style="margin-left: 24px;">
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td rowspan="1" style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Options
and Warrants</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">10,491,090</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">6,946,179</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Unvested
Restricted Stock</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">332,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">604,000</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Convertible
debt</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">1,133,355</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">-</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="color: #000000; font-family: Times New Roman; font-size: 13px">Total</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">11,956,945</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">&#xA0;</font><font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">7,550,179</font><font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">J.&#xA0;&#xA0;&#xA0;&#xA0;
<font style="text-decoration: underline">SUBSEQUENT
EVENTS</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">As of
January 1, 2018, the Company was indebted to Ergomed, plc for
services provided by Ergomed in connection with the Company&#x2019;s
Phase III clinical trial. On January 1, 2018 the Company agreed to
issue Ergomed 660,000 restricted shares of the Company&#x2019;s
common stock in partial payment of the amount the Company owed
Ergomed.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
January 12, 2018, the exercise price of the Company&#x2019;s
outstanding Series S warrants (CUSIP number 150837177), that are
publicly traded under the symbol &#x201C;CVM WS&#x201D; on the NYSE
American, was changed to $3.00 per share for a three month period
which will end on April 12, 2018. After this date, the exercise
price will revert back to $31.25 per share of common stock. As a
result of the reverse stock split which became effective on the
NYSE American on June 15, 2017, 25 Series S warrants are required
to purchase one share of common stock. The Series S warrants expire
on October 11, 2018.</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 24px; margin-right: 0px; text-indent: 0px;">
<font style="font-family: Times New Roman; font-size: 13px">On
February 5, 2018, the Company received subscription
agreements/commitments for the purchase of 2,608,097 shares of
common stock at the closing price on February 5, 2018 of $1.87 in
the principal amount of $4,877,140 from 20 investors. The common
stock is restricted unless registered. The purchasers of the common
stock also received warrants which entitle the purchasers to
acquire up to 1,956,074 shares of the Company&#x2019;s common stock.
The warrants are exercisable at a fixed price of $2.24 per share,
will not be exercisable for 6 months and one day and will expire on
February 5, 2023. Shares issuable upon the exercise of the warrants
are restricted securities unless registered.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">22</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 2px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<font style="text-decoration: underline">Liquidity
and Capital Resources</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s lead investigational therapy, Multikine<font style="font-size: 13px">&#xAE;</font> (Leukocyte Interleukin, Injection),
is cleared for a Phase 3 clinical trial in advanced primary head
and neck cancer. Multikine has been cleared by the regulators in
twenty four countries around the world, including the U.S.
FDA.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Multikine
(Leukocyte Interleukin, Injection) is the full name of this
investigational therapy, which, for simplicity, is referred to in
the remainder of this report as Multikine. Multikine is the
trademark that the Company has registered for this investigational
therapy, and this proprietary name is subject to FDA review in
connection with the Company&#x2019;s future anticipated regulatory
submission for approval. Multikine has not been licensed or
approved by the FDA or any other regulatory agency. Neither has its
safety or efficacy been established for any use.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company also owns and is developing a pre-clinical technology
called LEAPS (Ligand Epitope Antigen Presentation
System).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">All of
the Company&#x2019;s projects are under development. As a result,
the Company cannot predict when it will be able to generate any
revenue from the sale of any of its products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Since
inception, the Company has financed its operations through the sale
of equity securities, convertible notes, loans and certain research
grants. The Company&#x2019;s expenses will continue to exceed its
revenues as it continues the development of Multikine and brings
other drug candidates into clinical trials. Until such time as the
Company becomes profitable, any or all of these financing vehicles
or others may be utilized to assist the Company&#x2019;s capital
requirements.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font>Capital raised by the Company has been expended
primarily for patent applications, research and development,
administrative costs, and the construction of the Company&#x2019;s
laboratory facilities. The Company does not anticipate realizing
significant revenues until it enters into licensing arrangements
regarding its technology and know-how or until it receives
regulatory approval to sell its products (which could take a number
of years). As a result the Company has been dependent upon the
proceeds from the sale of its securities to meet all of its
liquidity and capital requirements and anticipates having to do so
in the future.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company will be required to raise additional capital or find
additional long-term financing in order to continue with its
research efforts. The ability to raise capital may be dependent
upon market conditions that are outside the control of the Company.
The ability of the Company to complete the necessary clinical
trials and obtain FDA approval for the sale of products to be
developed on a commercial basis is uncertain. Ultimately, the
Company must complete the development of its products, obtain the
appropriate regulatory approvals and obtain sufficient revenues to
support its cost structure. The Company is taking cost-cutting
initiatives, as well as exploring other sources of funding to
finance operations over the next 12 months. However there can be no
assurance that the Company will be able to raise sufficient capital
to support its operations.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Since the Company launched its Phase 3 clinical trial for
Multikine, the Company has incurred expenses of approximately $47.0
million as of December 31, 2017 on direct costs for the Phase 3
clinical trial. The Company estimates it will incur additional
expenses of approximately $12.2 million for the remainder of the
Phase 3 clinical trial. It should be noted that this estimate is
based only on the information currently available in the
Company&#x2019;s contracts with the Clinical Research Organizations
responsible for managing the Phase 3 clinical trial and does not
include other related costs, e.g., the manufacturing of the drug.
This number may be affected by the rate of death accumulation in
the study, foreign currency exchange rates, and many other factors,
some of which cannot be foreseen today. It is therefore possible
that the cost of the Phase 3 clinical trial will be higher than
currently estimated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
April 2013, the Company announced that it had replaced the CRO
running its Phase 3 clinical trial. This was necessary since the
patient enrollment in the study dropped off substantially following
a takeover of the CRO which caused most of the members of the
CRO&#x2019;s study team to leave the CRO. The Company announced that
it had hired two CRO&#x2019;s who will manage the global Phase 3
study; ICON and Ergomed, who are both international leaders in
managing oncology trials. Both CRO&#x2019;s helped the Company
expand the trial to over 80 clinical sites globally. As of
September 2016, the study had enrolled 928 patients.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Under a
co-development agreement, Ergomed will contribute up to $12 million
towards the study where it will perform clinical services in
exchange for a single digit percentage of milestone and royalty
payments, up to a specified maximum amount, only from sales for
head and neck cancer.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended December 31, 2017, the Company&#x2019;s cash
decreased by approximately $227,000.&#xA0; Significant components
of this decrease include net proceeds from the sale of the
Company&#x2019;s stock of approximately $2.4 million offset by net
cash used to fund the Company&#x2019;s regular operations, including
its Phase 3 clinical trial, of approximately $2.6 million. During
the three months ended December 31, 2016, the Company&#x2019;s cash
decreased by approximately $531,000.&#xA0; Significant components
of this decrease include net proceeds from the sale of the
Company&#x2019;s stock of approximately $3.7 million offset by net
cash used to fund the Company&#x2019;s regular operations, including
its Phase 3 clinical trial, of approximately $4.2 million and
payments on capital leases of approximately $2,000.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
On December 19, 2017, the Company completed a financing for the
purchase of 1,289,478 shares of common stock at a price of $1.90 in
the principal amount of $2.45 million.&#xA0; The purchasers of the
common stock received Series SS warrants which entitled the
purchasers to acquire 1,289,478 shares of the Company&#x2019;s
common stock.&#xA0;&#xA0;The warrants are exercisable at a fixed
price of $2.09 per share, are exercisable on June 20, 2018 and will
expire on December 18, 2022.</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">23</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Inventory at December 31, 2017 remained constant, only decreasing
by approximately $28,000 as compared to September 30, 2017. In
addition, receivables decreased by approximately $170,000,
primarily due to the timing of payments by the Company&#x2019;s
partners for reimbursed clinical study costs related to Phase 3
clinical trial. Receivables at December 31, 2017 includes a $25,000
stock subscription which was received in January 2018.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Results of Operations and Financial Condition</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended December 31, 2017, research and development
expenses decreased by approximately $1.2 million compared to the
three months ended December 31, 2016 since the study is fully
enrolled.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended December 31, 2017, general and
administrative expenses increased by approximately $1.3 million
compared to the three months ended December 31, 2016. This increase
is primarily due to an increase of approximately $1.1 million in
equity based compensation related to the Company&#x2019;s
shareholder approved 2014 Incentive Stock Bonus Plan, and an
increase of approximately $200,000 in accounting fees.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
loss on derivative instruments of approximately $0.9 million for
the three months ended December 31, 2017 and the gain on derivative
instruments of approximately $8.9 million for the three months
ended December 31, 2016 were the result of the change in fair value
of the derivative liabilities during the respective quarters. These
changes were caused by fluctuation in the share price of the
Company&#x2019;s common stock.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
&#xA0;</font>Net interest expense decreased by approximately
$150,000 for the three months ended December 31, 2017 compared to
the three months ended December 31, 2016. The decrease is primarily
due to the additional interest items in the current year, which
includes a reduction of interest expense of approximately $747,000
relating to a financing arrangement with Ergomed (as explained in
Note C), offset by approximately $590,000 in interest expense
relating to the amortization of the discount on notes payable (See
Note F).</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Research and Development Expenses</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s research and development efforts involve Multikine
and LEAPS. The table below shows the research and development
expenses associated with each project.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">
<tr>
<td rowspan="1" style="vertical-align: bottom; width: 72%;">
<div style="margin-left: 0px; padding-bottom: 2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align:bottom;width:28%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; font-size: 11px; padding-bottom: 2px;">&#xA0;</font><font style="text-align: center; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 90%; font-size: 11px; border-bottom: 2px solid rgb(0, 0, 0);">Three months ended December 31,</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; width: 5%; font-size: 11px; padding-bottom: 2px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;padding-bottom:2px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2017</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font><font style="text-align: center; font-family: Times\ New\ Roman; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; display: inline-block; font-weight: bold; width: 80%; font-size: 11px;">2016</font><font style="text-align: left; color: rgb(0, 0, 0); font-family: Times\ New\ Roman; vertical-align: bottom; display: inline-block; font-weight: bold; padding-bottom: 2px; width: 10%; font-size: 11px;">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: center; vertical-align:bottom;width:80%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">MULTIKINE</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,219,934</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,463,006</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">LEAPS</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">106,080</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">&#xA0;</font><font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">85,251</font><font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#cceeff;">
<td style="vertical-align:bottom;width:72%;">
<div style="margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr><tr style="background-color:#ffffff;">
<td style="vertical-align:bottom;width:72%;">
<div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;"><font style="font-family: Times New Roman; font-size: 13px">TOTAL</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">2,326,014</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
<td style="vertical-align:bottom;width:14%;">
<div><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font><font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">$</font><font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">3,548,257</font><font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Clinical
and other studies necessary to obtain regulatory approval of a new
drug involve significant costs and require several years to
complete. The extent of the Company&#x2019;s clinical trials and
research programs are primarily based upon the amount of capital
available to the Company and the extent to which the Company has
received regulatory approvals for clinical trials. The inability of
the Company to conduct clinical trials or research, whether due to
a lack of capital or regulatory approval, will prevent the Company
from completing the studies and research required to obtain
regulatory approval for any products which the Company is
developing. Without regulatory approval, the Company will be unable
to sell any of its products. Since all of the Company&#x2019;s
projects are under development, the Company cannot predict when it
will be able to generate any revenue from the sale of any of its
products.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-family: Times New Roman; font-size: 13px">
Critical Accounting Estimates and Policies</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Management&#x2019;s discussion and analysis of the Company&#x2019;s
financial condition and results of operations is based on its
unaudited condensed financial statements. The preparation of these
financial statements is based on the selection of accounting
policies and the application of significant accounting estimates,
some of which require management to make judgments, estimates and
assumptions that affect the amounts reported in the financial
statements and notes. The Company believes some of the more
critical estimates and policies that affect its financial condition
and results of operations are in the areas of operating leases and
stock-based compensation. For more information regarding the
Company&#x2019;s critical accounting estimates and policies, see
Part II, Item&#xA0;7 of the Company&#x2019;s Annual Report on Form
10-K for the year ended September 30, 2017. The application of
these critical accounting policies and estimates has been discussed
with the Audit Committee of the Company&#x2019;s Board of
Directors.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">24</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 72px; margin-right: 0px; text-indent: -72px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Item
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISKS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company does not believe that it has any significant exposures to
market risk.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 4. CONTROLS AND PROCEDURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-family: Times New Roman; font-size: 13px">
Evaluation of Disclosure Controls and Procedures</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Under
the direction and with the participation of the Company&#x2019;s
management, including the Company&#x2019;s Chief Executive and Chief
Financial Officer, the Company has conducted an evaluation of the
effectiveness of the design and operation of its disclosure
controls and procedures as of December 31, 2017. The Company
maintains disclosure controls and procedures that are designed to
ensure that information required to be disclosed in its periodic
reports with the Securities and Exchange Commission is recorded,
processed, summarized and reported within the time periods
specified in the SEC&#x2019;s rules and regulations, and that such
information is accumulated and communicated to the Company&#x2019;s
management, including its principal executive officer and principal
financial officer, as appropriate, to allow timely decisions
regarding required disclosure. The Company&#x2019;s disclosure
controls and procedures are designed to provide a reasonable level
of assurance of reaching its desired disclosure control objectives.
Based on the evaluation, the Chief Executive and Chief Financial
Officer concluded that the Company&#x2019;s disclosure controls and
procedures were effective as of December 31, 2017.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;<font style="text-decoration: underline">Changes
in Internal Control over Financial Reporting</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company&#x2019;s management, with the participation of the Chief
Executive and Chief Financial Officer, has made changes to the
Company&#x2019;s Internal Controls to address the material
weaknesses as discussed in the Company&#x2019;s September 30, 2017
10-K.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">25</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
PART II</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 2. Unregistered Sales of Equity Securities and Use of
Proceeds.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">During
the three months ended December 31, 2017 the Company issued 13,705
restricted shares of common stock to consultants for investor
relations services.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">The
Company relied upon the exemption provided by Section 4(a)(2) of
the Securities Act of 1933 with respect to the issuance of these
shares. The individuals who acquired these shares were
sophisticated investors and were provided full information
regarding our business and operations. There was no general
solicitation in connection with the offer or sale of these
securities. The individuals who acquired these shares acquired them
for their own accounts. The certificates representing these shares
bear a restricted legend providing that they cannot be sold except
pursuant to an effective registration statement or an exemption
from registration. No commission or other form of remuneration was
given to any person in connection with the issuance of these
shares.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">
Item 6.</font> <font style="font-weight: bold">Exhibits</font></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="text-decoration: underline">Number</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
&#xA0;&#xA0;&#xA0;&#xA0;<font style="text-decoration: underline">Exhibit</font></font></div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 48px">
<div style="display: table-row">
<div style="display: table-cell; width: 96px"><a href="cvm_ex31-1.htm"><font style="font-family: Times New Roman; font-size: 13px">31<br></font></a></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Rule 13a-14(a)
Certifications</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table; margin-left: 48px">
<div style="display: table-row">
<div style="display: table-cell; width: 96px"><a href="cvm_ex32.htm"><font style="font-family: Times New Roman; font-size: 13px">32<br></font></a></div>
<div style="text-align: left; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Section 1350
Certifications</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">26</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">
<tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td colspan="2" style="vertical-align: bottom; width: 38%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">CEL-SCI
CORPORATION</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%; border-bottom: 4px double #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date:
February 12, 2018</font></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: 4px double #ffffff">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px"><font style="font-size: 13px">
/s/&#xA0;</font><font style="font-size: 13px">&#xA0;</font><font style="font-size: 13px">Geert
Kersten</font></font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: 4px double #ffffff">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 49%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 3%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Principal
Executive Officer*&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%">
<div><font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">* Also
signing in the capacity of the Principal Accounting and Financial
Officer.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pn" style="text-align: center"><font style="font-family: Times New Roman; font-size: 13px">27</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>cvm_ex31-1.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times\ New\ Roman; font-size: 13px;">
<div id="pgbrk" style="text-align: right; width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: right; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold">&#xA0; <font style="font-family: Times New Roman; font-size: 13px">Exhibit
31.1</font><br></font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CERTIFICATIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">I,
Geert Kersten, certify that:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 47px"><font style="font-family: Times New Roman; font-size: 13px">1.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">I have reviewed
this quarterly report on Form 10-Q of CEL-SCI
Corporation;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">2.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Based on my
knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period
covered by this report;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">3.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Based on my
knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in
this report;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">4.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The registrant's
other certifying officer(s) and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13a-15(f) and
15d-15(f)) for the registrant and have:</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, is
made known to us by others within those entities, particularly
during the period in which this report is being
prepared;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such internal control over financial reporting, or cause such
internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">c)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;evaluated
the effectiveness of the registrant&#x2019;s disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such evaluation;
and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">d)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;disclosed
in this report any change in the registrant&#x2019;s internal
control over financial reporting that occurred during the
registrant&#x2019;s most recent fiscal quarter (the
registrant&#x2019;s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to
materially affect, the registrant&#x2019;s internal control over
financial reporting; and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">5.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The registrant's
other certifying officer(s) and I have disclosed, based on our most
recent evaluation of the internal control over financial reporting,
to the registrant's auditors and the audit committee of the
registrant's board of directors (or persons performing the
equivalent functions):</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;all
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#x2019;s
ability to record, process, summarize and report financial
information; and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;any
fraud, whether or not material, that involves management or other
employees who have significant role in the registrant&#x2019;s
internal control over financial reporting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit; margin-right:0px;width:100%;margin-left:0px;">
<tr>
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">February 12,
2018</font></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/</font>
<font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</font>&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Principal Executive
Officer</font>&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0; <font style="font-family: Times\ New\ Roman; font-size: 13px;"><br>
</font></div>
</div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>cvm_ex312.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times\ New\ Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: right; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0; <font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Exhibit 31.2</font><br></font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<br></font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
CERTIFICATIONS</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">I,
Geert Kersten, certify that:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 47px"><font style="font-family: Times New Roman; font-size: 13px">1.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">I have reviewed
this quarterly report on Form 10-Q of CEL-SCI
Corporation;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">2.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Based on my
knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period
covered by this report;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">3.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Based on my
knowledge, the financial statements, and other financial
information included in this report, fairly present in all material
respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in
this report;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">4.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The registrant's
other certifying officer(s) and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13a-15(f) and
15d-15(f)) for the registrant and have:</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, is
made known to us by others within those entities, particularly
during the period in which this report is being
prepared;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;designed
such internal control over financial reporting, or cause such
internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">c)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;evaluated
the effectiveness of the registrant&#x2019;s disclosure controls and
procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the
end of the period covered by this report based on such evaluation;
and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">d)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;disclosed
in this report any change in the registrant&#x2019;s internal
control over financial reporting that occurred during the
registrant&#x2019;s most recent fiscal quarter (the
registrant&#x2019;s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to
materially affect, the registrant&#x2019;s internal control over
financial reporting; and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px">5.&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The registrant's
other certifying officer(s) and I have disclosed, based on our most
recent evaluation of the internal control over financial reporting,
to the registrant's auditors and the audit committee of the
registrant's board of directors (or persons performing the
equivalent functions):</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">a)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;all
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&#x2019;s
ability to record, process, summarize and report financial
information; and</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">b)&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;any
fraud, whether or not material, that involves management or other
employees who have significant role in the registrant&#x2019;s
internal control over financial reporting.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit; margin-right:0px;width:100%;margin-left:0px;">
<tr>
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">February 12,
2018</font></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/</font>
<font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</font>&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Principal Financial
Officer</font>&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">&#xA0;</font></div>
</div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>cvm_ex32.htm
<DESCRIPTION>CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2018 Issuer Direct Corporation -->
<title>Blueprint</title>
</head>
<body style="font-family: Times\ New\ Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: right; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0; <font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Exhibit 32</font><br></font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
<br></font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: -1px; text-indent: 48px">
<font style="font-family: Times New Roman; font-size: 13px">In
connection with the Quarterly Report of CEL-SCI Corporation (the
&#x201C;Company&#x201D;) on Form 10-Q for the period ending December
31, 2017 as filed with the Securities and Exchange Commission (the
&#x201C;Report&#x201D;), Geert Kersten, the Principal Executive and
Financial Officer of the Company, certifies, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to the best of his
knowledge:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
<font style="font-family: Times\ New\ Roman; font-size: 13px;">(1)</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The Report fully
complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="margin-left: 48px; display: table">
<div style="display: table-row">
<div style="text-align: left; display: table-cell; width: 48px">
(2)</div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">The information
contained in the Report fairly presents, in all material respects,
the financial condition and results of the Company.</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
</div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit; margin-right:0px;width:100%;margin-left:0px;">
<tr>
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-family: Times New Roman; font-size: 13px">February 12,
2018</font></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/</font>
<font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Geert
Kersten</font>&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Principal Executive
and</font></font><br>
<font style="font-size: 13px; font-family: Times New Roman"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Principal Financial
Officer</font></font></font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0; <font style="font-family: Times\ New\ Roman; font-size: 13px;"><br>
</font></div>
</div>
</div>
<div><font style="font-family: Times New Roman; font-size: 10">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 2px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>cvm-20170630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 173321 12312017 10Q1.xfr; Date: 2018%2D02%2D09T15:11:46Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:CVM="http://cel-sci.com/20170630">
    <link:schemaRef xlink:href="cvm-20170630.xsd" xlink:type="simple" />
    <xbrli:context id="From2016-10-01to2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesWMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_IncentiveStockOptionPlansMember29250218">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:IncentiveStockOptionPlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_NonQualifiedStockOptionPlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:NonQualifiedStockOptionPlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_StockBonusPlansMember29250281">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:StockBonusPlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_StockCompensationPlanMember29250296">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_SeriesNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_ConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:ConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesVMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesVMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_IncentiveStockBonusPlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:IncentiveStockBonusPlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_IncentiveStockOptionPlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:IncentiveStockOptionPlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_NonQualifiedStockOptionPlansMember29250250">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:NonQualifiedStockOptionPlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_StockBonusPlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:StockBonusPlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_StockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_IncentiveStockBonusPlansMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CVM:IncentiveStockBonusPlansMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesWMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesWMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesYMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesYMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesNMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesNMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesXMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesXMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesDdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesDdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesEeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesEeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesZzMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZzMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesBbMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesBbMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesFfMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesFfMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesCcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesCcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesAaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesDdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesDdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesEeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesEeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesZMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesZzMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesZzMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesBbMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesBbMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesFfMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesFfMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesCcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesCcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesAaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesAaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesHhMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesHhMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesJjMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesJjMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesGgMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesGgMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesIiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesIiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesHhMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesHhMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesJjMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesJjMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesGgMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesGgMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesIiMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesIiMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesLlMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesLlMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesMmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesMmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesKkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesKkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesLlMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesLlMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesMmMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesMmMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesKkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesKkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-02-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-02-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesNnMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesNnMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesNnMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesNnMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesOoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesOoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesOoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesOoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesQqMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesQqMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesQqMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesQqMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesRrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesRrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesRrMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesRrMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesSsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesSsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesSsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_SeriesPpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesPpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_custom_SeriesPpMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CVM:SeriesPpMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_HeadquartersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">CVM:HeadquartersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_HeadquartersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">CVM:HeadquartersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_ResearchAndDevelopmentLabMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">CVM:ResearchAndDevelopmentLabMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-09-30_custom_ResearchAndDevelopmentLabMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">CVM:ResearchAndDevelopmentLabMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2016-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2016-12-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-01to2017-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2016-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000725363</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2017-10-01to2017-12-31">CEL SCI CORP</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2017-10-01to2017-12-31">0000725363</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2017-10-01to2017-12-31">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2017-10-01to2017-12-31">2017-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2017-10-01to2017-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2017-10-01to2017-12-31">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2017-10-01to2017-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2017-10-01to2017-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2017-10-01to2017-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2017-10-01to2017-12-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2017-10-01to2017-12-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2017-10-01to2017-12-31">2018</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-09-30" unitRef="USDPShares" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">600000000</us-gaap:CommonStockSharesAuthorized>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2018-02-04" unitRef="Shares" decimals="INF">13993957</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Assets contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">22173822</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">22924174</us-gaap:Assets>
    <us-gaap:DepositAssets contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1670917</us-gaap:DepositAssets>
    <us-gaap:DepositAssets contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">1670917</us-gaap:DepositAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">214872</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">223167</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">16647211</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">16793220</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">3640822</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">4236870</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">644749</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">672522</us-gaap:InventoryNet>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">0</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">150000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">805729</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">826429</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">47610</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">218481</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">2142734</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">2369438</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">2917996</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">2386673</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">10595724</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">10844554</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">11815</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">12449</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">19724</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">10984</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:NotesAndLoansPayableCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">874593</us-gaap:NotesAndLoansPayableCurrent>
    <us-gaap:NotesAndLoansPayableCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">994258</us-gaap:NotesAndLoansPayableCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">846751</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:DueToOfficersOrStockholdersCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">693831</us-gaap:DueToOfficersOrStockholdersCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">970042</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">936698</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">7872799</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">8196334</us-gaap:AccountsPayableCurrent>
    <us-gaap:Liabilities contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">27007862</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">26261151</us-gaap:Liabilities>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">38212</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">37254</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredRevenue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">126550</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">125000</us-gaap:DeferredRevenue>
    <CVM:LeaseLiability contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">13255468</CVM:LeaseLiability>
    <CVM:LeaseLiability contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">13211925</CVM:LeaseLiability>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">2991908</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">2042418</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:PreferredStockValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">22173822</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">22924174</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">-4834040</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">-3336977</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">-305942239</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">-299754409</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">300975618</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">296298401</us-gaap:AdditionalPaidInCapital>
    <us-gaap:CommonStockValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">132581</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">119031</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">13258051</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">11903133</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">13258051</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-09-30" unitRef="Shares" decimals="INF">11903133</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OperatingExpenses contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">4955266</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">5025327</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">1407009</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">2699313</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">3548257</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">2326014</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingIncomeLoss contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-4938008</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-4911430</us-gaap:OperatingIncomeLoss>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">8928312</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-958230</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-469151</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-318170</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">3521153</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-6187830</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted contextRef="From2016-10-01to2016-12-31" unitRef="USDPShares" decimals="INF">0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2017-10-01to2017-12-31" unitRef="USDPShares" decimals="INF">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic contextRef="From2016-10-01to2016-12-31" unitRef="USDPShares" decimals="INF">0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2017-10-01to2017-12-31" unitRef="USDPShares" decimals="INF">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2016-10-01to2016-12-31" unitRef="Shares" decimals="INF">6084708</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2017-10-01to2017-12-31" unitRef="Shares" decimals="INF">11636730</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2016-10-01to2016-12-31" unitRef="Shares" decimals="INF">5994431</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2017-10-01to2017-12-31" unitRef="Shares" decimals="INF">11636730</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <CVM:CapitalizedLeaseInterest contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">51213</CVM:CapitalizedLeaseInterest>
    <CVM:CapitalizedLeaseInterest contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">43543</CVM:CapitalizedLeaseInterest>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">611717</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-1187</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">312375</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">1448098</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">78553</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">42342</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DepreciationAndAmortization contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">159173</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">155417</us-gaap:DepreciationAndAmortization>
    <us-gaap:IncreaseDecreaseInDeposits contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">150000</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInDeposits contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">150000</us-gaap:IncreaseDecreaseInDeposits>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-314138</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-27773</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-96507</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-3765</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-85046</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-195871</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-1496</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">1506</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">17110</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">152920</us-gaap:IncreaseDecreaseInDueToOfficersAndStockholders>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">1550</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-59196</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">33344</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-75029</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-286984</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-4239206</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-2612858</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-959</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">2048</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">2282</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">3709931</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">2389395</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">3707883</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">2387113</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-531323</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-226704</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:InterestPaidNet contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">469366</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">433707</us-gaap:InterestPaidNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">75000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <CVM:IncreaseInPrepaidServices contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-18183</CVM:IncreaseInPrepaidServices>
    <CVM:IncreaseInPrepaidServices contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-16935</CVM:IncreaseInPrepaidServices>
    <CVM:IncreaseInDirectFinancingCosts contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">77987</CVM:IncreaseInDirectFinancingCosts>
    <CVM:IncreaseInDirectFinancingCosts contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">0</CVM:IncreaseInDirectFinancingCosts>
    <CVM:LiabilitiesAssumed contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">2316084</CVM:LiabilitiesAssumed>
    <CVM:LiabilitiesAssumed contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">0</CVM:LiabilitiesAssumed>
    <us-gaap:CapitalLeaseObligationsIncurred contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">26104</us-gaap:CapitalLeaseObligationsIncurred>
    <us-gaap:CapitalLeaseObligationsIncurred contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">0</us-gaap:CapitalLeaseObligationsIncurred>
    <CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">372</CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd>
    <CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">790</CVM:LeasePaymentsIncludedInAccountsPayableAtYearEnd>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">6813</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">6967</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">305341</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">38372</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">35880</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify; text-indent: 40pt"&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;The accompanying condensed financial&#13;statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included&#13;in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of&#13;America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of&#13;the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim&#13;condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&amp;#8217;s&#13;annual report on Form 10-K for the year ended September 30, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;In the opinion of management, the&#13;accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring&#13;nature) necessary for a fair presentation of the Company&amp;#8217;s financial position as of December 31, 2017 and the results of&#13;its operations for the three months then ended. The condensed balance sheet as of September 30, 2017 is derived from the September&#13;30, 2017 audited financial statements. Significant accounting policies have been consistently applied in the interim financial&#13;statements and the annual financial statements. The results of operations for the three months ended December 31, 2017 and 2016&#13;are not necessarily indicative of the results to be expected for the entire year.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;The financial statements have been&#13;prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity&#13;needs, there is substantial doubt about the Company&amp;#8217;s ability to continue as a going concern. The financial statements do&#13;not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;u&gt;Summary of Significant Accounting&#13;Policies:&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;i&gt;Research and Office Equipment&#13;and Leasehold Improvements&lt;/i&gt; - Research and office equipment is recorded at cost and depreciated using the straight-line method&#13;over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful&#13;life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when&#13;incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;i&gt;Patents&lt;/i&gt; - Patent expenditures&#13;are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of&#13;the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate&#13;adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted&#13;cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset.&#13;The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&#13;- Research and development costs are expensed as incurred. Management accrues CRO expenses and clinical trial study expenses based&#13;on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study.&#13;Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated&#13;expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;i&gt;Income Taxes&lt;/i&gt; - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability&#13;method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the&#13;financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss&#13;carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in&#13;the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and&#13;liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records&#13;a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. &amp;#160;A full&#13;valuation allowance was recorded against the deferred tax assets as of December 31, 2017 and September 30, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;On December&#13;22, 2017, the "Tax Cuts and Jobs Act" (the "Tax Act"), was signed into law by the President of the United States (U.S.). The&#13;Tax Act includes significant changes to corporate taxation, including reduction of the U.S. corporate tax rate from 35% to&#13;21%, effective January 1, 2018, limitation of the tax deduction for interest expense to 30% of earnings (execpt for&#13;certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and&#13;elimination of net operating loss carrybacks. The Company has accounted for certain income tax effects of the Act in applying&#13;FASB ASC 740 to the current reporting period. Because the Company records a valuation allowance for its entire deferred&#13;income tax asset, there was no impact to the amounts reported in the Companys&amp;#8217; financial statements resulting from the&#13;Tax Act.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;i&gt;Derivative Instruments&lt;/i&gt; &amp;#8211;&#13;The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative&#13;features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &amp;#8220;Accounting&#13;for Derivative Instruments and Hedging Activities.&amp;#8221; In accordance with accounting principles generally accepted in the United&#13;States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance&#13;sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the&#13;nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments&#13;based on available market data using appropriate valuation models giving consideration to all of the rights and obligations of&#13;each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;i&gt;Deferred Rent&lt;/i&gt;&amp;#8211; Certain&#13;of the Company&amp;#8217;s operating leases provide for minimum annual payments that adjust over the life of the lease.&amp;#160; The aggregate&#13;minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent&#13;liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent&#13;liability when the lease payments exceed the straight-line rent expense.&amp;#160; For tenant improvement allowances and rent holidays,&#13;the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;i&gt;Leases &amp;#8211;&lt;/i&gt; Leases are&#13;categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over&#13;the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of&#13;capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes&#13;an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural&#13;improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit&#13;leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance.&#13;If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on&#13;the Company's balance sheet.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt; &amp;#8211;&#13;Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of&#13;ASC 718 &amp;#8220;Compensation &amp;#8211; Stock Compensation.&amp;#8221; The fair value of stock options is calculated using the Black-Scholes&#13;option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option&#13;life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service&#13;or vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;Equity instruments issued to non-employees&#13;are accounted for in accordance with ASC 505-50, &amp;#8220;Equity-Based Payments to Non Employees.&amp;#8221; Accordingly, compensation&#13;is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model&#13;requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected&#13;life of the options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;The Company has Incentive Stock Option&#13;Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some&#13;cases, these Plans are collectively referred to as the &amp;#34;Plans&amp;#34;. All Plans have been approved by the stockholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;The Company&amp;#8217;s stock options&#13;are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess&#13;of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility&#13;on the variance of daily closing prices of the Company&amp;#8217;s stock. The risk-free interest rate assumption was based on the U.S.&#13;Treasury rate at date of the grant with term equal to the expected life of the option. Forfeitures are accounted for when they&#13;occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined&#13;based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly,&#13;stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;Vesting of restricted stock granted&#13;under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity&#13;awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria&#13;is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance&#13;criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;u&gt;New Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;In May 2017, the FASB issued ASU&#13;2017-09,&amp;#160;&lt;i&gt;Compensation &amp;#8211; Stock Compensation (Topic 718)&lt;/i&gt;, which affects any entity that changes the terms or conditions&#13;of a share-based payment award.&amp;#160; This Update amends the definition of modification by qualifying that modification accounting&#13;does not apply to changes to outstanding share-based payment awards that do not affect the total fair value, vesting requirements,&#13;or equity/liability classification of the awards.&amp;#160; The amendments in this Update are effective for all entities for annual&#13;periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including&#13;adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not&#13;yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available&#13;for issuance. The amendments in this Update should be applied prospectively to an award modified on or after the adoption date.&#13;The Company is currently evaluating the impact the adoption of the standard will have on the Company&amp;#8217;s financial position&#13;or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;In July 2017, the FASB issued ASU&#13;2017-11,&amp;#160;&lt;i&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivative and Hedging&#13;(Topic 815)&lt;/i&gt;. The amendments in Part I of this Update change the classification analysis of certain equity-linked financial&#13;instruments (or embedded features) with down-round features. When determining whether certain financial instruments should be classified&#13;as liabilities or equity instruments, a down-round feature no longer precludes equity classification when assessing whether the&#13;instrument is indexed to an entity&amp;#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified&#13;instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be&#13;accounted for as a derivative liability at fair value as a result of the existence of a down-round feature. For freestanding equity&#13;classified financial instruments, the amendments require entities that present earnings per share (&amp;#8220;EPS&amp;#8221;) in accordance&#13;with Topic 260 to recognize the effect of the down-round feature when it is triggered. That effect is treated as a dividend and&#13;as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options&#13;that have down-round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic&#13;470-20,&amp;#160;&lt;i&gt;Debt&amp;#8212;Debt with Conversion and Other Options&lt;/i&gt;), including related EPS guidance (in Topic 260). The amendments&#13;in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as&#13;pending content in the Accounting Standards Codification, to a scope exception. Those amendments do not have an accounting effect.&#13;For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within&#13;those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If&#13;an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal&#13;year that includes that interim period. The amendments in Part I of this Update should be applied either retrospectively to outstanding&#13;financial instruments with a down-round feature by means of a cumulative-effect adjustment to the statement of financial position&#13;as of the beginning of the first fiscal year and interim period(s) in which the pending content that links to this paragraph is&#13;effective or retrospectively to outstanding financial instruments with a down-round feature for each prior reporting period presented&#13;in accordance with the guidance on accounting changes in paragraphs 250-10-45-5 through 45-10. The amendments in Part II of this&#13;Update do not require any transition guidance because those amendments do not have an accounting effect.&amp;#160;The Company does&#13;not expect the adoption of this standard to have a significant impact on its EPS calculations, as it does not have any free-standing&#13;equity based financial instruments with down-round provisions.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;In August 2017, the FASB issued ASU&#13;2017-12,&amp;#160;&lt;i&gt;Derivatives and Hedging (Topic 850)&lt;/i&gt;, the objective of which is to improve the financial reporting of hedging&#13;relationships to better portray the economic results of an entity&amp;#8217;s risk management activities in its financial statements.&#13;In addition, the amendments in this Update make certain targeted improvements to simplify the application and disclosure of the&#13;hedge accounting guidance in current general accepted accounting principles.&amp;#160;&amp;#160;For public business entities, the amendments&#13;in&amp;#160;this Update are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&#13;For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods beginning&#13;after December 15, 2020. Early adoption is permitted in any period after issuance.&amp;#160;&amp;#160;For cash flow and net investment&#13;hedges existing at the date of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate&amp;#160;measurement&#13;of ineffectiveness to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained&#13;earnings as of the beginning of the fiscal year that an entity adopts the amendments in this Update. The amended presentation and&#13;disclosure guidance is required only prospectively.&amp;#160;&amp;#160;The Company is currently evaluating the impact the adoption of the&#13;standard will have on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;In February&#13;2016, the FASB issued ASU 2016-02,&amp;#160;&lt;i&gt;Leases&lt;/i&gt;, which will require most long-term leases to be recognized on the&#13;balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease.&#13;Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital&#13;lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal&#13;years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the&#13;modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating&#13;the effect of the new standard on its financial statements and related disclosures. The Company is currently evaluating the&#13;impact the adoptin of the standard will have on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;In March 2016, the FASB issued ASU&#13;2016-09 &lt;i&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/i&gt;. The&#13;guidance simplified the accounting and financial reporting of the income tax impact of share-based compensation arrangements. This&#13;guidance requires excess tax benefits to be recorded as a discrete item within income tax expense rather than additional paid-in-capital.&#13;In addition, excess tax benefits are required to be classified as cash from operating activities rather than cash from financing&#13;activities. The Company adopted the provisions of ASU 2016-09 effective October&amp;#160;1, 2017. The Company elected to apply the&#13;cash flow guidance of ASU 2016-09 retrospectively to all prior periods with no impact to historical periods. The Company also adopted&#13;a change in accounting policy to recognize forfeitures of awards as they occur instead of estimating potential forfeitures with&#13;no material impact on historical periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;The Company has considered all other&#13;recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact&#13;on its financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NatureOfOperations contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company has incurred significant&#13;costs since its inception for the acquisition of certain patented and unpatented proprietary technology and know-how relating to&#13;the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory&#13;facilities, and clinical trials.&amp;#160; The Company has funded such costs with proceeds from loans and the public and private sale&#13;of its common stock.&amp;#160; The Company will be required to raise additional capital or find additional long-term financing in order&#13;to continue with its research efforts.&amp;#160; To date, the Company has not generated any revenue from product sales. As a result,&#13;the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements&#13;and anticipates having to do so in the future.&amp;#160; The ability of the Company to complete the necessary clinical trials and obtain&#13;US Food &amp;#38; Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately,&#13;the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues&#13;to support its cost structure.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company is currently running&#13;a large multi-national Phase 3 clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma.&#13;During the three months ended December 31, 2017, the Company raised approximately $2.45 million net proceeds from a public offering.&#13;To finance the study beyond the next twelve months, the Company plans to raise additional capital in the form of corporate partnerships,&#13;debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so&#13;consistently in the past and because Multikine is a product in the Phase 3 clinical trial stage. However, there can be no assurance&#13;that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company&#13;on acceptable terms or at all.&amp;#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations&#13;until such time as it is able to raise the required funding. The financial statements have been prepared assuming the Company will&#13;continue as a going concern, but due to the Company&amp;#8217;s negative working capital, stockholders&amp;#8217; deficit, recurring losses&#13;from operations and future liquidity needs, there is substantial doubt about the Company&amp;#8217;s ability to continue as a going&#13;concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;Since the Company launched its Phase&#13;3 clinical trial for Multikine, the Company has incurred expenses of approximately $47.0 million as of December 31, 2017 on direct&#13;costs for the Phase 3 clinical trial. the Company estimates it will incur additional expenses of approximately $12.2 million for&#13;the remainder of the Phase 3 clinical trial. It should be noted that this estimate is based only on the information currently available&#13;in the Company&amp;#8217;s contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and&#13;does not include other related costs, e.g., the manufacturing of the drug. This number may be affected by the rate of death accumulation&#13;in the study, foreign currency exchange rates, and many other factors, some of which cannot be foreseen today. It is therefore&#13;possible that the cost of the Phase 3 clinical trial will be higher than currently estimated.&amp;#160;Nine hundred twenty-eight (928)&#13;head and neck cancer patients have been enrolled and have completed treatment in the Phase 3 study. The study end point is a 10%&#13;increase in overall survival of patients between the two main comparator groups in favor of the group receiving the Multikine treatment&#13;regimen. The determination if the study end point is met will occur when there are a total of 298 deaths in those two groups.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company&amp;#8217;s shareholders&#13;approved a reverse split of the Company&amp;#8217;s common stock which became effective on the NYSE American on June 15, 2017. On that&#13;date, every twenty-five issued and outstanding shares of the Company&amp;#8217;s common stock automatically converted into one outstanding&#13;share of common stock. As a result of the reverse stock split, the number of outstanding shares of common stock decreased from&#13;230,127,331 (pre-split) shares to 9,201,645 (post-split) shares. By reducing the number of outstanding shares, the Company&amp;#8217;s&#13;loss per share in all prior periods increased by a factor of twenty-five. The reverse stock split affected all stockholders of&#13;the Company&amp;#8217;s common stock uniformly, and did not affect any stockholder&amp;#8217;s percentage of ownership interest. The par&#13;value of the Company&amp;#8217;s stock remained unchanged at $0.01 per share&amp;#160;and the number of authorized shares of common stock&#13;remained the same after the reverse stock split.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <CVM:StockholdersEquityTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;Stock options, stock bonuses and&#13;compensation granted by the Company as of December 31, 2017 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Name of Plan&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total Shares Reserved Under Plans&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Reserved for Outstanding Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Issued&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Remaining Options/Shares Under Plans&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 48%"&gt;&lt;font style="font-size: 8pt"&gt;Incentive Stock Options Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;138,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;124,758&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;454&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Non-Qualified Stock Option Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,187,200&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,107,054&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;46,798&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Stock Bonus Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;383,760&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;222,574&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;161,153&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Stock Compensation Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;134,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;115,590&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;18,410&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Incentive Stock Bonus Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;640,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;624,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;Stock options, stock bonuses and&#13;compensation granted by the Company as of September 30, 2017 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; border-bottom: black 0.75pt solid"&gt;&lt;b&gt;Name of Plan&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total Shares Reserved Under Plans&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Reserved for Outstanding Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Issued&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Remaining Options/Shares Under Plans&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 48%"&gt;&lt;font style="font-size: 8pt"&gt;Incentive Stock Option Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;138,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;124,758&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;454&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Non-Qualified Stock Option Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,187,200&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,115,086&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,830&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Bonus Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;383,760&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;206,390&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;177,337&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Stock Compensation Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;134,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;115,590&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;18,410&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Incentive Stock Bonus Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;640,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;624,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;u&gt;Stock option activity&lt;/u&gt;:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Three Months Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,523&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,081&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;809&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"&gt;&lt;u&gt;Stock-Based Compensation Expense&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Three months Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 8pt"&gt;Employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,448,098&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;312,375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Non-employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,342&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;78,553&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;Employee compensation expense includes the expense related to options issued or vested and restricted stock. The increase&#13;in employee's expense in 2017 is primarily due to an increase of approximately $1.1 million in equity based compensation related&#13;to the Company's shareholder approved 2014 Incentive Stock Bonus Plan. Non&amp;#173;employee expense includes the expense related&#13;to options and stock issued to consultants expensed over the period of their service contracts. Stock based compensation expense&#13;is included in general and administrative expenses on the statements of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"&gt;&lt;u&gt;Warrants and Non-employee Options&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The following chart presents the&#13;outstanding warrants and non-employee options, listed by expiration date at December 31, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 15%; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 28%; border-bottom: black 1pt solid; padding-right: 18.75pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; border-bottom: black 1pt solid; padding-right: 7.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Issuable upon Exercise of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 1pt solid; padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Expiration Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Reference&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,360,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$4.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3/1/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,360,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$4.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3/1/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/18/2008&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;85,339&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/18/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series S&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/11/13- 10/24/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,037,120&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$31.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/11/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/28/2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;810,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$19.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5/28/2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/28/2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;688,930&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$16.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/28/2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series X&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1/13/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;120,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$9.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1/13/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Y&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/15/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;26,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/15/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5/18/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;264,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;11/23/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;68,048&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/1/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;680,480&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/23/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/16/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/14/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3/8/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series LL&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4/30/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;26,398&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;4/30/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series MM&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6/22/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;893,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$1.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;6/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series NN&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7/24/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;539,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.52&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;7/24/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series OO&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7/31/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;60,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.52&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;7/31/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series QQ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;87,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/23/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;400,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/23/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/14/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;600,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;9/14/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series RR&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/30/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;583,057&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$1.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/30/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/3/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;395,970&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;11/3/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series SS&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/19/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,289,478&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.09&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/18/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series PP&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/28/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,750,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/28/2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/30/15- 7/28/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;40,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.18- $25.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3/29/18- 7/27/27&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;1.&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Derivative Liabilities&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The table below presents the warrant&#13;liabilities and their respective balances at the balance sheet dates:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;December 31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;September 30, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Series S warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;19,705&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,773&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;171,225&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;72,912&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;213,221&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;83,754&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;132,751&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;77,216&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,096&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,753&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;112,447&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;65,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,953&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,322&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;591,041&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;394,220&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;65,201&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,154&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;457,305&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;342,173&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,676&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;690,442&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;511,636&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,745&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,203&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;460,747&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;345,720&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series LL warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;28,059&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,481&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total warrant liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,011,632&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,053,402&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"&gt;The table below presents the gains and (losses) on the&#13;warrant liabilities for the three months ended December 31:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Series S Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,068&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,621,321&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(98,313&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,417,721&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(129,467&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,667,604&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(55,535&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;868,787&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(3,343&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;63,884&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(47,360&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;679,569&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,631&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;52,672&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(196,821&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;604,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,483&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;370,919&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,483&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;514,603&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(18,047&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;66,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(115,132&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(5,662&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(178,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(8,542&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(115,027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Series LL warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(7,578&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Net (loss) gain on warrant liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(958,230&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,928,312&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: right; text-indent: -0.25in"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company reviews all outstanding&#13;warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate&#13;whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&amp;#8217;s&#13;contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain&#13;dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company&amp;#8217;s stock because&#13;future equity offerings or sales of the Company&amp;#8217;s stock are not an input to the fair value of a &amp;#8220;fixed-for-fixed&amp;#8221;&#13;option on equity shares, and equity classification is therefore precluded.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In accordance with ASC 815, derivative&#13;liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration.&#13;Any change in fair value between the respective reporting dates is recognized as a gain or loss.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;2. &lt;u&gt;Issuance of Equity Warrants&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Series SS Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;On December 19, 2017 the Company&#13;received subscription agreements for the purchase of 1,289,478 shares of CEL-SCI common stock at a price of $1.90 in the principal&#13;amount of $2.45 million.&amp;#160; The purchasers of the common stock also received Series SS warrants which entitle the purchasers&#13;to acquire up to 1,289,478 shares of the Company&amp;#8217;s common stock.&amp;#160;&amp;#160;The warrants are exercisable at a fixed price&#13;of $2.09 per share, are exercisable on June 20, 2018 and will expire on December 18, 2022. Shares issuable upon the exercise of&#13;the warrants will be restricted securities unless registered. The Company allocated the proceeds received to the shares and the&#13;Series SS warrants on a relative fair value basis. As a result of such allocation, the Company determined the initial carrying&#13;value of the Series SS warrants to be approximately $1.0 million. The Series SS warrants qualify for equity treatment in accordance&#13;with ASC 815.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Series RR Warrants&lt;/i&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;On October 30, 2017, holders of convertible&#13;notes in the principal amount of $1.1 million issued in June 2017 and holders of convertible notes in the principal amount of $1.2&#13;million issued in July 2017 agreed to extend the maturity date of these notes to September 21, 2018.&amp;#160;&amp;#160;In consideration&#13;for the extension of the maturity date of the convertible notes, the Company issued a total of 583,057 Series RR warrants to the&#13;convertible note holders that agreed to the extension.&amp;#160;&amp;#160;Each Series RR warrant entitles the holder to purchase one share&#13;of the Company&amp;#8217;s common stock.&amp;#160;&amp;#160;The Series RR warrants may be exercised at any time on or before October 30, 2022&#13;at an exercise price of $1.65 per share. The Series RR warrants were recorded at the fair value on the date of issuance of approximately&#13;$0.7 million, as described in Note F.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Expiration of Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;On October 17, 2017, 17,821 Series&#13;U warrants, with an exercise price of $43.75 expired. The fair value of the Series U warrants was $0 on the date of expiration.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;On December 6, 2016, 105,000 Series&#13;R warrants, with an exercise price of $100.00, expired. The fair value of the Series R warrants was $0 on the date of expiration.&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;font style="font-size: 8pt"&gt;3.&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt"&gt;&lt;font style="font-size: 8pt"&gt;&lt;u&gt;Options and shares issued to Consultants&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company typically enters into&#13;consulting arrangements in exchange for common stock or stock options. During the three months ended December 31, 2017, the Company&#13;issued 13,705 shares of common stock, of which 13,705 were restricted shares. During the three months ended December 31, 2016,&#13;the Company issued 14,900 shares of common stock, of which 10,800 were restricted shares. The weighted average grant value of the&#13;shares issued to consultants was $1.85 and $4.98 during the three months ended December 31, 2017 and 2016, respectively. The aggregate&#13;values of the issuances of restricted common stock and common stock options are recorded as prepaid expenses and are charged to&#13;general and administrative expenses over the periods of service.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;During the three months ended December&#13;31, 2017 and 2016, the Company recorded total expense of approximately $42,000 and $79,000, respectively, relating to these consulting&#13;agreements. At December 31, 2017 and September 30, 2017, approximately $28,000 and $45,000, respectively, are included in prepaid&#13;expenses. As of December 31, 2017, the Company had 40,000 options outstanding, which were issued to consultants as payment for&#13;services. All off these options were vested and all were issued from the Non-Qualified Stock Option plans.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Other Equity Transactions&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;On August 15, 2017, the Company entered&#13;into a Securities Purchase Agreement with Ergomed plc, the Company&amp;#8217;s Clinical Research Provider, to facilitate a partial&#13;payment of the accounts payable balances due Ergomed. Under the Agreement, the Company issued Ergomed 480,000 shares, with a fair&#13;market value of approximately $1.3 million, as a forbearance fee in exchange for Ergomed&amp;#8217;s agreement to provisionally forbear&#13;collection of the payables in an amount equal to the net proceeds from the resales of the shares issued to Ergomed. During the&#13;year ended September 30, 2017, the Company recorded the full amount of the expense upon issuance, offset by amounts realized through&#13;the resale of 64,792 shares and the corresponding reduction of the payables, for a net expense of $1.2 million. During the quarter&#13;ended December 31, 2017, the Company realized approximately $0.7 million through the resale of the remaining 415,208 shares and&#13;reduced the payables and interest expense by that amount.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</CVM:StockholdersEquityTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In accordance with ASC 820-10, &lt;i&gt;&amp;#8220;Fair&#13;Value Measurements,&amp;#8221;&lt;/i&gt; the Company determines fair value as the price that would be received to sell an asset or paid to&#13;transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies&#13;the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present&#13;amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;ASC 820-10 establishes a fair value&#13;hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for&#13;identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The&#13;Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy&#13;are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 60px; padding-left: 27pt; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Level 1 &amp;#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 60px; padding-left: 27pt; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Level 2 &amp;#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" style="width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 60px; padding-left: 27pt; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#9679;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Level 3 &amp;#8211; Unobservable inputs that reflect management&amp;#8217;s assumptions&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;For disclosure purposes, assets and&#13;liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant&#13;to the overall fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value&#13;measurement requires judgment and may affect the placement within the fair value hierarchy levels.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The table below sets forth the assets&#13;and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Other Observable Inputs (Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Derivative instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;19,705&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,991,927&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,011,632&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The table below sets forth the assets&#13;and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Other Observable Inputs (Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Derivative instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,773&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,020,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,053,402&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The following sets forth the reconciliation&#13;of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three&#13;months ended December 31, 2017 and the year ended September 30, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;3 months ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;12 months ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;December 31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;September 30, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Beginning balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,020,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Issuances&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,665,683&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Realized and unrealized losses and (gains)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;971,298&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(7,928,627&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Ending balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,991,927&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,020,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The fair values of the Company&amp;#8217;s&#13;derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such&#13;as historical price and volatility of the Company&amp;#8217;s stock, as well as U.S. Treasury Bill rates, are observable in active&#13;markets.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;On July 24, 2017, the Company issued&#13;convertible notes (Series NN Notes) in the aggregate principal amount of $1.2 million to 12 individual investors. A trust in which&#13;Geert Kersten, the Company&amp;#8217;s Chief Executive Officer, holds a beneficial interest participated in the offering and purchased&#13;a note in the principal amount of $250,000. Patricia B. Prichep, the Company&amp;#8217;s Senior Vice President of Operations, participated&#13;in the offering and purchased a note in the principal amount of $25,000. The terms of the trust&amp;#8217;s note and Ms. Prichep&amp;#8217;s&#13;note were identical to the other participants. The number of shares of the Company&amp;#8217;s common stock issued upon conversion&#13;will be determined by dividing the principal amount to be converted by $2.29, which would result in the issuance of 109,170 shares&#13;to the trust and 10,917 shares to Ms. Prichep upon conversion. Along with the other purchasers of the convertible notes, the trust&#13;and Ms. Prichep also received Series NN warrants to purchase up to 109,170 and 10,917 shares, respectively, of the Company&amp;#8217;s&#13;common stock. The Series NN warrants are exercisable at a fixed price of $2.52 per share and expire on July 24, 2022. Shares issuable&#13;upon the exercise of the notes and warrants were restricted securities unless registered. The shares were registered effective&#13;September 1, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;On June 22, 2017, CEL-SCI issued&#13;convertible notes (Series MM Notes) in the aggregate principal amount of $1.5 million to six individual investors. Geert Kersten,&#13;the Company&amp;#8217;s Chief Executive Officer, participated in the offering and purchased notes in the principal amount of $250,000.&#13;The terms of Mr. Kersten&amp;#8217;s note were identical to the other participants. The number of shares of the Company&amp;#8217;s common&#13;stock issued upon conversion will be determined by dividing the principal amount to be converted by $1.69, which would result in&#13;the issuance of 147,929 shares to Mr. Kersten upon conversion. Along with the other purchasers of the convertible notes, Mr. Kersten&#13;also received Series MM warrants to purchase up to 147,929 shares of the Company&amp;#8217;s common stock. The Series MM warrants are&#13;exercisable at a fixed price of $1.86 per share and expire on June 22, 2022. Shares issuable upon the exercise of the notes and&#13;warrants were restricted securities unless registered. The shares were registered effective August 8, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;On October 30, 2017, the due date&#13;of the Series NN and Series MM Notes was extended from December 22, 2017 to September 21, 2018 in exchange for Series RR warrants.&#13;Mr. Kersten, the Trust and Ms. Prichep received 73,965, 54,585 and 5,459 Series RR warrants, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;Approximately $6,000 in accrued interest was due the officers at December 31, 2017. No interest payments were made to officers&#13;during the three months ended December 31, 2017.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; color: #292929"&gt;&lt;i&gt;Clinical Research Agreements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In March 2013, the Company entered&#13;into an agreement with Aptiv Solutions, Inc. (which was subsequently acquired by ICON Inc.) to provide certain clinical research&#13;services in accordance with a master service agreement. The Company will reimburse ICON for costs incurred. The agreement required&#13;the Company to make $600,000 in advance payments which are being credited against future invoices in $150,000 annual increments&#13;through December 2017. As of December 31, 2017, all advance payments have been expensed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In April 2013, the Company entered&#13;into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million&#13;towards the Company&amp;#8217;s Phase 3 Clinical Trial in the form of offering discounted clinical services in exchange for a single&#13;digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into&#13;a second &lt;font style="color: #292929"&gt;co-development and revenue sharing agreement with Ergomed&lt;/font&gt; for an additional $2 million,&#13;for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808&#13;&amp;#8220;Collaborative Arrangements&amp;#8221;. The Company determined the payments to Ergomed are within the scope of ASC 730 &amp;#8220;Research&#13;and Development.&amp;#8221; Therefore, the Company records the discount on the clinical services as a credit to research and development&#13;expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed,&#13;it has incurred research and development expenses of approximately $25.9 million related to Ergomed&amp;#8217;s services. This amount&#13;is net of Ergomed&amp;#8217;s discount of approximately $8.6 million. During the three months ended December 31, 2017 and 2016, the&#13;Company recorded, net of Ergomed&amp;#8217;s discount, approximately $0.9 million and $1.3 million, respectively, as research and development&#13;expense related to Ergomed&amp;#8217;s services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company is currently involved&#13;in a pending arbitration proceeding, CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet GmbH&#13;(f/k/a PharmaNet AG). The Company initiated the proceedings against inVentiv Health Clinical, LLC, or inVentiv, the former third-party&#13;CRO, and is seeking payment for damages related to inVentiv&amp;#8217;s prior involvement in the Phase 3 clinical trial of Multikine.&#13;The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges (i) breach of contract,&#13;(ii) fraud in the inducement, and (iii) common law fraud. Currently, the Company is seeking at least $50 million in damages in&#13;its amended statement of claim.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In an amended statement of claim,&#13;the Company asserted the claims set forth above as well as an additional claim for professional malpractice.&amp;#160;&amp;#160;The arbitrator&#13;subsequently granted inVentiv&amp;#8217;s motion to dismiss the professional malpractice claim based on the &amp;#8220;economic loss doctrine&amp;#8221;&#13;which, under New Jersey law, is a legal doctrine that, under certain circumstances, prohibits bringing a negligence-based claim&#13;alongside a claim for breach of contract.&amp;#160;&amp;#160;The arbitrator denied the remainder of inVentiv&amp;#8217;s motion, which had&#13;sought to dismiss certain other aspects of the amended statement of claim.&amp;#160;&amp;#160;In particular, the arbitrator rejected inVentiv&amp;#8217;s&#13;argument that several aspects of the amended statement of claim were beyond the arbitrator&amp;#8217;s jurisdiction.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In connection with the pending arbitration&#13;proceedings, inVentiv has asserted counterclaims against the Company for (i) breach of contract, seeking at least $2 million in&#13;damages for services allegedly performed by inVentiv; (ii) breach of contract, seeking at least $1 million in damages for the alleged&#13;use of inVentiv&amp;#8217;s name in connection with publications and promotions in violation of the parties&amp;#8217; contract; (iii)&#13;opportunistic breach, restitution and unjust enrichment, seeking at least $20 million in disgorgement of alleged unjust profits&#13;allegedly made by the Company as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking&#13;at least $1 million in damages for allegedly defamatory statements made about inVentiv. The Company believes inVentiv&amp;#8217;s counterclaims&#13;are meritless&amp;#160;and has defended against them. However, if such defense is unsuccessful, and inVentiv successfully asserts any&#13;of its counterclaims, such an adverse determination could have a material adverse effect on the Company&amp;#8217;s business, results,&#13;financial condition and liquidity.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In October 2015 the Company signed&#13;an arbitration funding agreement with a company established by Lake Whillans Litigation Finance, LLC, a firm specializing in funding&#13;litigation expenses. Pursuant to the agreement, an affiliate of Lake Whillans provided the Company with up to $5 million in funding&#13;for litigation expenses to support its arbitration claims against inVentiv. The funding was available to the Company to fund the&#13;expenses of the ongoing arbitration and will only be repaid if the Company receives proceeds from the arbitration. All related&#13;legal fees are directly billed to and paid by Lake Whillans. As part of the agreement with Lake Whillans, the law firm agreed to&#13;cap its fees and expenses for the arbitration at $5 million.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The hearing (the&#13;&amp;#8220;trial&amp;#8221;) started on September 26, 2016. The last witness in the arbitration hearing testified on November 8,&#13;2017, and no further witnesses or testimony are expected. With that final witness, the testimony phase of the arbitration&#13;concluded. All that remained after November 8, 2017 at the trial level were closing statements and post&amp;#173;trial&#13;submissions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Lease Agreements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company leases a manufacturing&#13;facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&amp;#8217;s specifications&#13;so that it can be used by the Company to manufacture Multikine for the Company&amp;#8217;s Phase 3 clinical trial and sales of the&#13;drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%.&#13;The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs&#13;and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building&#13;at the end of the 20-year lease. The Company contributed approximately $9.3 million towards the tenant-directed improvements, of&#13;which $3.2 million is being refunded during years six through twenty through reduced rental payments. The landlord paid approximately&#13;$11.9 million towards the purchase of the building, land and the tenant-directed improvements. The Company placed the building&#13;in service in October 2008.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company was deemed to be the&#13;owner of the building for accounting purpose under the build-to-suit guidance in ASC 840-40-55. In addition to tenant improvements&#13;the Company incurred, the Company also recorded an asset for tenant-directed improvements and for the costs paid by the lessor&#13;to purchase the building and to perform improvements, as well as a corresponding liability for the landlord costs. Upon completion&#13;of the improvements, the Company did not meet the &amp;#8220;sale-leaseback&amp;#8221; criteria under ASC 840-40-25, Accounting for Lease,&#13;Sale-Leaseback Transactions, and therefore, treated the lease as a financing obligation. Thus, the asset and corresponding liability&#13;were not de-recognized. As of December 31, 2017 and September 30, 2017, the leased building asset has a net book value of approximately&#13;$16.5 and $16.6 million, respectively, and the landlord liability has a balance of approximately $13.3 and $13.2 million, respectively.&#13;The leased building is being depreciated using a straight line method over the 20 year lease term to a residual value. The landlord&#13;liability is being amortized over the 20 years using the effective interest method. Lease payments allocated to the landlord liability&#13;are accounted for as debt service payments on that liability using the finance method of accounting per ASC 840-40-55.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company was required to deposit&#13;the equivalent of one year of base rent in accordance with the lease. When the Company meets the minimum cash balance required&#13;by the lease, the deposit will be returned to the Company. The approximate $1.7 million deposit is included in non-current assets&#13;at December 31, 2016 and September 30, 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;Approximate future minimum&#13;lease payments under the San Tomas lease as of December 31, 2017 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Nine months ending September 30, 2018&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,314,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Year ending September 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,808,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,872,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,937,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,004,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,073,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;11,685,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Total future minimum lease obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,693,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Less imputed interest on financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(9,438,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Net present value of lease financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,255,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company subleases a portion of&#13;its rental space on a month-to-month term lease, which requires a 30 day notice for termination. The Company receives approximately&#13;$6,000 per month in rent for the sub-leased space.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company leases its research and&#13;development laboratory under a 60 month lease which expires February 28, 2022. The operating lease includes escalating rental payments.&#13;The Company is recognizing the related rent expense on a straight-line basis over the full 60 month term of the lease at the rate&#13;of approximately $13,000 per month. As of December 31, 2017 and September 30, 2017, the Company has recorded a deferred rent liability&#13;of approximately $8,000 and $5,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company leases its office headquarters&#13;under a 60 month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing&#13;the related rent expense on a straight line basis over the full 60 month term of the lease at the rate approximately $8,000 per&#13;month. As of December 31, 2017 and September 30, 2017, the Company has recorded a deferred rent liability of approximately $17,000&#13;and $18,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;As of December 31, 2017, material&#13;contractual obligations, excluding the San Tomas lease, consisting of non-cancelable operating lease payments are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;Nine months ending September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;189,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Year ending September 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;258,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;238,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;163,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;69,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;917,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company leases office equipment&#13;under a capital lease arrangement. The term of the capital lease is 60 months and expires on October 31, 2021. The monthly lease&#13;payment is $505. The lease bears interest at approximately 6.25% per annum.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;During the three months ended December&#13;31, 2017 and 2016, no patent impairment charges were recorded. For the three months ended December 31, 2017 and 2016, amortization&#13;of patent costs totaled approximately $9,000. Approximate estimated future amortization expense is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;Nine months ending September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;27,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Year ending September 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;35,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;29,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;52,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;215,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;following table provides the details of the basic and diluted earnings (loss) per-share computations:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Three&#13;    Months Ended December 31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Net&#13;    loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#13;    Average Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;LPS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic&#13;    and diluted loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(6,187,830)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11,636,730&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(0.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Three&#13;    Months Ended December 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Net&#13;    Income&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#13;    Average Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;EPS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 58%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic&#13;    earnings per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,521,153&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5,994,431&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Gain&#13;    on derivatives (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(1,556,754&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;90,277&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Dilutive&#13;    earnings per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,964,399&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6,084,708&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;(1)&#13;    Includes certain Series CC, DD, EE and FF warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;The&#13;gain on derivatives priced lower than the average market price during the period is excluded from the numerator and the related&#13;shares are excluded from the denominator in calculating diluted loss per share.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -20pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;In&#13;accordance with the contingently issuable shares guidance of FASB ASC Topic 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, the calculation of&#13;diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive&#13;as of December 31:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 74%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Options&#13;    and Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;10,491,090&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6,946,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Unvested&#13;    Restricted Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;332,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Convertible&#13;    debt&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,133,355&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11,956,945&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;7,550,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;As of January 1, 2018, the Company&#13;was indebted to Ergomed, plc for services provided by Ergomed in connection with the Company&amp;#8217;s Phase III clinical trial.&#13;On January 1, 2018 the Company agreed to issue Ergomed 660,000 restricted shares of the Company&amp;#8217;s common stock in partial&#13;payment of the amount the Company owed Ergomed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;On January 12, 2018, the exercise&#13;price of the Company&amp;#8217;s outstanding Series S warrants (CUSIP number 150837177), that are publicly traded under the symbol&#13;&amp;#8220;CVM WS&amp;#8221; on the NYSE American, was changed to $3.00 per share for a three month period which will end on April 12,&#13;2018. After this date, the exercise price will revert back to $31.25 per share of common stock. As a result of the reverse stock&#13;split which became effective on the NYSE American on June 15, 2017, 25 Series S warrants are required to purchase one share of&#13;common stock. The Series S warrants expire on October 11, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;On February 5, 2018, the Company&#13;received subscription agreements/commitments for the purchase of 2,608,097 shares of common stock at the closing price on February&#13;5, 2018 of $1.87 in the principal amount of $4,877,140 from 20 investors. The common stock is restricted unless registered. The&#13;purchasers of the common stock also received warrants which entitle the purchasers to acquire up to 1,956,074 shares of the Company&amp;#8217;s&#13;common stock. The warrants are exercisable at a fixed price of $2.24 per share, will not be exercisable for 6 months and one day&#13;and will expire on February 5, 2023. Shares issuable upon the exercise of the warrants are restricted securities unless registered.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -20pt; text-align: justify; text-indent: 0.25in"&gt;&lt;u&gt;Basis of Presentation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The accompanying condensed financial&#13;statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included&#13;in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of&#13;America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of&#13;the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim&#13;condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&amp;#8217;s&#13;annual report on Form 10-K for the year ended September 30, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In the opinion of management, the&#13;accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring&#13;nature) necessary for a fair presentation of the Company&amp;#8217;s financial position as of December 31, 2017 and the results of&#13;its operations for the three months then ended. The condensed balance sheet as of September 30, 2017 is derived from the September&#13;30, 2017 audited financial statements. Significant accounting policies have been consistently applied in the interim financial&#13;statements and the annual financial statements. The results of operations for the three months ended December 31, 2017 and 2016&#13;are not necessarily indicative of the results to be expected for the entire year.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The financial statements have been&#13;prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity&#13;needs, there is substantial doubt about the Company&amp;#8217;s ability to continue as a going concern. The financial statements do&#13;not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentImpairment contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Research and Office Equipment&#13;and Leasehold Improvements&lt;/i&gt; - Research and office equipment is recorded at cost and depreciated using the straight-line method&#13;over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful&#13;life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when&#13;incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Patents&lt;/i&gt; - Patent expenditures&#13;are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of&#13;the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate&#13;adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted&#13;cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset.&#13;The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&#13;- Research and development costs are expensed as incurred. Management accrues CRO expenses and clinical trial study expenses based&#13;on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study.&#13;Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated&#13;expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:DerivativesReportingOfDerivativeActivity contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Derivative Instruments&lt;/i&gt; &amp;#8211;&#13;The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative&#13;features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &amp;#8220;Accounting&#13;for Derivative Instruments and Hedging Activities.&amp;#8221; In accordance with accounting principles generally accepted in the United&#13;States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance&#13;sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the&#13;nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments&#13;based on available market data using appropriate valuation models giving consideration to all of the rights and obligations of&#13;each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DerivativesReportingOfDerivativeActivity>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Deferred Rent&lt;/i&gt;&amp;#8211; Certain&#13;of the Company&amp;#8217;s operating leases provide for minimum annual payments that adjust over the life of the lease.&amp;#160; The aggregate&#13;minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent&#13;liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent&#13;liability when the lease payments exceed the straight-line rent expense.&amp;#160; For tenant improvement allowances and rent holidays,&#13;the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Leases &amp;#8211;&lt;/i&gt; Leases are&#13;categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over&#13;the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of&#13;capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes&#13;an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural&#13;improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit&#13;leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance.&#13;If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on&#13;the Company's balance sheet.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt; &amp;#8211;&#13;Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of&#13;ASC 718 &amp;#8220;Compensation &amp;#8211; Stock Compensation.&amp;#8221; The fair value of stock options is calculated using the Black-Scholes&#13;option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option&#13;life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service&#13;or vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;Equity instruments issued to non-employees&#13;are accounted for in accordance with ASC 505-50, &amp;#8220;Equity-Based Payments to Non Employees.&amp;#8221; Accordingly, compensation&#13;is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model&#13;requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected&#13;life of the options.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company has Incentive Stock Option&#13;Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some&#13;cases, these Plans are collectively referred to as the &amp;#34;Plans&amp;#34;. All Plans have been approved by the stockholders.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company&amp;#8217;s stock options&#13;are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess&#13;of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility&#13;on the variance of daily closing prices of the Company&amp;#8217;s stock. The risk-free interest rate assumption was based on the U.S.&#13;Treasury rate at date of the grant with term equal to the expected life of the option. Forfeitures are accounted for when they&#13;occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined&#13;based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly,&#13;stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;Vesting of restricted stock granted&#13;under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity&#13;awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria&#13;is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance&#13;criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&lt;u&gt;New Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In May 2017, the FASB issued ASU&#13;2017-09,&amp;#160;&lt;i&gt;Compensation &amp;#8211; Stock Compensation (Topic 718)&lt;/i&gt;, which affects any entity that changes the terms or conditions&#13;of a share-based payment award.&amp;#160; This Update amends the definition of modification by qualifying that modification accounting&#13;does not apply to changes to outstanding share-based payment awards that do not affect the total fair value, vesting requirements,&#13;or equity/liability classification of the awards.&amp;#160; The amendments in this Update are effective for all entities for annual&#13;periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including&#13;adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not&#13;yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available&#13;for issuance. The amendments in this Update should be applied prospectively to an award modified on or after the adoption date.&#13;The Company is currently evaluating the impact the adoption of the standard will have on the Company&amp;#8217;s financial position&#13;or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In July 2017, the FASB issued ASU&#13;2017-11,&amp;#160;&lt;i&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivative and Hedging&#13;(Topic 815)&lt;/i&gt;. The amendments in Part I of this Update change the classification analysis of certain equity-linked financial&#13;instruments (or embedded features) with down-round features. When determining whether certain financial instruments should be classified&#13;as liabilities or equity instruments, a down-round feature no longer precludes equity classification when assessing whether the&#13;instrument is indexed to an entity&amp;#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified&#13;instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be&#13;accounted for as a derivative liability at fair value as a result of the existence of a down-round feature. For freestanding equity&#13;classified financial instruments, the amendments require entities that present earnings per share (&amp;#8220;EPS&amp;#8221;) in accordance&#13;with Topic 260 to recognize the effect of the down-round feature when it is triggered. That effect is treated as a dividend and&#13;as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options&#13;that have down-round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic&#13;470-20,&amp;#160;&lt;i&gt;Debt&amp;#8212;Debt with Conversion and Other Options&lt;/i&gt;), including related EPS guidance (in Topic 260). The amendments&#13;in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as&#13;pending content in the Accounting Standards Codification, to a scope exception. Those amendments do not have an accounting effect.&#13;For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within&#13;those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If&#13;an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal&#13;year that includes that interim period. The amendments in Part I of this Update should be applied either retrospectively to outstanding&#13;financial instruments with a down-round feature by means of a cumulative-effect adjustment to the statement of financial position&#13;as of the beginning of the first fiscal year and interim period(s) in which the pending content that links to this paragraph is&#13;effective or retrospectively to outstanding financial instruments with a down-round feature for each prior reporting period presented&#13;in accordance with the guidance on accounting changes in paragraphs 250-10-45-5 through 45-10. The amendments in Part II of this&#13;Update do not require any transition guidance because those amendments do not have an accounting effect.&amp;#160;The Company does&#13;not expect the adoption of this standard to have a significant impact on its EPS calculations, as it does not have any free-standing&#13;equity based financial instruments with down-round provisions.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In August 2017, the FASB issued ASU&#13;2017-12,&amp;#160;&lt;i&gt;Derivatives and Hedging (Topic 850)&lt;/i&gt;, the objective of which is to improve the financial reporting of hedging&#13;relationships to better portray the economic results of an entity&amp;#8217;s risk management activities in its financial statements.&#13;In addition, the amendments in this Update make certain targeted improvements to simplify the application and disclosure of the&#13;hedge accounting guidance in current general accepted accounting principles.&amp;#160;&amp;#160;For public business entities, the amendments&#13;in&amp;#160;this Update are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&#13;For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods beginning&#13;after December 15, 2020. Early adoption is permitted in any period after issuance.&amp;#160;&amp;#160;For cash flow and net investment&#13;hedges existing at the date of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate&amp;#160;measurement&#13;of ineffectiveness to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained&#13;earnings as of the beginning of the fiscal year that an entity adopts the amendments in this Update. The amended presentation and&#13;disclosure guidance is required only prospectively.&amp;#160;&amp;#160;The Company is currently evaluating the impact the adoption of the&#13;standard will have on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In February 2016, the FASB issued&#13;ASU 2016-02,&amp;#160;&lt;i&gt;Leases&lt;/i&gt;, which will require most long-term leases to be recognized on the balance sheet as an asset&#13;and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed&#13;using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current&#13;standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after&#13;December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified&#13;retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the effect&#13;of the new standard on its financial statements and related disclosures. The Company is currently evaluating the impact the&#13;adoption of the standard will have on the Company&amp;#8217;s financial position or results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;In March 2016, the FASB issued ASU&#13;2016-09 &lt;i&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/i&gt;. The&#13;guidance simplified the accounting and financial reporting of the income tax impact of share-based compensation arrangements. This&#13;guidance requires excess tax benefits to be recorded as a discrete item within income tax expense rather than additional paid-in-capital.&#13;In addition, excess tax benefits are required to be classified as cash from operating activities rather than cash from financing&#13;activities. The Company adopted the provisions of ASU 2016-09 effective October&amp;#160;1, 2017. The Company elected to apply the&#13;cash flow guidance of ASU 2016-09 retrospectively to all prior periods with no impact to historical periods. The Company also adopted&#13;a change in accounting policy to recognize forfeitures of awards as they occur instead of estimating potential forfeitures with&#13;no material impact on historical periods.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Company has considered all other&#13;recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact&#13;on its financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <CVM:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify; text-indent: -20pt"&gt;Stock options, stock bonuses and&#13;compensation granted by the Company as of December 31, 2017 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Name of Plan&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total Shares Reserved Under Plans&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Reserved for Outstanding Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Issued&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Remaining Options/Shares Under Plans&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 48%"&gt;&lt;font style="font-size: 8pt"&gt;Incentive Stock Options Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;138,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;124,758&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;454&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Non-Qualified Stock Option Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,187,200&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,107,054&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;46,798&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Stock Bonus Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;383,760&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;222,574&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;161,153&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Stock Compensation Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;134,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;115,590&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;18,410&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Incentive Stock Bonus Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;640,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;624,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify; text-indent: -20pt"&gt;Stock options, stock bonuses and&#13;compensation granted by the Company as of September 30, 2017 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&#13;        &lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; border-bottom: black 0.75pt solid"&gt;&lt;b&gt;Name of Plan&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total Shares Reserved Under Plans&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Reserved for Outstanding Options&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Issued&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Remaining Options/Shares Under Plans&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 48%"&gt;&lt;font style="font-size: 8pt"&gt;Incentive Stock Option Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;138,400&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;124,758&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;454&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Non-Qualified Stock Option Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,187,200&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,115,086&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,830&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Bonus Plans&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;383,760&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;206,390&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;177,337&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Stock Compensation Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;134,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;115,590&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;18,410&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Incentive Stock Bonus Plan&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;640,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;N/A&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;624,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Three Months Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 8pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;17,523&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,081&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;809&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;/p&gt;</CVM:ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2017-10-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Three months Ended December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 8pt"&gt;Employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,448,098&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 0%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;312,375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Non-employees&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;42,342&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;78,553&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <CVM:ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions contextRef="From2017-10-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 15%; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Warrant&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 28%; border-bottom: black 1pt solid; padding-right: 18.75pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Issue Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; border-bottom: black 1pt solid; padding-right: 7.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Shares Issuable upon Exercise of Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; border-bottom: black 1pt solid; padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Expiration Date&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Reference&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,360,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$4.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3/1/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,360,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$4.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3/1/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series N&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/18/2008&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;85,339&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/18/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series S&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/11/13- 10/24/14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,037,120&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$31.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/11/2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/28/2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;810,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$19.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5/28/2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/28/2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;688,930&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$16.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/28/2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series X&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1/13/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;120,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$9.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1/13/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;-&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Y&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/15/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;26,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$12.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/15/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;5/18/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/23/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;264,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;11/23/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;68,048&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/1/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;680,480&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/8/2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/23/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/16/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/26/2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;200,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$13.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/14/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3/8/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series LL&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4/30/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;26,398&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;4/30/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series MM&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6/22/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;893,491&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$1.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;6/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series NN&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7/24/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;539,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.52&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;7/24/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series OO&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7/31/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;60,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.52&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;7/31/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series QQ&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;87,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/22/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2/23/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;400,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;8/23/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/14/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;600,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;9/14/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series RR&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10/30/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;583,057&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$1.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;10/30/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5/3/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;395,970&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$3.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;11/3/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;1&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series SS&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;12/19/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,289,478&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.09&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;12/18/2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series PP&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8/28/2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,750,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.30&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;2/28/2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Consultants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3/30/15- 7/28/17&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;40,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: -4.5pt; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;$2.18- $25.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3/29/18- 7/27/27&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;3&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</CVM:ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions>
    <CVM:ScheduleOfDerivativeLiabilitiesAtFairValue contextRef="From2017-10-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;December 31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;September 30, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Series S warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;19,705&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,773&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;171,225&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;72,912&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;213,221&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;83,754&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;132,751&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;77,216&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,096&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,753&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;112,447&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;65,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,953&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,322&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;591,041&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;394,220&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;9&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;65,201&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;47,154&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;457,305&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;342,173&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;21,676&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;16,014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;690,442&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;511,636&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,745&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;24,203&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;460,747&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;345,720&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series LL warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;28,059&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;20,481&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total warrant liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,011,632&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,053,402&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</CVM:ScheduleOfDerivativeLiabilitiesAtFairValue>
    <CVM:ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock contextRef="From2017-10-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Series S Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,068&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,621,321&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series V warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(98,313&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,417,721&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series W warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(129,467&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,667,604&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series Z warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(55,535&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;868,787&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series ZZ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(3,343&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;63,884&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series AA warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(47,360&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;679,569&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series BB warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(2,631&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;52,672&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series CC warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(196,821&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;604,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series DD warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,483&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;370,919&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series EE warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,483&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;514,603&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series FF warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(18,047&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;66,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series GG warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(115,132&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series HH warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(5,662&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series II warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(178,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series JJ warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(8,542&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Series KK warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(115,027&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Series LL warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(7,578&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 8pt"&gt;Net (loss) gain on warrant liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(958,230&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;8,928,312&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</CVM:ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The table below sets forth the assets&#13;and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Other Observable Inputs (Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Derivative instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;19,705&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,991,927&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;3,011,632&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The table below sets forth the assets&#13;and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Other Observable Inputs (Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Significant Unobservable Inputs (Level 3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 48%"&gt;&lt;font style="font-size: 8pt"&gt;Derivative instruments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,773&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,020,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,053,402&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2017-10-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;3 months ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;12 months ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;December 31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;September 30, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Beginning balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,020,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;5,283,573&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Issuances&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;4,665,683&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Realized and unrealized losses and (gains)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;971,298&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(7,928,627&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Ending balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,991,927&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,020,629&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="From2017-10-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Nine months ending September 30, 2018&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,314,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Year ending September 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,808,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,872,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,937,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,004,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;2,073,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;11,685,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Total future minimum lease obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;22,693,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Less imputed interest on financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;(9,438,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 8pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;&amp;#160;Net present value of lease financing obligation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;13,255,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2017-10-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;Nine months ending September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;189,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Year ending September 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;258,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;238,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;163,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;69,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;917,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2017-10-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 87%"&gt;&lt;font style="font-size: 8pt"&gt;Nine months ending September 30, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;27,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Year ending September 30,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;35,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;32,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;29,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;25,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;15,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;52,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;215,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2017-10-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Three&#13;    Months Ended December 31, 2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Net&#13;    loss&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#13;    Average Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;LPS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic&#13;    and diluted loss per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(6,187,830)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;11,636,730&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(0.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Three&#13;    Months Ended December 31, 2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Net&#13;    Income&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#13;    Average Shares&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;b&gt;EPS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 58%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Basic&#13;    earnings per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;3,521,153&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;5,994,431&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 0%; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Gain&#13;    on derivatives (1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;(1,556,754&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;90,277&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;Dilutive&#13;    earnings per share&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;1,964,399&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;6,084,708&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;0.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="font: 8pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;(1)&#13;    Includes certain Series CC, DD, EE and FF warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 8pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;font style="font: 8pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2017-10-01to2017-12-31">&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;font style="font-size: 8pt"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 74%"&gt;&lt;font style="font-size: 8pt"&gt;Options and Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;10,491,090&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;6,946,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Unvested Restricted Stock&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;332,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;604,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Convertible debt&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;1,133,355&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1pt solid; text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 8pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;11,956,945&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 8pt"&gt;7,550,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-12-31_IncentiveStockOptionPlansMember29250218" unitRef="Shares" decimals="INF">454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-12-31_custom_NonQualifiedStockOptionPlansMember" unitRef="Shares" decimals="INF">46798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-12-31_StockBonusPlansMember29250281" unitRef="Shares" decimals="INF">161153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-12-31_StockCompensationPlanMember29250296" unitRef="Shares" decimals="INF">18410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-12-31_custom_IncentiveStockBonusPlansMember" unitRef="Shares" decimals="INF">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-09-30_custom_IncentiveStockOptionPlansMember" unitRef="Shares" decimals="INF">454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-09-30_custom_NonQualifiedStockOptionPlansMember29250250" unitRef="Shares" decimals="INF">42830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-09-30_custom_StockBonusPlansMember" unitRef="Shares" decimals="INF">177337</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-09-30_us-gaap_StockCompensationPlanMember" unitRef="Shares" decimals="INF">18410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2017-09-30_custom_IncentiveStockBonusPlansMember" unitRef="Shares" decimals="INF">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharesIssued contextRef="AsOf2017-12-31_IncentiveStockOptionPlansMember29250218" unitRef="Shares" decimals="INF">0</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2017-12-31_custom_NonQualifiedStockOptionPlansMember" unitRef="Shares" decimals="INF">0</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2017-12-31_StockBonusPlansMember29250281" unitRef="Shares" decimals="INF">222574</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2017-12-31_StockCompensationPlanMember29250296" unitRef="Shares" decimals="INF">115590</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2017-12-31_custom_IncentiveStockBonusPlansMember" unitRef="Shares" decimals="INF">624000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2017-09-30_custom_IncentiveStockOptionPlansMember" unitRef="Shares" decimals="INF">0</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2017-09-30_custom_NonQualifiedStockOptionPlansMember29250250" unitRef="Shares" decimals="INF">0</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2017-09-30_custom_StockBonusPlansMember" unitRef="Shares" decimals="INF">206390</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2017-09-30_us-gaap_StockCompensationPlanMember" unitRef="Shares" decimals="INF">115590</us-gaap:SharesIssued>
    <us-gaap:SharesIssued contextRef="AsOf2017-09-30_custom_IncentiveStockBonusPlansMember" unitRef="Shares" decimals="INF">624000</us-gaap:SharesIssued>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2017-12-31_IncentiveStockOptionPlansMember29250218" unitRef="Shares" decimals="INF">124758</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2017-12-31_custom_NonQualifiedStockOptionPlansMember" unitRef="Shares" decimals="INF">1107054</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2017-12-31_StockBonusPlansMember29250281" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2017-12-31_StockCompensationPlanMember29250296" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2017-12-31_custom_IncentiveStockBonusPlansMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2017-09-30_custom_IncentiveStockOptionPlansMember" unitRef="Shares" decimals="INF">124758</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2017-09-30_custom_NonQualifiedStockOptionPlansMember29250250" unitRef="Shares" decimals="INF">1115086</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2017-09-30_custom_StockBonusPlansMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2017-09-30_us-gaap_StockCompensationPlanMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="AsOf2017-09-30_custom_IncentiveStockBonusPlansMember" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-12-31_IncentiveStockOptionPlansMember29250218" unitRef="Shares" decimals="INF">138400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-12-31_custom_NonQualifiedStockOptionPlansMember" unitRef="Shares" decimals="INF">1187200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-12-31_StockBonusPlansMember29250281" unitRef="Shares" decimals="INF">383760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-12-31_StockCompensationPlanMember29250296" unitRef="Shares" decimals="INF">134000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-12-31_custom_IncentiveStockBonusPlansMember" unitRef="Shares" decimals="INF">640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-09-30_custom_IncentiveStockOptionPlansMember" unitRef="Shares" decimals="INF">138400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-09-30_custom_NonQualifiedStockOptionPlansMember29250250" unitRef="Shares" decimals="INF">1187200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-09-30_custom_StockBonusPlansMember" unitRef="Shares" decimals="INF">383760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-09-30_us-gaap_StockCompensationPlanMember" unitRef="Shares" decimals="INF">134000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2017-09-30_custom_IncentiveStockBonusPlansMember" unitRef="Shares" decimals="INF">640000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-10-01to2016-12-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-10-01to2017-12-31" unitRef="Shares" decimals="INF">10300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2016-10-01to2016-12-31" unitRef="Shares" decimals="INF">15081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2017-10-01to2017-12-31" unitRef="Shares" decimals="INF">17523</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2016-10-01to2016-12-31" unitRef="Shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2017-10-01to2017-12-31" unitRef="Shares" decimals="INF">809</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">312375</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">1448098</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <CVM:NonemployeesShareBasedCompensation contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">78553</CVM:NonemployeesShareBasedCompensation>
    <CVM:NonemployeesShareBasedCompensation contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">42342</CVM:NonemployeesShareBasedCompensation>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesWMember" unitRef="Shares" decimals="INF">688930</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesVMember" unitRef="Shares" decimals="INF">810127</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_ConsultantsMember" unitRef="Shares" decimals="INF">40000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesSMember" unitRef="Shares" decimals="INF">1037120</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesXMember" unitRef="Shares" decimals="INF">120000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesYMember" unitRef="Shares" decimals="INF">26000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesNMember" unitRef="Shares" decimals="INF">85339</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesDdMember" unitRef="Shares" decimals="INF">1360960</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesEeMember" unitRef="Shares" decimals="INF">1360960</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesZMember" unitRef="Shares" decimals="INF">264000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesZzMember" unitRef="Shares" decimals="INF">20000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesBbMember" unitRef="Shares" decimals="INF">16000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesFfMember" unitRef="Shares" decimals="INF">68048</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesCcMember" unitRef="Shares" decimals="INF">680480</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesAaMember" unitRef="Shares" decimals="INF">200000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesHhMember" unitRef="Shares" decimals="INF">20000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesJjMember" unitRef="Shares" decimals="INF">30000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesGgMember" unitRef="Shares" decimals="INF">400000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesIiMember" unitRef="Shares" decimals="INF">600000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesLlMember" unitRef="Shares" decimals="INF">26398</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesMmMember" unitRef="Shares" decimals="INF">893491</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesKkMember" unitRef="Shares" decimals="INF">395970</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesNnMember" unitRef="Shares" decimals="INF">539300</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesOoMember" unitRef="Shares" decimals="INF">60000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesQqMember" unitRef="Shares" decimals="INF">87500</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesRrMember" unitRef="Shares" decimals="INF">583057</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesSsMember" unitRef="Shares" decimals="INF">1289478</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:SharesIssuableUponExerciseOfwarrant contextRef="AsOf2017-12-31_custom_SeriesPpMember" unitRef="Shares" decimals="INF">1750000</CVM:SharesIssuableUponExerciseOfwarrant>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesWMember" unitRef="USDPShares" decimals="INF">16.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesVMember" unitRef="USDPShares" decimals="INF">19.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesSMember" unitRef="USDPShares" decimals="INF">31.25</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesXMember" unitRef="USDPShares" decimals="INF">9.25</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesYMember" unitRef="USDPShares" decimals="INF">12.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesNMember" unitRef="USDPShares" decimals="INF">3.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesDdMember" unitRef="USDPShares" decimals="INF">4.50</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesEeMember" unitRef="USDPShares" decimals="INF">4.50</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesZMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesZzMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesBbMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesFfMember" unitRef="USDPShares" decimals="INF">3.91</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesCcMember" unitRef="USDPShares" decimals="INF">5.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesAaMember" unitRef="USDPShares" decimals="INF">13.75</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesHhMember" unitRef="USDPShares" decimals="INF">3.13</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesJjMember" unitRef="USDPShares" decimals="INF">3.13</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesGgMember" unitRef="USDPShares" decimals="INF">3.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesIiMember" unitRef="USDPShares" decimals="INF">3.00</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesLlMember" unitRef="USDPShares" decimals="INF">3.59</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesMmMember" unitRef="USDPShares" decimals="INF">1.86</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesKkMember" unitRef="USDPShares" decimals="INF">3.04</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesNnMember" unitRef="USDPShares" decimals="INF">2.52</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesOoMember" unitRef="USDPShares" decimals="INF">2.52</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesQqMember" unitRef="USDPShares" decimals="INF">2.50</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesRrMember" unitRef="USDPShares" decimals="INF">1.65</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesSsMember" unitRef="USDPShares" decimals="INF">2.09</CVM:ExercisePrice>
    <CVM:ExercisePrice contextRef="AsOf2017-12-31_custom_SeriesPpMember" unitRef="USDPShares" decimals="INF">2.30</CVM:ExercisePrice>
    <CVM:ExercisePriceMinimum contextRef="AsOf2017-12-31_ConsultantsMember" unitRef="USDPShares" decimals="INF">2.18</CVM:ExercisePriceMinimum>
    <CVM:ExercisePriceMaximum contextRef="AsOf2017-12-31_ConsultantsMember" unitRef="USDPShares" decimals="INF">25.50</CVM:ExercisePriceMaximum>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_SeriesNMember">8/18/2018</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_ConsultantsMember">3/29/18- 7/27/27</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesSMember">10/11/2018</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesVMember">5/28/2020</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesWMember">10/28/2020</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesYMember">2/15/2021</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesXMember">1/13/2021</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesDdMember">3/1/2018</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesEeMember">3/1/2018</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesZMember">11/23/2021</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesZzMember">5/18/2021</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesBbMember">8/22/2021</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesFfMember">12/1/2021</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesCcMember">12/8/2021</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesAaMember">2/22/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesHhMember">2/16/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesJjMember">3/8/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesGgMember">8/23/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesIiMember">9/14/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesLlMember">4/30/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesMmMember">6/22/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesKkMember">11/3/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesNnMember">7/24/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesOoMember">7/31/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesQqMember">8/22/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesRrMember">10/30/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesSsMember">12/18/2022</CVM:ExpirationDate>
    <CVM:ExpirationDate contextRef="From2017-10-01to2017-12-31_custom_SeriesPpMember">2/28/2023</CVM:ExpirationDate>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_SeriesNMember">8/18/2008</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_ConsultantsMember">3/30/15- 7/28/17</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesSMember">10/11/13- 10/24/14</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesVMember">5/28/2015</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesWMember">10/28/2015</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesYMember">2/15/2016</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesXMember">1/13/2016</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesDdMember">12/8/2016</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesEeMember">12/8/2016</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesZMember">5/23/2016</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesZzMember">5/23/2016</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesBbMember">8/26/2016</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesFfMember">12/8/2016</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesCcMember">12/8/2016</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesAaMember">8/26/2016</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesHhMember">2/23/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesJjMember">3/14/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesGgMember">2/23/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesIiMember">3/14/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesLlMember">4/30/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesMmMember">6/22/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesKkMember">5/3/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesNnMember">7/24/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesOoMember">7/31/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesQqMember">8/22/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesRrMember">10/30/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesSsMember">12/19/2017</CVM:IssueDate1>
    <CVM:IssueDate1 contextRef="From2017-10-01to2017-12-31_custom_SeriesPpMember">8/28/2017</CVM:IssueDate1>
    <CVM:TotalFairValueOfDerivativeLiabilities contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">3011632</CVM:TotalFairValueOfDerivativeLiabilities>
    <CVM:TotalFairValueOfDerivativeLiabilities contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">2053402</CVM:TotalFairValueOfDerivativeLiabilities>
    <CVM:FairValueOfSeriesLlWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">28059</CVM:FairValueOfSeriesLlWarrants>
    <CVM:FairValueOfSeriesLlWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">20481</CVM:FairValueOfSeriesLlWarrants>
    <CVM:FairValueOfSeriesKkWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">460747</CVM:FairValueOfSeriesKkWarrants>
    <CVM:FairValueOfSeriesKkWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">345720</CVM:FairValueOfSeriesKkWarrants>
    <CVM:FairValueOfSeriesJjWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">32745</CVM:FairValueOfSeriesJjWarrants>
    <CVM:FairValueOfSeriesJjWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">24203</CVM:FairValueOfSeriesJjWarrants>
    <CVM:FairValueOfSeriesIiWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">690442</CVM:FairValueOfSeriesIiWarrants>
    <CVM:FairValueOfSeriesIiWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">511636</CVM:FairValueOfSeriesIiWarrants>
    <CVM:FairValueOfSeriesHhWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">21676</CVM:FairValueOfSeriesHhWarrants>
    <CVM:FairValueOfSeriesHhWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">16014</CVM:FairValueOfSeriesHhWarrants>
    <CVM:FairValueOfSeriesGgWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">457305</CVM:FairValueOfSeriesGgWarrants>
    <CVM:FairValueOfSeriesGgWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">342173</CVM:FairValueOfSeriesGgWarrants>
    <CVM:FairValueOfSeriesFfWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">65201</CVM:FairValueOfSeriesFfWarrants>
    <CVM:FairValueOfSeriesFfWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">47154</CVM:FairValueOfSeriesFfWarrants>
    <CVM:FairValueOfSeriesEeWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">9</CVM:FairValueOfSeriesEeWarrants>
    <CVM:FairValueOfSeriesEeWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">5492</CVM:FairValueOfSeriesEeWarrants>
    <CVM:FairValueOfSeriesDdWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">9</CVM:FairValueOfSeriesDdWarrants>
    <CVM:FairValueOfSeriesDdWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">5492</CVM:FairValueOfSeriesDdWarrants>
    <CVM:FairValueOfSeriesCcWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">591041</CVM:FairValueOfSeriesCcWarrants>
    <CVM:FairValueOfSeriesCcWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">394220</CVM:FairValueOfSeriesCcWarrants>
    <CVM:FairValueOfSeriesBbWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">6953</CVM:FairValueOfSeriesBbWarrants>
    <CVM:FairValueOfSeriesBbWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">4322</CVM:FairValueOfSeriesBbWarrants>
    <CVM:FairValueOfSeriesAaWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">112447</CVM:FairValueOfSeriesAaWarrants>
    <CVM:FairValueOfSeriesAaWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">65087</CVM:FairValueOfSeriesAaWarrants>
    <CVM:FairValueOfSeriesZzWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">8096</CVM:FairValueOfSeriesZzWarrants>
    <CVM:FairValueOfSeriesZzWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">4753</CVM:FairValueOfSeriesZzWarrants>
    <CVM:FairValueOfSeriesZwarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">132751</CVM:FairValueOfSeriesZwarrants>
    <CVM:FairValueOfSeriesZwarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">77216</CVM:FairValueOfSeriesZwarrants>
    <CVM:FairValueOfSeriesWWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">213221</CVM:FairValueOfSeriesWWarrants>
    <CVM:FairValueOfSeriesWWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">83754</CVM:FairValueOfSeriesWWarrants>
    <CVM:FairValueOfSeriesVWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">171225</CVM:FairValueOfSeriesVWarrants>
    <CVM:FairValueOfSeriesVWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">72912</CVM:FairValueOfSeriesVWarrants>
    <CVM:FairValueOfSeriesSWarrants contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">19705</CVM:FairValueOfSeriesSWarrants>
    <CVM:FairValueOfSeriesSWarrants contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">32773</CVM:FairValueOfSeriesSWarrants>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">8928312</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-958230</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <CVM:GainLossSeriesLlWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</CVM:GainLossSeriesLlWarrants>
    <CVM:GainLossSeriesLlWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-7578</CVM:GainLossSeriesLlWarrants>
    <CVM:GainLossSeriesKkWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</CVM:GainLossSeriesKkWarrants>
    <CVM:GainLossSeriesKkWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-115027</CVM:GainLossSeriesKkWarrants>
    <CVM:GainLossSeriesJjWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</CVM:GainLossSeriesJjWarrants>
    <CVM:GainLossSeriesJjWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-8542</CVM:GainLossSeriesJjWarrants>
    <CVM:GainLossSeriesIiWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</CVM:GainLossSeriesIiWarrants>
    <CVM:GainLossSeriesIiWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-178806</CVM:GainLossSeriesIiWarrants>
    <CVM:GainLossSeriesHhWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</CVM:GainLossSeriesHhWarrants>
    <CVM:GainLossSeriesHhWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-5662</CVM:GainLossSeriesHhWarrants>
    <CVM:GainLossSeriesGgWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</CVM:GainLossSeriesGgWarrants>
    <CVM:GainLossSeriesGgWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-115132</CVM:GainLossSeriesGgWarrants>
    <CVM:GainLossSeriesFfWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">66740</CVM:GainLossSeriesFfWarrants>
    <CVM:GainLossSeriesFfWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-18047</CVM:GainLossSeriesFfWarrants>
    <CVM:GainLossSeriesEeWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">514603</CVM:GainLossSeriesEeWarrants>
    <CVM:GainLossSeriesEeWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">5483</CVM:GainLossSeriesEeWarrants>
    <CVM:GainLossSeriesDdWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">370919</CVM:GainLossSeriesDdWarrants>
    <CVM:GainLossSeriesDdWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">5483</CVM:GainLossSeriesDdWarrants>
    <CVM:GainLossSeriesCcWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">604492</CVM:GainLossSeriesCcWarrants>
    <CVM:GainLossSeriesCcWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-196821</CVM:GainLossSeriesCcWarrants>
    <CVM:GainLossSeriesBbWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">52672</CVM:GainLossSeriesBbWarrants>
    <CVM:GainLossSeriesBbWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-2631</CVM:GainLossSeriesBbWarrants>
    <CVM:GainLossSeriesAaWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">679569</CVM:GainLossSeriesAaWarrants>
    <CVM:GainLossSeriesAaWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-47360</CVM:GainLossSeriesAaWarrants>
    <CVM:GainLossSeriesZzWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">63884</CVM:GainLossSeriesZzWarrants>
    <CVM:GainLossSeriesZzWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-3343</CVM:GainLossSeriesZzWarrants>
    <CVM:GainLossSeriesZWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">868787</CVM:GainLossSeriesZWarrants>
    <CVM:GainLossSeriesZWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-55535</CVM:GainLossSeriesZWarrants>
    <CVM:GainLossSeriesWWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">1667604</CVM:GainLossSeriesWWarrants>
    <CVM:GainLossSeriesWWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-129467</CVM:GainLossSeriesWWarrants>
    <CVM:GainLossSeriesVWarrants contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">1417721</CVM:GainLossSeriesVWarrants>
    <CVM:GainLossSeriesVWarrants contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">-98313</CVM:GainLossSeriesVWarrants>
    <CVM:GainLossSeriesSWarrant contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">2621321</CVM:GainLossSeriesSWarrant>
    <CVM:GainLossSeriesSWarrant contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">13068</CVM:GainLossSeriesSWarrant>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2016-10-01to2016-12-31" unitRef="Shares" decimals="INF">14900</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-10-01to2017-12-31" unitRef="Shares" decimals="INF">13705</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">3011632</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">2053402</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-12-31_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">19705</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-12-31_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">2991927</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_us-gaap_FairValueInputsLevel1Member" unitRef="USD" decimals="0">32773</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_us-gaap_FairValueInputsLevel2Member" unitRef="USD" decimals="0">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="AsOf2017-09-30_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">2020629</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">2991927</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2017-09-30" unitRef="USD" decimals="0">2020629</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="AsOf2016-09-30" unitRef="USD" decimals="0">5283573</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">4665683</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">971298</us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings contextRef="From2016-10-01to2017-09-30" unitRef="USD" decimals="0">-7928627</us-gaap:FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings>
    <us-gaap:InterestExpenseRelatedParty contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">0</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2017-10-01to2017-12-31" unitRef="Shares" decimals="INF">32751</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">13255000</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">9438000</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">22693000</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">11685000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">2073000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">2004000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1937000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1872000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1808000</us-gaap:CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1314000</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">69000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">163000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">238000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">258000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">189000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">917000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2017-12-31_custom_HeadquartersMember" unitRef="USD" decimals="0">17000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2017-09-30_custom_HeadquartersMember" unitRef="USD" decimals="0">18000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2017-12-31_custom_ResearchAndDevelopmentLabMember" unitRef="USD" decimals="0">8000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2017-09-30_custom_ResearchAndDevelopmentLabMember" unitRef="USD" decimals="0">5000</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">27000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">35000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">32000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">29000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">15000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">15000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">52000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">9000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">9000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-10-01to2016-12-31" unitRef="Shares" decimals="INF">7550179</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-10-01to2017-12-31" unitRef="Shares" decimals="INF">11956945</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-10-01to2017-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">10491090</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-10-01to2016-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">6946179</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-10-01to2017-12-31_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">332000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-10-01to2016-12-31_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">604000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-10-01to2017-12-31_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="Shares" decimals="INF">1133355</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2016-10-01to2016-12-31_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="Shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-10-01to2017-12-31" unitRef="Shares" decimals="INF">11636730</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-10-01to2017-12-31" unitRef="USDPShares" decimals="INF">-.53</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">3521153</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">-1556754</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">1964399</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="From2016-10-01to2016-12-31" unitRef="Shares" decimals="INF">90277</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;On October 30, 2017, the Company&#13;extended the due dates of the Series MM and Series NN Notes (the &amp;#8220;Notes&amp;#8221;) from December 22, 2017 to September 2l, 20l8,&#13;and issued the note holders an additional 583,057 of Series RR Warrants. The Series RR warrants expire on October 30, 2022 and&#13;are priced at $ 1.65 per share, the closing price on October 27, 2017. These Series RR warrants are classified as equity warrants&#13;and are recorded at approximately $0.7 million, the fair value on the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;Because the Company is experiencing&#13;financial difficulties and the creditors granted the Company a concession they would not have otherwise considered in the form&#13;of a lower effective interest rate, this modification was accounted for under ASC 470-60, &amp;#8220;&lt;i&gt;Troubled Debt Restructuring.&lt;/i&gt;&amp;#8221;&#13;The Company calculated the future cash flows of the restructured debt to be greater than the carrying value of the debt and accounted&#13;for the change in debt prospectively, using the effective interest rate that equated the carrying amount to the future cash flows.&#13;The carrying value of the debt on the date of restructuring was approximately $0.7 million, which was net of a discount of approximately&#13;$1.6 million. The discount is being amortized to interest expense over the life of the Notes using the effective interest method.&#13;The Company recorded approximately $0.6 million in interest expense, relating to the amortization of the debt discount. As of December&#13;31, 2017, after conversions, the carrying value of the Notes is approximately $0.9 million, net of a discount of approximately&#13;$1.3 million. The Notes bear interest at 4% and are convertible in shares of common stock. At the option of the note holders, the&#13;Notes can be converted into shares of the Company&amp;#8217;s common stock at a fixed conversion rate of $1.69 for the Series MM Notes&#13;and $2.29 for the Series NN Notes.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;During the quarter ended December&#13;31, 2017, a note holder converted a Series NN note, in the principal amount of $75,000, into 32,751 shares of common stock. The&#13;unamortized debt discount relating to the converted Note was charged to interest expense.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"&gt;The Series MM and Series NN Notes&#13;are secured by a first lien on all of the Company&amp;#8217;s assets.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:OtherIncome contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">17258</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">113897</us-gaap:OtherIncome>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2016-10-01to2016-12-31" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2017-10-01to2017-12-31" unitRef="USD" decimals="0">959</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2017-10-01to2017-12-31">&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;i&gt;Income Taxes&lt;/i&gt; - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability&#13;method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the&#13;financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss&#13;carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in&#13;the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and&#13;liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records&#13;a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. &amp;#160;A full&#13;valuation allowance was recorded against the deferred tax assets as of December 31, 2017 and September 30, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"&gt;On December&#13;22, 2017, the "Tax Cuts and Jobs Act" (the "Tax Act"), was signed into law by the President of the United States (U.S.). The&#13;Tax Act includes significant changes to corporate taxation, including reduction of the U.S. corporate tax rate from 35% to&#13;21%, effective January 1, 2018, limitation of the tax deduction for interest expense to 30% of earnings (execpt for&#13;certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and&#13;elimination of net operating loss carrybacks. The Company has accounted for certain income tax effects of the Act in applying&#13;FASB ASC 740 to the current reporting period. Because the Company records a valuation allowance for its entire deferred&#13;income tax asset, there was no impact to the amounts reported in the Companys&amp;#8217; financial statements resulting from the&#13;Tax Act.&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cvm-20170630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 173321 12312017 10Q1.xfr; Date: 2018%2D02%2D09T15:11:46Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6kps7xRiXgen8uKYXQsSaaFmaPtxZp8iZlBuWp+belqTyAiXlWm1yIYH+dmsU4G -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:CVM="http://cel-sci.com/20170630" elementFormDefault="qualified" targetNamespace="http://cel-sci.com/20170630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000005 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
	  <link:definition>00000006 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/B.OperationsAndFinancing" id="B.OperationsAndFinancing">
	  <link:definition>00000007 - Disclosure - B. OPERATIONS AND FINANCING</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/C.StockholdersEquity" id="C.StockholdersEquity">
	  <link:definition>00000008 - Disclosure - C. STOCKHOLDERS EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/D.FairValueMeasurements" id="D.FairValueMeasurements">
	  <link:definition>00000009 - Disclosure - D. FAIR VALUE MEASUREMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/E.RelatedPartyTransactions" id="E.RelatedPartyTransactions">
	  <link:definition>00000010 - Disclosure - E. RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/F.NotesPayable" id="F.NotesPayable">
	  <link:definition>00000011 - Disclosure - F. NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/G.CommitmentsAndContingencies" id="G.CommitmentsAndContingencies">
	  <link:definition>00000012 - Disclosure - G. COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/H.Patents" id="H.Patents">
	  <link:definition>00000013 - Disclosure - H. PATENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShare" id="I.EarningsLossPerCommonShare">
	  <link:definition>00000014 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/J.SubsequentEvents" id="J.SubsequentEvents">
	  <link:definition>00000015 - Disclosure - J. SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000016 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/C.StockholdersEquityTables" id="C.StockholdersEquityTables">
	  <link:definition>00000017 - Disclosure - C. STOCKHOLDERS EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/D.FairValueMeasurementsTables" id="D.FairValueMeasurementsTables">
	  <link:definition>00000018 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesTables" id="G.CommitmentsAndContingenciesTables">
	  <link:definition>00000019 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/H.PatentsTables" id="H.PatentsTables">
	  <link:definition>00000020 - Disclosure - H. PATENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareTables" id="I.EarningsLossPerCommonShareTables">
	  <link:definition>00000021 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails" id="C.StockholdersEquityDetails">
	  <link:definition>00000022 - Disclosure - C. STOCKHOLDERS EQUITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails1" id="C.StockholdersEquityDetails1">
	  <link:definition>00000023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails2" id="C.StockholdersEquityDetails2">
	  <link:definition>00000024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails3" id="C.StockholdersEquityDetails3">
	  <link:definition>00000025 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails4" id="C.StockholdersEquityDetails4">
	  <link:definition>00000026 - Disclosure - C. STOCKHOLDERS EQUITY (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/C.StockholdersEquityDetailsNarrative" id="C.StockholdersEquityDetailsNarrative">
	  <link:definition>00000027 - Disclosure - C. STOCKHOLDERS EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/D.FairValueMeasurementsDetails" id="D.FairValueMeasurementsDetails">
	  <link:definition>00000028 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/D.FairValueMeasurementsDetails1" id="D.FairValueMeasurementsDetails1">
	  <link:definition>00000029 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/E.RelatedPartyLoanDetailsNarrative" id="E.RelatedPartyLoanDetailsNarrative">
	  <link:definition>00000030 - Disclosure - E. RELATED PARTY LOAN (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/F.NotesPayableDetailsNarrative" id="F.NotesPayableDetailsNarrative">
	  <link:definition>00000031 - Disclosure - F. NOTES PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails" id="G.CommitmentsAndContingenciesDetails">
	  <link:definition>00000032 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails1" id="G.CommitmentsAndContingenciesDetails1">
	  <link:definition>00000033 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetailsNarrative" id="G.CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000034 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/H.PatentsDetails" id="H.PatentsDetails">
	  <link:definition>00000035 - Disclosure - H. PATENTS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/H.PatentsDetailsNarrative" id="H.PatentsDetailsNarrative">
	  <link:definition>00000036 - Disclosure - H. PATENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails" id="I.EarningsLossPerCommonShareDetails">
	  <link:definition>00000037 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails1" id="I.EarningsLossPerCommonShareDetails1">
	  <link:definition>00000038 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20170630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20170630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20170630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cvm-20170630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="CVM_LeaseLiability" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CapitalizedLeaseInterest" name="CapitalizedLeaseInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncreaseInPrepaidServices" name="IncreaseInPrepaidServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncreaseInDirectFinancingCosts" name="IncreaseInDirectFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_LiabilitiesAssumed" name="LiabilitiesAssumed" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" name="LeasePaymentsIncludedInAccountsPayableAtYearEnd" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockholdersEquityTextBlock" name="StockholdersEquityTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" name="ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" name="ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ScheduleOfDerivativeLiabilitiesAtFairValue" name="ScheduleOfDerivativeLiabilitiesAtFairValue" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock" name="ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NonemployeesShareBasedCompensation" name="NonemployeesShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SharesIssuableUponExerciseOfwarrant" name="SharesIssuableUponExerciseOfwarrant" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisePrice" name="ExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisePriceMinimum" name="ExercisePriceMinimum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisePriceMaximum" name="ExercisePriceMaximum" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExpirationDate" name="ExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IssueDate1" name="IssueDate1" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_TotalFairValueOfDerivativeLiabilities" name="TotalFairValueOfDerivativeLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesLlWarrants" name="FairValueOfSeriesLlWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesKkWarrants" name="FairValueOfSeriesKkWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesJjWarrants" name="FairValueOfSeriesJjWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesIiWarrants" name="FairValueOfSeriesIiWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesHhWarrants" name="FairValueOfSeriesHhWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesGgWarrants" name="FairValueOfSeriesGgWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesFfWarrants" name="FairValueOfSeriesFfWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesEeWarrants" name="FairValueOfSeriesEeWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesDdWarrants" name="FairValueOfSeriesDdWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesCcWarrants" name="FairValueOfSeriesCcWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesBbWarrants" name="FairValueOfSeriesBbWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesAaWarrants" name="FairValueOfSeriesAaWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesZzWarrants" name="FairValueOfSeriesZzWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesZwarrants" name="FairValueOfSeriesZwarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesWWarrants" name="FairValueOfSeriesWWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesVWarrants" name="FairValueOfSeriesVWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesSWarrants" name="FairValueOfSeriesSWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesLlWarrants" name="GainLossSeriesLlWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesKkWarrants" name="GainLossSeriesKkWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesJjWarrants" name="GainLossSeriesJjWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesIiWarrants" name="GainLossSeriesIiWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesHhWarrants" name="GainLossSeriesHhWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesGgWarrants" name="GainLossSeriesGgWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesFfWarrants" name="GainLossSeriesFfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesEeWarrants" name="GainLossSeriesEeWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesDdWarrants" name="GainLossSeriesDdWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesCcWarrants" name="GainLossSeriesCcWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesBbWarrants" name="GainLossSeriesBbWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesAaWarrants" name="GainLossSeriesAaWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesZzWarrants" name="GainLossSeriesZzWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesZWarrants" name="GainLossSeriesZWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesWWarrants" name="GainLossSeriesWWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesVWarrants" name="GainLossSeriesVWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_GainLossSeriesSWarrant" name="GainLossSeriesSWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesWMember" name="SeriesWMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CSchleuningSeriesAMember" name="CSchleuningSeriesAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesCMember" name="SeriesCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesEMember" name="SeriesEMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesFMember" name="SeriesFMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesGMember" name="SeriesGMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesHMember" name="SeriesHMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesQMember" name="SeriesQMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesLMember" name="SeriesLMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesVMember" name="SeriesVMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesMModifiedMember" name="SeriesMModifiedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesPMember" name="SeriesPMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorsMember" name="PrivateInvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_WarrantsHeldbyOfficerAndDirectorMember" name="WarrantsHeldbyOfficerAndDirectorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ConsultantsMember" name="ConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesKwarrantsMember" name="SeriesKwarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Financings2009WarrantsSeriesAToEMember" name="Financings2009WarrantsSeriesAToEMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_Warrants2008SeriesNMember" name="Warrants2008SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesFAndGWarrantsMember" name="SeriesFAndGWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesHWarrantsMember" name="SeriesHWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesQWarrantsMember" name="SeriesQWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ConvertibleNotesSettlementMember" name="ConvertibleNotesSettlementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncentiveStockOptionPlansMember" name="IncentiveStockOptionPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NonQualifiedStockOptionPlansMember" name="NonQualifiedStockOptionPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockBonusPlansMember" name="StockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesRMember" name="SeriesRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesMModififedMember" name="SeriesMModififedMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesOMember" name="SeriesOMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_OutstandingMember" name="OutstandingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExercisableMember" name="ExercisableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesAThroughEWarrantsMember" name="SeriesAThroughEWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesNMember" name="SeriesNMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DeferredRentLiabilityMember" name="DeferredRentLiabilityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeniorConvertibleNotesMember" name="SeniorConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrantsMember" name="PrivateInvestorWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrants1Member" name="PrivateInvestorWarrants1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrants2Member" name="PrivateInvestorWarrants2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PrivateInvestorWarrants3Member" name="PrivateInvestorWarrants3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PatentMember" name="PatentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesSMember" name="SeriesSMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesOandPMember" name="SeriesOandPMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesTMember" name="SeriesTMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesUMember" name="SeriesUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_IncentiveStockBonusPlansMember" name="IncentiveStockBonusPlansMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ExcludedResearchExpenseMember" name="ExcludedResearchExpenseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesXMember" name="SeriesXMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesYMember" name="SeriesYMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesDdMember" name="SeriesDdMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesEeMember" name="SeriesEeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesZMember" name="SeriesZMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesZzMember" name="SeriesZzMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesBbMember" name="SeriesBbMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesFfMember" name="SeriesFfMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesCcMember" name="SeriesCcMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesAaMember" name="SeriesAaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesHhMember" name="SeriesHhMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesJjMember" name="SeriesJjMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesGgMember" name="SeriesGgMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesIiMember" name="SeriesIiMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesLlMember" name="SeriesLlMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesMmMember" name="SeriesMmMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesKkMember" name="SeriesKkMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesNnMember" name="SeriesNnMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesOoMember" name="SeriesOoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesQqMember" name="SeriesQqMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesRrMember" name="SeriesRrMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesSsMember" name="SeriesSsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_SeriesPpMember" name="SeriesPpMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_HeadquartersMember" name="HeadquartersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_ResearchAndDevelopmentLabMember" name="ResearchAndDevelopmentLabMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_F.NotesPayableAbstract" name="F.NotesPayableAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" name="OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockholdersEquityTablesAbstract" name="StockholdersEquityTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueMeasurementsTablesAbstract" name="FairValueMeasurementsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_F.CommitmentsAndContingenciesTablesAbstract" name="F.CommitmentsAndContingenciesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PatentsTablesAbstract" name="PatentsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_NetIncomeLossPerCommonShareTablesAbstract" name="NetIncomeLossPerCommonShareTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_C.StockholdersEquityDetailsAbstract" name="C.StockholdersEquityDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_C.StockholdersEquityDetails1Abstract" name="C.StockholdersEquityDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_StockholdersEquityDetails2Abstract" name="StockholdersEquityDetails2Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_DerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" name="DerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" name="FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueOfSeriesUWarrants" name="FairValueOfSeriesUWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_C.StockholdersEquityDetailsNarrativeAbstract" name="C.StockholdersEquityDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueMeasurementsDetailsAbstract" name="FairValueMeasurementsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueMeasurementsAbstract" name="FairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_FairValueMeasurementsDetails1Abstract" name="FairValueMeasurementsDetails1Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_E.LoansFromOfficerDetailsNarrativeAbstract" name="E.LoansFromOfficerDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_F.NotesPayableDetailsNarrativeAbstract" name="F.NotesPayableDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_CommitmentsAndContingenciesDetailsAbstract" name="CommitmentsAndContingenciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_F.CommitmentsAndContingenciesDetailsAbstract" name="F.CommitmentsAndContingenciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_G.CommitmentsAndContingenciesDetailsNarrativeAbstract" name="G.CommitmentsAndContingenciesDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PatentsDetailsAbstract" name="PatentsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_PatentsDetailsNarrativeAbstract" name="PatentsDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_I.EarningsPerShareDetailsAbstract" name="I.EarningsPerShareDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CVM_I.EarningsPerShareDetailsNarrativeAbstract" name="I.EarningsPerShareDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cvm-20170630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 173321 12312017 10Q1.xfr; Date: 2018%2D02%2D09T15:11:46Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:href="cvm-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheets" xlink:href="cvm-20170630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20170630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfOperations" xlink:href="cvm-20170630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfCashFlows" xlink:href="cvm-20170630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20170630.xsd#A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/B.OperationsAndFinancing" xlink:href="cvm-20170630.xsd#B.OperationsAndFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquity" xlink:href="cvm-20170630.xsd#C.StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurements" xlink:href="cvm-20170630.xsd#D.FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/E.RelatedPartyTransactions" xlink:href="cvm-20170630.xsd#E.RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/F.NotesPayable" xlink:href="cvm-20170630.xsd#F.NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingencies" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.Patents" xlink:href="cvm-20170630.xsd#H.Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShare" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/J.SubsequentEvents" xlink:href="cvm-20170630.xsd#J.SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20170630.xsd#A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityTables" xlink:href="cvm-20170630.xsd#C.StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurementsTables" xlink:href="cvm-20170630.xsd#D.FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesTables" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.PatentsTables" xlink:href="cvm-20170630.xsd#H.PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareTables" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails1" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails2" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails3" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails4" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetailsNarrative" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurementsDetails" xlink:href="cvm-20170630.xsd#D.FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurementsDetails1" xlink:href="cvm-20170630.xsd#D.FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/E.RelatedPartyLoanDetailsNarrative" xlink:href="cvm-20170630.xsd#E.RelatedPartyLoanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/F.NotesPayableDetailsNarrative" xlink:href="cvm-20170630.xsd#F.NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails1" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.PatentsDetails" xlink:href="cvm-20170630.xsd#H.PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.PatentsDetailsNarrative" xlink:href="cvm-20170630.xsd#H.PatentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails1" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShareDetails1" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="loc_us-gaapNotesAndLoansPayableCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesAndLoansPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_LeaseLiability" xlink:label="loc_CVMLeaseLiability" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_CVMLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_CapitalizedLeaseInterest" xlink:label="loc_CVMCapitalizedLeaseInterest" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CVMCapitalizedLeaseInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000006 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/B.OperationsAndFinancing" xlink:title="00000007 - Disclosure - B. OPERATIONS AND FINANCING" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquity" xlink:title="00000008 - Disclosure - C. STOCKHOLDERS EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurements" xlink:title="00000009 - Disclosure - D. FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/E.RelatedPartyTransactions" xlink:title="00000010 - Disclosure - E. RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/F.NotesPayable" xlink:title="00000011 - Disclosure - F. NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - G. COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.Patents" xlink:title="00000013 - Disclosure - H. PATENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShare" xlink:title="00000014 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/J.SubsequentEvents" xlink:title="00000015 - Disclosure - J. SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000016 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityTables" xlink:title="00000017 - Disclosure - C. STOCKHOLDERS EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurementsTables" xlink:title="00000018 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesTables" xlink:title="00000019 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.PatentsTables" xlink:title="00000020 - Disclosure - H. PATENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShareTables" xlink:title="00000021 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails" xlink:title="00000022 - Disclosure - C. STOCKHOLDERS EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails1" xlink:title="00000023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails2" xlink:title="00000024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails3" xlink:title="00000025 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails4" xlink:title="00000026 - Disclosure - C. STOCKHOLDERS EQUITY (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetailsNarrative" xlink:title="00000027 - Disclosure - C. STOCKHOLDERS EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurementsDetails" xlink:title="00000028 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurementsDetails1" xlink:title="00000029 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/E.RelatedPartyLoanDetailsNarrative" xlink:title="00000030 - Disclosure - E. RELATED PARTY LOAN (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/F.NotesPayableDetailsNarrative" xlink:title="00000031 - Disclosure - F. NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails" xlink:title="00000032 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails1" xlink:title="00000033 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000034 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.PatentsDetails" xlink:title="00000035 - Disclosure - H. PATENTS (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.PatentsDetailsNarrative" xlink:title="00000036 - Disclosure - H. PATENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails" xlink:title="00000037 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails1" xlink:title="00000038 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Details 1)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cvm-20170630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 173321 12312017 10Q1.xfr; Date: 2018%2D02%2D09T15:11:46Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:href="cvm-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheets" xlink:href="cvm-20170630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20170630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfOperations" xlink:href="cvm-20170630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfCashFlows" xlink:href="cvm-20170630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20170630.xsd#A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/B.OperationsAndFinancing" xlink:href="cvm-20170630.xsd#B.OperationsAndFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquity" xlink:href="cvm-20170630.xsd#C.StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurements" xlink:href="cvm-20170630.xsd#D.FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/E.RelatedPartyTransactions" xlink:href="cvm-20170630.xsd#E.RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/F.NotesPayable" xlink:href="cvm-20170630.xsd#F.NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingencies" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.Patents" xlink:href="cvm-20170630.xsd#H.Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShare" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/J.SubsequentEvents" xlink:href="cvm-20170630.xsd#J.SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20170630.xsd#A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityTables" xlink:href="cvm-20170630.xsd#C.StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurementsTables" xlink:href="cvm-20170630.xsd#D.FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesTables" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.PatentsTables" xlink:href="cvm-20170630.xsd#H.PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareTables" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails1" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails2" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails3" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails4" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetailsNarrative" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurementsDetails" xlink:href="cvm-20170630.xsd#D.FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurementsDetails1" xlink:href="cvm-20170630.xsd#D.FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/E.RelatedPartyLoanDetailsNarrative" xlink:href="cvm-20170630.xsd#E.RelatedPartyLoanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/F.NotesPayableDetailsNarrative" xlink:href="cvm-20170630.xsd#F.NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails1" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.PatentsDetails" xlink:href="cvm-20170630.xsd#H.PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.PatentsDetailsNarrative" xlink:href="cvm-20170630.xsd#H.PatentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails1" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShareDetails1" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000006 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/B.OperationsAndFinancing" xlink:title="00000007 - Disclosure - B. OPERATIONS AND FINANCING" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquity" xlink:title="00000008 - Disclosure - C. STOCKHOLDERS EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurements" xlink:title="00000009 - Disclosure - D. FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/E.RelatedPartyTransactions" xlink:title="00000010 - Disclosure - E. RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/F.NotesPayable" xlink:title="00000011 - Disclosure - F. NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - G. COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.Patents" xlink:title="00000013 - Disclosure - H. PATENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShare" xlink:title="00000014 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/J.SubsequentEvents" xlink:title="00000015 - Disclosure - J. SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000016 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityTables" xlink:title="00000017 - Disclosure - C. STOCKHOLDERS EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurementsTables" xlink:title="00000018 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesTables" xlink:title="00000019 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.PatentsTables" xlink:title="00000020 - Disclosure - H. PATENTS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShareTables" xlink:title="00000021 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails" xlink:title="00000022 - Disclosure - C. STOCKHOLDERS EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IncentiveStockOptionPlansMember" xlink:label="loc_CVMIncentiveStockOptionPlansMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMIncentiveStockOptionPlansMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NonQualifiedStockOptionPlansMember" xlink:label="loc_CVMNonQualifiedStockOptionPlansMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMNonQualifiedStockOptionPlansMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_StockBonusPlansMember" xlink:label="loc_CVMStockBonusPlansMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMStockBonusPlansMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockCompensationPlanMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IncentiveStockBonusPlansMember" xlink:label="loc_CVMIncentiveStockBonusPlansMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMIncentiveStockBonusPlansMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails1" xlink:title="00000023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails2" xlink:title="00000024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails3" xlink:title="00000025 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesDdMember" xlink:label="loc_CVMSeriesDdMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesDdMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesEeMember" xlink:label="loc_CVMSeriesEeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesEeMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesNMember" xlink:label="loc_CVMSeriesNMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesNMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesVMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesWMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesXMember" xlink:label="loc_CVMSeriesXMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesXMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesYMember" xlink:label="loc_CVMSeriesYMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesYMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesZzMember" xlink:label="loc_CVMSeriesZzMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZzMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesBbMember" xlink:label="loc_CVMSeriesBbMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesBbMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesFfMember" xlink:label="loc_CVMSeriesFfMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesFfMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesCcMember" xlink:label="loc_CVMSeriesCcMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesCcMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesHhMember" xlink:label="loc_CVMSeriesHhMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesHhMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesAaMember" xlink:label="loc_CVMSeriesAaMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAaMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesJjMember" xlink:label="loc_CVMSeriesJjMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesJjMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesLlMember" xlink:label="loc_CVMSeriesLlMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesLlMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesMmMember" xlink:label="loc_CVMSeriesMmMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesMmMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesNnMember" xlink:label="loc_CVMSeriesNnMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesNnMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesOoMember" xlink:label="loc_CVMSeriesOoMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesOoMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesQqMember" xlink:label="loc_CVMSeriesQqMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesQqMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesGgMember" xlink:label="loc_CVMSeriesGgMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesGgMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesIiMember" xlink:label="loc_CVMSeriesIiMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesIiMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesRrMember" xlink:label="loc_CVMSeriesRrMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesRrMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesKkMember" xlink:label="loc_CVMSeriesKkMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesKkMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesSsMember" xlink:label="loc_CVMSeriesSsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSsMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesPpMember" xlink:label="loc_CVMSeriesPpMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesPpMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ConsultantsMember" xlink:label="loc_CVMConsultantsMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMConsultantsMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteAbstract_570" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IssueDate1" xlink:label="loc_CVMIssueDate1_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_570" xlink:to="loc_CVMIssueDate1_570" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_CVMSharesIssuableUponExerciseOfwarrant_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_570" xlink:to="loc_CVMSharesIssuableUponExerciseOfwarrant_570" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExercisePrice" xlink:label="loc_CVMExercisePrice_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_570" xlink:to="loc_CVMExercisePrice_570" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExercisePriceMinimum" xlink:label="loc_CVMExercisePriceMinimum_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_570" xlink:to="loc_CVMExercisePriceMinimum_570" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExercisePriceMaximum" xlink:label="loc_CVMExercisePriceMaximum_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_570" xlink:to="loc_CVMExercisePriceMaximum_570" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExpirationDate" xlink:label="loc_CVMExpirationDate_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract_570" xlink:to="loc_CVMExpirationDate_570" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails4" xlink:title="00000026 - Disclosure - C. STOCKHOLDERS EQUITY (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetailsNarrative" xlink:title="00000027 - Disclosure - C. STOCKHOLDERS EQUITY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurementsDetails" xlink:title="00000028 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueMeasurementsAbstract" xlink:label="loc_CVMFairValueMeasurementsAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMFairValueMeasurementsAbstract_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CVMFairValueMeasurementsAbstract_90" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurementsDetails1" xlink:title="00000029 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/E.RelatedPartyLoanDetailsNarrative" xlink:title="00000030 - Disclosure - E. RELATED PARTY LOAN (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/F.NotesPayableDetailsNarrative" xlink:title="00000031 - Disclosure - F. NOTES PAYABLE (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails" xlink:title="00000032 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails1" xlink:title="00000033 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000034 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaapStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ResearchAndDevelopmentLabMember" xlink:label="loc_CVMResearchAndDevelopmentLabMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_CVMResearchAndDevelopmentLabMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_HeadquartersMember" xlink:label="loc_CVMHeadquartersMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_CVMHeadquartersMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRentCreditCurrent_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.PatentsDetails" xlink:title="00000035 - Disclosure - H. PATENTS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.PatentsDetailsNarrative" xlink:title="00000036 - Disclosure - H. PATENTS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails" xlink:title="00000037 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails1" xlink:title="00000038 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_90" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cvm-20170630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 173321 12312017 10Q1.xfr; Date: 2018%2D02%2D09T15:11:46Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class Of Warrant Or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesWMember" xlink:label="CVM_SeriesWMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesWMember" xlink:to="CVM_SeriesWMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesWMember_lbl" xml:lang="en-US">Series W [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesVMember" xlink:label="CVM_SeriesVMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesVMember" xlink:to="CVM_SeriesVMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesVMember_lbl" xml:lang="en-US">Series V [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ConsultantsMember" xlink:label="CVM_ConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ConsultantsMember" xlink:to="CVM_ConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ConsultantsMember_lbl" xml:lang="en-US">Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IncentiveStockOptionPlansMember" xlink:label="CVM_IncentiveStockOptionPlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncentiveStockOptionPlansMember" xlink:to="CVM_IncentiveStockOptionPlansMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncentiveStockOptionPlansMember_lbl" xml:lang="en-US">Incentive Stock Option Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NonQualifiedStockOptionPlansMember" xlink:label="CVM_NonQualifiedStockOptionPlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NonQualifiedStockOptionPlansMember" xlink:to="CVM_NonQualifiedStockOptionPlansMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NonQualifiedStockOptionPlansMember_lbl" xml:lang="en-US">Non Qualified Stock Option Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_StockBonusPlansMember" xlink:label="CVM_StockBonusPlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockBonusPlansMember" xlink:to="CVM_StockBonusPlansMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockBonusPlansMember_lbl" xml:lang="en-US">Stock Bonus Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US">Stock Compensation Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesNMember" xlink:label="CVM_SeriesNMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesNMember" xlink:to="CVM_SeriesNMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesNMember_lbl" xml:lang="en-US">Series N [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesSMember" xlink:label="CVM_SeriesSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesSMember" xlink:to="CVM_SeriesSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesSMember_lbl" xml:lang="en-US">Series S [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IncentiveStockBonusPlansMember" xlink:label="CVM_IncentiveStockBonusPlansMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncentiveStockBonusPlansMember" xlink:to="CVM_IncentiveStockBonusPlansMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncentiveStockBonusPlansMember_lbl" xml:lang="en-US">Incentive Stock Bonus Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesXMember" xlink:label="CVM_SeriesXMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesXMember" xlink:to="CVM_SeriesXMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesXMember_lbl" xml:lang="en-US">Series X [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesYMember" xlink:label="CVM_SeriesYMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesYMember" xlink:to="CVM_SeriesYMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesYMember_lbl" xml:lang="en-US">Series Y [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesDdMember" xlink:label="CVM_SeriesDdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesDdMember" xlink:to="CVM_SeriesDdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesDdMember_lbl" xml:lang="en-US">Series DD [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesEeMember" xlink:label="CVM_SeriesEeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesEeMember" xlink:to="CVM_SeriesEeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesEeMember_lbl" xml:lang="en-US">Series EE [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesZMember" xlink:label="CVM_SeriesZMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesZMember" xlink:to="CVM_SeriesZMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesZMember_lbl" xml:lang="en-US">Series Z [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesZzMember" xlink:label="CVM_SeriesZzMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesZzMember" xlink:to="CVM_SeriesZzMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesZzMember_lbl" xml:lang="en-US">Series ZZ [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesBbMember" xlink:label="CVM_SeriesBbMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesBbMember" xlink:to="CVM_SeriesBbMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesBbMember_lbl" xml:lang="en-US">Series BB [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesFfMember" xlink:label="CVM_SeriesFfMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesFfMember" xlink:to="CVM_SeriesFfMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesFfMember_lbl" xml:lang="en-US">Series FF [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesCcMember" xlink:label="CVM_SeriesCcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesCcMember" xlink:to="CVM_SeriesCcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesCcMember_lbl" xml:lang="en-US">Series CC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesAaMember" xlink:label="CVM_SeriesAaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesAaMember" xlink:to="CVM_SeriesAaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesAaMember_lbl" xml:lang="en-US">Series AA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesHhMember" xlink:label="CVM_SeriesHhMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesHhMember" xlink:to="CVM_SeriesHhMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesHhMember_lbl" xml:lang="en-US">Series HH [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesJjMember" xlink:label="CVM_SeriesJjMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesJjMember" xlink:to="CVM_SeriesJjMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesJjMember_lbl" xml:lang="en-US">Series JJ [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesGgMember" xlink:label="CVM_SeriesGgMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesGgMember" xlink:to="CVM_SeriesGgMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesGgMember_lbl" xml:lang="en-US">Series GG [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesIiMember" xlink:label="CVM_SeriesIiMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesIiMember" xlink:to="CVM_SeriesIiMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesIiMember_lbl" xml:lang="en-US">Series II [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesLlMember" xlink:label="CVM_SeriesLlMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesLlMember" xlink:to="CVM_SeriesLlMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesLlMember_lbl" xml:lang="en-US">Series LL [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesMmMember" xlink:label="CVM_SeriesMmMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesMmMember" xlink:to="CVM_SeriesMmMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesMmMember_lbl" xml:lang="en-US">Series MM [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesKkMember" xlink:label="CVM_SeriesKkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesKkMember" xlink:to="CVM_SeriesKkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesKkMember_lbl" xml:lang="en-US">Series KK [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">FairValueByFairValueHierarchyLevel [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesNnMember" xlink:label="CVM_SeriesNnMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesNnMember" xlink:to="CVM_SeriesNnMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesNnMember_lbl" xml:lang="en-US">Series NN [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesOoMember" xlink:label="CVM_SeriesOoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesOoMember" xlink:to="CVM_SeriesOoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesOoMember_lbl" xml:lang="en-US">Series OO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesQqMember" xlink:label="CVM_SeriesQqMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesQqMember" xlink:to="CVM_SeriesQqMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesQqMember_lbl" xml:lang="en-US">Series QQ [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesRrMember" xlink:label="CVM_SeriesRrMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesRrMember" xlink:to="CVM_SeriesRrMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesRrMember_lbl" xml:lang="en-US">Series RR [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesSsMember" xlink:label="CVM_SeriesSsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesSsMember" xlink:to="CVM_SeriesSsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesSsMember_lbl" xml:lang="en-US">Series SS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesPpMember" xlink:label="CVM_SeriesPpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesPpMember" xlink:to="CVM_SeriesPpMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SeriesPpMember_lbl" xml:lang="en-US">Series PP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_HeadquartersMember" xlink:label="CVM_HeadquartersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_HeadquartersMember" xlink:to="CVM_HeadquartersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_HeadquartersMember_lbl" xml:lang="en-US">Headquarters</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ResearchAndDevelopmentLabMember" xlink:label="CVM_ResearchAndDevelopmentLabMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ResearchAndDevelopmentLabMember" xlink:to="CVM_ResearchAndDevelopmentLabMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ResearchAndDevelopmentLabMember_lbl" xml:lang="en-US">Research and Development Lab</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options and Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Unvested Restricted Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible debt</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_DocumentAndEntityInformationAbstract" xlink:label="CVM_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DocumentAndEntityInformationAbstract" xlink:to="CVM_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Is Entity a Well-known Seasoned Issuer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Is Entity a Voluntary Filer?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Is Entity's Reporting Status Current?</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory used for R&amp;D and manufacturing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Plant, property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patent costs, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOfficersOrStockholdersCurrent" xlink:to="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOfficersOrStockholdersCurrent_lbl" xml:lang="en-US">Due to employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="us-gaap_NotesAndLoansPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansPayableCurrent" xlink:to="us-gaap_NotesAndLoansPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative instruments, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US">Derivative instruments - net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_LeaseLiability" xlink:label="CVM_LeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_LeaseLiability" xlink:to="CVM_LeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_LeaseLiability_lbl" xml:lang="en-US">Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' DEFICIT</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $.01 par value - 600,000,000 shares authorized; 13,258,051 and 11,903,133 shares issued and outstanding at December 31, 2017 and September 30, 2017, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock Shares Par Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock Shares Par Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Grant and other income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General &amp; administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">(Loss) gain on derivative instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net (ioss) income available to common shareholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET (LOSS) INCOME PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net (loss) Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net (loss) income to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Share-based payments for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Equity based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_lbl" xml:lang="en-US">Common stock contributed to 401(k) plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on retired equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Loss (gain) on derivative instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_CapitalizedLeaseInterest" xlink:label="CVM_CapitalizedLeaseInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CapitalizedLeaseInterest" xlink:to="CVM_CapitalizedLeaseInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_CapitalizedLeaseInterest_lbl" xml:lang="en-US">Capitalized lease interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">(Increase)/decrease in assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory used for R&amp;D and manufacturing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="us-gaap_IncreaseDecreaseInDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeposits_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract_lbl" xml:lang="en-US">Increase/(decrease) in liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_lbl" xml:lang="en-US">Due to employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xml:lang="en-US">Deferred rent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Expenditures for patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Payments on obligations under capital lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, END OF PERIOD</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease in receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capitalizable patent costs included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:label="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:to="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd_lbl" xml:lang="en-US">Capital lease obligation included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="us-gaap_CapitalLeaseObligationsIncurred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsIncurred" xlink:to="us-gaap_CapitalLeaseObligationsIncurred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsIncurred_lbl" xml:lang="en-US">Property and equipment acquired through capital lease</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_LiabilitiesAssumed" xlink:label="CVM_LiabilitiesAssumed" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_LiabilitiesAssumed" xlink:to="CVM_LiabilitiesAssumed_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_LiabilitiesAssumed_lbl" xml:lang="en-US">Fair value of warrants issued in connection with public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IncreaseInDirectFinancingCosts" xlink:label="CVM_IncreaseInDirectFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncreaseInDirectFinancingCosts" xlink:to="CVM_IncreaseInDirectFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncreaseInDirectFinancingCosts_lbl" xml:lang="en-US">Financing costs included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IncreaseInPrepaidServices" xlink:label="CVM_IncreaseInPrepaidServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncreaseInPrepaidServices" xlink:to="CVM_IncreaseInPrepaidServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IncreaseInPrepaidServices_lbl" xml:lang="en-US">Prepaid consulting services paid with issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Notes payable converted into common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="CVM_NotesToFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NotesToFinancialStatementsAbstract" xlink:to="CVM_NotesToFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">B. OPERATIONS AND FINANCING</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_StockholdersEquityTextBlock" xlink:label="CVM_StockholdersEquityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityTextBlock" xlink:to="CVM_StockholdersEquityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockholdersEquityTextBlock_lbl" xml:lang="en-US">C. STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">D. FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">E. RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_F.NotesPayableAbstract" xlink:label="CVM_F.NotesPayableAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_F.NotesPayableAbstract" xlink:to="CVM_F.NotesPayableAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_F.NotesPayableAbstract_lbl" xml:lang="en-US">F. Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">F. NOTES PAYABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">G. COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">H. PATENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">I. LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">J. SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:label="CVM_OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="CVM_OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract_lbl" xml:lang="en-US">Dilutive EPS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentImpairment_lbl" xml:lang="en-US">Research and Office Equipment and Leasehold Improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesReportingOfDerivativeActivity" xlink:to="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesReportingOfDerivativeActivity_lbl" xml:lang="en-US">Derivative Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_StockholdersEquityTablesAbstract" xlink:label="CVM_StockholdersEquityTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityTablesAbstract" xlink:to="CVM_StockholdersEquityTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockholdersEquityTablesAbstract_lbl" xml:lang="en-US">C. Stockholders Equity Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" xlink:label="CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" xlink:to="CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany_lbl" xml:lang="en-US">Stock options, stock bonuses and compensation granted by the Company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of employees and non-employees stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" xlink:label="CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" xlink:to="CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions_lbl" xml:lang="en-US">Derivative Liabilities, Warrants and Other Options</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ScheduleOfDerivativeLiabilitiesAtFairValue" xlink:label="CVM_ScheduleOfDerivativeLiabilitiesAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleOfDerivativeLiabilitiesAtFairValue" xlink:to="CVM_ScheduleOfDerivativeLiabilitiesAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ScheduleOfDerivativeLiabilitiesAtFairValue_lbl" xml:lang="en-US">Tabular disclosure of derivative liabilities at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock" xlink:label="CVM_ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock" xlink:to="CVM_ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock_lbl" xml:lang="en-US">Schedule Of Gains and (Losses) on Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueMeasurementsTablesAbstract" xlink:label="CVM_FairValueMeasurementsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueMeasurementsTablesAbstract" xlink:to="CVM_FairValueMeasurementsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueMeasurementsTablesAbstract_lbl" xml:lang="en-US">D. Fair Value Measurements Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Measured at fair value on a recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_F.CommitmentsAndContingenciesTablesAbstract" xlink:label="CVM_F.CommitmentsAndContingenciesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_F.CommitmentsAndContingenciesTablesAbstract" xlink:to="CVM_F.CommitmentsAndContingenciesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_F.CommitmentsAndContingenciesTablesAbstract_lbl" xml:lang="en-US">G. Commitments And Contingencies Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US">Future minimum lease payments under the San Tomas lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum payments under operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PatentsTablesAbstract" xlink:label="CVM_PatentsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PatentsTablesAbstract" xlink:to="CVM_PatentsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_PatentsTablesAbstract_lbl" xml:lang="en-US">H. Patents Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of total estimated future amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NetIncomeLossPerCommonShareTablesAbstract" xlink:label="CVM_NetIncomeLossPerCommonShareTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NetIncomeLossPerCommonShareTablesAbstract" xlink:to="CVM_NetIncomeLossPerCommonShareTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NetIncomeLossPerCommonShareTablesAbstract_lbl" xml:lang="en-US">I. Earnings Loss Per Common Share Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Computation of dilutive net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Antidilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Total Shares Reserved Under Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Shares Reserved for Outstanding Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Remaining Options/Shares Under Plans</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_C.StockholdersEquityDetails1Abstract" xlink:label="CVM_C.StockholdersEquityDetails1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_C.StockholdersEquityDetails1Abstract" xlink:to="CVM_C.StockholdersEquityDetails1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_C.StockholdersEquityDetails1Abstract_lbl" xml:lang="en-US">C. Stockholders Equity Details 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_StockholdersEquityDetails2Abstract" xlink:label="CVM_StockholdersEquityDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityDetails2Abstract" xlink:to="CVM_StockholdersEquityDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_StockholdersEquityDetails2Abstract_lbl" xml:lang="en-US">C. Stockholders Equity Details 2</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xml:lang="en-US">Employees</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NonemployeesShareBasedCompensation" xlink:label="CVM_NonemployeesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NonemployeesShareBasedCompensation" xlink:to="CVM_NonemployeesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_NonemployeesShareBasedCompensation_lbl" xml:lang="en-US">Non-employees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_2_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IssueDate1" xlink:label="CVM_IssueDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssueDate1" xlink:to="CVM_IssueDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_IssueDate1_lbl" xml:lang="en-US">Issue Date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SharesIssuableUponExerciseOfwarrant" xlink:label="CVM_SharesIssuableUponExerciseOfwarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SharesIssuableUponExerciseOfwarrant" xlink:to="CVM_SharesIssuableUponExerciseOfwarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_SharesIssuableUponExerciseOfwarrant_lbl" xml:lang="en-US">Shares Issuable upon Exercise of Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExercisePrice" xlink:label="CVM_ExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePrice" xlink:to="CVM_ExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExercisePriceMinimum" xlink:label="CVM_ExercisePriceMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMinimum" xlink:to="CVM_ExercisePriceMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExercisePriceMinimum_lbl" xml:lang="en-US">Exercise Price Minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExercisePriceMaximum" xlink:label="CVM_ExercisePriceMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMaximum" xlink:to="CVM_ExercisePriceMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExercisePriceMaximum_lbl" xml:lang="en-US">Exercise Price Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExpirationDate" xlink:label="CVM_ExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationDate" xlink:to="CVM_ExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_ExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:label="CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract_lbl" xml:lang="en-US">C. Stockholders Equity Details 4</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesSWarrants" xlink:label="CVM_FairValueOfSeriesSWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesSWarrants" xlink:to="CVM_FairValueOfSeriesSWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesSWarrants_lbl" xml:lang="en-US">Series S warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesUWarrants" xlink:label="CVM_FairValueOfSeriesUWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesUWarrants" xlink:to="CVM_FairValueOfSeriesUWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesUWarrants_lbl" xml:lang="en-US">Series U warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesVWarrants" xlink:label="CVM_FairValueOfSeriesVWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesVWarrants" xlink:to="CVM_FairValueOfSeriesVWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesVWarrants_lbl" xml:lang="en-US">Series V warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesWWarrants" xlink:label="CVM_FairValueOfSeriesWWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesWWarrants" xlink:to="CVM_FairValueOfSeriesWWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesWWarrants_lbl" xml:lang="en-US">Series W warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesZwarrants" xlink:label="CVM_FairValueOfSeriesZwarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesZwarrants" xlink:to="CVM_FairValueOfSeriesZwarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesZwarrants_lbl" xml:lang="en-US">Series Z warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesZzWarrants" xlink:label="CVM_FairValueOfSeriesZzWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesZzWarrants" xlink:to="CVM_FairValueOfSeriesZzWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesZzWarrants_lbl" xml:lang="en-US">Series ZZ warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesAaWarrants" xlink:label="CVM_FairValueOfSeriesAaWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesAaWarrants" xlink:to="CVM_FairValueOfSeriesAaWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesAaWarrants_lbl" xml:lang="en-US">Series AA warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesBbWarrants" xlink:label="CVM_FairValueOfSeriesBbWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesBbWarrants" xlink:to="CVM_FairValueOfSeriesBbWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesBbWarrants_lbl" xml:lang="en-US">Series BB warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesCcWarrants" xlink:label="CVM_FairValueOfSeriesCcWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesCcWarrants" xlink:to="CVM_FairValueOfSeriesCcWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesCcWarrants_lbl" xml:lang="en-US">Series CC warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesDdWarrants" xlink:label="CVM_FairValueOfSeriesDdWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesDdWarrants" xlink:to="CVM_FairValueOfSeriesDdWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesDdWarrants_lbl" xml:lang="en-US">Series DD warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesEeWarrants" xlink:label="CVM_FairValueOfSeriesEeWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesEeWarrants" xlink:to="CVM_FairValueOfSeriesEeWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesEeWarrants_lbl" xml:lang="en-US">Series EE warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesFfWarrants" xlink:label="CVM_FairValueOfSeriesFfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesFfWarrants" xlink:to="CVM_FairValueOfSeriesFfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesFfWarrants_lbl" xml:lang="en-US">Series FF warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesGgWarrants" xlink:label="CVM_FairValueOfSeriesGgWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesGgWarrants" xlink:to="CVM_FairValueOfSeriesGgWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesGgWarrants_lbl" xml:lang="en-US">Series GG warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesHhWarrants" xlink:label="CVM_FairValueOfSeriesHhWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesHhWarrants" xlink:to="CVM_FairValueOfSeriesHhWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesHhWarrants_lbl" xml:lang="en-US">Series HH warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesIiWarrants" xlink:label="CVM_FairValueOfSeriesIiWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesIiWarrants" xlink:to="CVM_FairValueOfSeriesIiWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesIiWarrants_lbl" xml:lang="en-US">Series II warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesJjWarrants" xlink:label="CVM_FairValueOfSeriesJjWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesJjWarrants" xlink:to="CVM_FairValueOfSeriesJjWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesJjWarrants_lbl" xml:lang="en-US">Series JJ warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesKkWarrants" xlink:label="CVM_FairValueOfSeriesKkWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesKkWarrants" xlink:to="CVM_FairValueOfSeriesKkWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesKkWarrants_lbl" xml:lang="en-US">Series KK warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesLlWarrants" xlink:label="CVM_FairValueOfSeriesLlWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesLlWarrants" xlink:to="CVM_FairValueOfSeriesLlWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueOfSeriesLlWarrants_lbl" xml:lang="en-US">Series LL warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_TotalFairValueOfDerivativeLiabilities" xlink:label="CVM_TotalFairValueOfDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_TotalFairValueOfDerivativeLiabilities" xlink:to="CVM_TotalFairValueOfDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_TotalFairValueOfDerivativeLiabilities_lbl" xml:lang="en-US">Total warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesSWarrant" xlink:label="CVM_GainLossSeriesSWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesSWarrant" xlink:to="CVM_GainLossSeriesSWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesSWarrant_lbl" xml:lang="en-US">Series S warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesVWarrants" xlink:label="CVM_GainLossSeriesVWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesVWarrants" xlink:to="CVM_GainLossSeriesVWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesVWarrants_lbl" xml:lang="en-US">Series V warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesWWarrants" xlink:label="CVM_GainLossSeriesWWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesWWarrants" xlink:to="CVM_GainLossSeriesWWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesWWarrants_lbl" xml:lang="en-US">Series W warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesZWarrants" xlink:label="CVM_GainLossSeriesZWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesZWarrants" xlink:to="CVM_GainLossSeriesZWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesZWarrants_lbl" xml:lang="en-US">Series Z warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesZzWarrants" xlink:label="CVM_GainLossSeriesZzWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesZzWarrants" xlink:to="CVM_GainLossSeriesZzWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesZzWarrants_lbl" xml:lang="en-US">Series ZZ warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesAaWarrants" xlink:label="CVM_GainLossSeriesAaWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesAaWarrants" xlink:to="CVM_GainLossSeriesAaWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesAaWarrants_lbl" xml:lang="en-US">Series AA warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesBbWarrants" xlink:label="CVM_GainLossSeriesBbWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesBbWarrants" xlink:to="CVM_GainLossSeriesBbWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesBbWarrants_lbl" xml:lang="en-US">Series BB warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesCcWarrants" xlink:label="CVM_GainLossSeriesCcWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesCcWarrants" xlink:to="CVM_GainLossSeriesCcWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesCcWarrants_lbl" xml:lang="en-US">Series CC warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesDdWarrants" xlink:label="CVM_GainLossSeriesDdWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesDdWarrants" xlink:to="CVM_GainLossSeriesDdWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesDdWarrants_lbl" xml:lang="en-US">Series DD warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesEeWarrants" xlink:label="CVM_GainLossSeriesEeWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesEeWarrants" xlink:to="CVM_GainLossSeriesEeWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesEeWarrants_lbl" xml:lang="en-US">Series EE warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesFfWarrants" xlink:label="CVM_GainLossSeriesFfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesFfWarrants" xlink:to="CVM_GainLossSeriesFfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesFfWarrants_lbl" xml:lang="en-US">Series FF warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesGgWarrants" xlink:label="CVM_GainLossSeriesGgWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesGgWarrants" xlink:to="CVM_GainLossSeriesGgWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesGgWarrants_lbl" xml:lang="en-US">Series GG warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesHhWarrants" xlink:label="CVM_GainLossSeriesHhWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesHhWarrants" xlink:to="CVM_GainLossSeriesHhWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesHhWarrants_lbl" xml:lang="en-US">Series HH warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesIiWarrants" xlink:label="CVM_GainLossSeriesIiWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesIiWarrants" xlink:to="CVM_GainLossSeriesIiWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesIiWarrants_lbl" xml:lang="en-US">Series II warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesJjWarrants" xlink:label="CVM_GainLossSeriesJjWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesJjWarrants" xlink:to="CVM_GainLossSeriesJjWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesJjWarrants_lbl" xml:lang="en-US">Series JJ warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesKkWarrants" xlink:label="CVM_GainLossSeriesKkWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesKkWarrants" xlink:to="CVM_GainLossSeriesKkWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesKkWarrants_lbl" xml:lang="en-US">Series KK warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesLlWarrants" xlink:label="CVM_GainLossSeriesLlWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesLlWarrants" xlink:to="CVM_GainLossSeriesLlWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CVM_GainLossSeriesLlWarrants_lbl" xml:lang="en-US">Series LL warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDerivativeInstrumentsNetPretax_lbl" xml:lang="en-US">Net (loss) gain on warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_C.StockholdersEquityDetailsNarrativeAbstract" xlink:label="CVM_C.StockholdersEquityDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_C.StockholdersEquityDetailsNarrativeAbstract" xlink:to="CVM_C.StockholdersEquityDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_C.StockholdersEquityDetailsNarrativeAbstract_lbl" xml:lang="en-US">C. Stockholders Equity Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued for consulting agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Consulting agreement expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueMeasurementsAbstract" xlink:label="CVM_FairValueMeasurementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueMeasurementsAbstract" xlink:to="CVM_FairValueMeasurementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueMeasurementsAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xml:lang="en-US">Derivative instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueMeasurementsDetails1Abstract" xlink:label="CVM_FairValueMeasurementsDetails1Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueMeasurementsDetails1Abstract" xlink:to="CVM_FairValueMeasurementsDetails1Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_FairValueMeasurementsDetails1Abstract_lbl" xml:lang="en-US">D. Fair Value Measurements Details 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US">Issuances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings_lbl" xml:lang="en-US">Realized and unrealized gains</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_E.LoansFromOfficerDetailsNarrativeAbstract" xlink:label="CVM_E.LoansFromOfficerDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_E.LoansFromOfficerDetailsNarrativeAbstract" xlink:to="CVM_E.LoansFromOfficerDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_E.LoansFromOfficerDetailsNarrativeAbstract_lbl" xml:lang="en-US">E. Related Party Loan Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="us-gaap_InterestExpenseRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense paid to officers</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_F.NotesPayableDetailsNarrativeAbstract" xlink:label="CVM_F.NotesPayableDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_F.NotesPayableDetailsNarrativeAbstract" xlink:to="CVM_F.NotesPayableDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_F.NotesPayableDetailsNarrativeAbstract_lbl" xml:lang="en-US">F. Notes Payable Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Common shares issued for notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:label="CVM_CommitmentsAndContingenciesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:to="CVM_CommitmentsAndContingenciesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_CommitmentsAndContingenciesDetailsAbstract_lbl" xml:lang="en-US">Commitments And Contingencies Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">Nine months ending September 30, 2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xml:lang="en-US">Total future minimum lease obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xml:lang="en-US">Less imputed interest on financing obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Net present value of lease financing obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_F.CommitmentsAndContingenciesDetailsAbstract" xlink:label="CVM_F.CommitmentsAndContingenciesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_F.CommitmentsAndContingenciesDetailsAbstract" xlink:to="CVM_F.CommitmentsAndContingenciesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_F.CommitmentsAndContingenciesDetailsAbstract_lbl" xml:lang="en-US">G. Commitments And Contingencies Details 1</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Nine months ending September 30, 2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">Year ending September 30, 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">Year ending September 30, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">Year ending September 30, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">Year ending September 30, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PatentsDetailsAbstract" xlink:label="CVM_PatentsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PatentsDetailsAbstract" xlink:to="CVM_PatentsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_PatentsDetailsAbstract_lbl" xml:lang="en-US">H. Patents Details</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">Nine months ending September 30, 2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Year ending September 30, 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">Year ending September 30, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">Year ending September 30, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">Year ending September 30, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">Year ending September 30, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PatentsDetailsNarrativeAbstract" xlink:label="CVM_PatentsDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PatentsDetailsNarrativeAbstract" xlink:to="CVM_PatentsDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_PatentsDetailsNarrativeAbstract_lbl" xml:lang="en-US">H. Patents Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Patent impairment charges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_I.EarningsPerShareDetailsAbstract" xlink:label="CVM_I.EarningsPerShareDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_I.EarningsPerShareDetailsAbstract" xlink:to="CVM_I.EarningsPerShareDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_I.EarningsPerShareDetailsAbstract_lbl" xml:lang="en-US">I. Earnings Loss Per Common Share Details</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net (loss) income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Shares - Basic and Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and dilutive loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US">Gain on derivatives</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net Income, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Shares - Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US">Gain on derivatives, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted Average Shares - Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic earnings per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Dilutive earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_CSchleuningSeriesAMember" xlink:label="CVM_CSchleuningSeriesAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CSchleuningSeriesAMember" xlink:to="CVM_CSchleuningSeriesAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_CSchleuningSeriesAMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ConsultantsMember" xlink:to="CVM_ConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ConsultantsMember_doc" xml:lang="en-US">Consultants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ConvertibleNotesSettlementMember" xlink:label="CVM_ConvertibleNotesSettlementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ConvertibleNotesSettlementMember" xlink:to="CVM_ConvertibleNotesSettlementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ConvertibleNotesSettlementMember_doc" xml:lang="en-US">Convertible Notes Settlement.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_DeferredRentLiabilityMember" xlink:label="CVM_DeferredRentLiabilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_DeferredRentLiabilityMember" xlink:to="CVM_DeferredRentLiabilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_DeferredRentLiabilityMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExercisableMember" xlink:label="CVM_ExercisableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisableMember" xlink:to="CVM_ExercisableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisableMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePrice" xlink:to="CVM_ExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisePrice_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMaximum" xlink:to="CVM_ExercisePriceMaximum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisePriceMaximum_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExercisePriceMinimum" xlink:to="CVM_ExercisePriceMinimum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExercisePriceMinimum_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ExpirationDate" xlink:to="CVM_ExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ExpirationDate_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueMeasurementsAbstract" xlink:to="CVM_FairValueMeasurementsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_FairValueMeasurementsAbstract_doc" xml:lang="en-US">Fair Value Measurements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_FairValueOfSeriesSWarrants" xlink:to="CVM_FairValueOfSeriesSWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_FairValueOfSeriesSWarrants_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_Financings2009WarrantsSeriesAToEMember" xlink:label="CVM_Financings2009WarrantsSeriesAToEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Financings2009WarrantsSeriesAToEMember" xlink:to="CVM_Financings2009WarrantsSeriesAToEMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Financings2009WarrantsSeriesAToEMember_doc" xml:lang="en-US">Financings 2009 Warrants Series A To E.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesSWarrant" xlink:to="CVM_GainLossSeriesSWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_GainLossSeriesSWarrant_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncentiveStockBonusPlansMember" xlink:to="CVM_IncentiveStockBonusPlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IncentiveStockBonusPlansMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IncentiveStockOptionPlansMember" xlink:to="CVM_IncentiveStockOptionPlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IncentiveStockOptionPlansMember_doc" xml:lang="en-US">Incentive Stock Option Plans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_IssueDate1" xlink:to="CVM_IssueDate1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_IssueDate1_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NonQualifiedStockOptionPlansMember" xlink:to="CVM_NonQualifiedStockOptionPlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NonQualifiedStockOptionPlansMember_doc" xml:lang="en-US">Non Qualified Stock Option Plans.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_NonemployeesShareBasedCompensation" xlink:to="CVM_NonemployeesShareBasedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_NonemployeesShareBasedCompensation_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_OutstandingMember" xlink:label="CVM_OutstandingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_OutstandingMember" xlink:to="CVM_OutstandingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_OutstandingMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PatentMember" xlink:label="CVM_PatentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PatentMember" xlink:to="CVM_PatentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PatentMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PrivateInvestorWarrants1Member" xlink:label="CVM_PrivateInvestorWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrants1Member" xlink:to="CVM_PrivateInvestorWarrants1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrants1Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PrivateInvestorWarrants2Member" xlink:label="CVM_PrivateInvestorWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrants2Member" xlink:to="CVM_PrivateInvestorWarrants2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrants2Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PrivateInvestorWarrants3Member" xlink:label="CVM_PrivateInvestorWarrants3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrants3Member" xlink:to="CVM_PrivateInvestorWarrants3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrants3Member_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PrivateInvestorWarrantsMember" xlink:label="CVM_PrivateInvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorWarrantsMember" xlink:to="CVM_PrivateInvestorWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorWarrantsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PrivateInvestorsMember" xlink:label="CVM_PrivateInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_PrivateInvestorsMember" xlink:to="CVM_PrivateInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_PrivateInvestorsMember_doc" xml:lang="en-US">Private Investors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleOfDerivativeLiabilitiesAtFairValue" xlink:to="CVM_ScheduleOfDerivativeLiabilitiesAtFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ScheduleOfDerivativeLiabilitiesAtFairValue_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" xlink:to="CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" xlink:to="CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeniorConvertibleNotesMember" xlink:label="CVM_SeniorConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeniorConvertibleNotesMember" xlink:to="CVM_SeniorConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeniorConvertibleNotesMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesAThroughEWarrantsMember" xlink:label="CVM_SeriesAThroughEWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesAThroughEWarrantsMember" xlink:to="CVM_SeriesAThroughEWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesAThroughEWarrantsMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesCMember" xlink:label="CVM_SeriesCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesCMember" xlink:to="CVM_SeriesCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesCMember_doc" xml:lang="en-US">Series C.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesEMember" xlink:label="CVM_SeriesEMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesEMember" xlink:to="CVM_SeriesEMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesEMember_doc" xml:lang="en-US">Series E.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesFAndGWarrantsMember" xlink:label="CVM_SeriesFAndGWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesFAndGWarrantsMember" xlink:to="CVM_SeriesFAndGWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesFAndGWarrantsMember_doc" xml:lang="en-US">Series F And G Warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesFMember" xlink:label="CVM_SeriesFMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesFMember" xlink:to="CVM_SeriesFMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesFMember_doc" xml:lang="en-US">Series F.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesGMember" xlink:label="CVM_SeriesGMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesGMember" xlink:to="CVM_SeriesGMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesGMember_doc" xml:lang="en-US">Series G.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesHMember" xlink:label="CVM_SeriesHMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesHMember" xlink:to="CVM_SeriesHMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesHMember_doc" xml:lang="en-US">Series H.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesHWarrantsMember" xlink:label="CVM_SeriesHWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesHWarrantsMember" xlink:to="CVM_SeriesHWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesHWarrantsMember_doc" xml:lang="en-US">Series H Warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesKwarrantsMember" xlink:label="CVM_SeriesKwarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesKwarrantsMember" xlink:to="CVM_SeriesKwarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesKwarrantsMember_doc" xml:lang="en-US">Series K warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesLMember" xlink:label="CVM_SeriesLMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesLMember" xlink:to="CVM_SeriesLMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesLMember_doc" xml:lang="en-US">Series L.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesMModifiedMember" xlink:label="CVM_SeriesMModifiedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesMModifiedMember" xlink:to="CVM_SeriesMModifiedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesMModifiedMember_doc" xml:lang="en-US">Series M Modified.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesMModififedMember" xlink:label="CVM_SeriesMModififedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesMModififedMember" xlink:to="CVM_SeriesMModififedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesMModififedMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesNMember" xlink:to="CVM_SeriesNMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesNMember_doc" xml:lang="en-US">Series N.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesOMember" xlink:label="CVM_SeriesOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesOMember" xlink:to="CVM_SeriesOMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesOMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesOandPMember" xlink:label="CVM_SeriesOandPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesOandPMember" xlink:to="CVM_SeriesOandPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesOandPMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesPMember" xlink:label="CVM_SeriesPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesPMember" xlink:to="CVM_SeriesPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesPMember_doc" xml:lang="en-US">Series P.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesQMember" xlink:label="CVM_SeriesQMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesQMember" xlink:to="CVM_SeriesQMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesQMember_doc" xml:lang="en-US">Series Q.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesQWarrantsMember" xlink:label="CVM_SeriesQWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesQWarrantsMember" xlink:to="CVM_SeriesQWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesQWarrantsMember_doc" xml:lang="en-US">Series Q Warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesRMember" xlink:label="CVM_SeriesRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesRMember" xlink:to="CVM_SeriesRMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesRMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesSMember" xlink:to="CVM_SeriesSMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesSMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesTMember" xlink:label="CVM_SeriesTMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesTMember" xlink:to="CVM_SeriesTMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesTMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesUMember" xlink:label="CVM_SeriesUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SeriesUMember" xlink:to="CVM_SeriesUMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SeriesUMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_SharesIssuableUponExerciseOfwarrant" xlink:to="CVM_SharesIssuableUponExerciseOfwarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_SharesIssuableUponExerciseOfwarrant_doc" xml:lang="en-US">Shares Issuable Upon Exercise Of warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockBonusPlansMember" xlink:to="CVM_StockBonusPlansMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockBonusPlansMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_StockholdersEquityTextBlock" xlink:to="CVM_StockholdersEquityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_StockholdersEquityTextBlock_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_Warrants2008SeriesNMember" xlink:label="CVM_Warrants2008SeriesNMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_Warrants2008SeriesNMember" xlink:to="CVM_Warrants2008SeriesNMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_Warrants2008SeriesNMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_WarrantsHeldbyOfficerAndDirectorMember" xlink:label="CVM_WarrantsHeldbyOfficerAndDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_WarrantsHeldbyOfficerAndDirectorMember" xlink:to="CVM_WarrantsHeldbyOfficerAndDirectorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_WarrantsHeldbyOfficerAndDirectorMember_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:to="CVM_CommitmentsAndContingenciesDetailsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CVM_CommitmentsAndContingenciesDetailsAbstract_doc" xml:lang="en-US">Custom Element.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeposits" xlink:to="us-gaap_IncreaseDecreaseInDeposits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeposits_2_lbl" xml:lang="en-US">Increase (Decrease) in Deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:to="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders_2_lbl" xml:lang="en-US">Increase (Decrease) in Due to Officers and Stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2_lbl" xml:lang="en-US">Repayments of Debt and Capital Lease Obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesSWarrant" xlink:to="CVM_GainLossSeriesSWarrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesSWarrant_3_lbl" xml:lang="en-US">GainLossSeriesSWarrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesVWarrants" xlink:to="CVM_GainLossSeriesVWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesVWarrants_2_lbl" xml:lang="en-US">GainLossSeriesVWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesWWarrants" xlink:to="CVM_GainLossSeriesWWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesWWarrants_2_lbl" xml:lang="en-US">GainLossSeriesWWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesZWarrants" xlink:to="CVM_GainLossSeriesZWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesZWarrants_2_lbl" xml:lang="en-US">GainLossSeriesZWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesZzWarrants" xlink:to="CVM_GainLossSeriesZzWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesZzWarrants_2_lbl" xml:lang="en-US">GainLossSeriesZzWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesAaWarrants" xlink:to="CVM_GainLossSeriesAaWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesAaWarrants_2_lbl" xml:lang="en-US">GainLossSeriesAaWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesBbWarrants" xlink:to="CVM_GainLossSeriesBbWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesBbWarrants_2_lbl" xml:lang="en-US">GainLossSeriesBbWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesCcWarrants" xlink:to="CVM_GainLossSeriesCcWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesCcWarrants_2_lbl" xml:lang="en-US">GainLossSeriesCcWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesDdWarrants" xlink:to="CVM_GainLossSeriesDdWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesDdWarrants_2_lbl" xml:lang="en-US">GainLossSeriesDdWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesEeWarrants" xlink:to="CVM_GainLossSeriesEeWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesEeWarrants_2_lbl" xml:lang="en-US">GainLossSeriesEeWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesFfWarrants" xlink:to="CVM_GainLossSeriesFfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesFfWarrants_2_lbl" xml:lang="en-US">GainLossSeriesFfWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesGgWarrants" xlink:to="CVM_GainLossSeriesGgWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesGgWarrants_2_lbl" xml:lang="en-US">GainLossSeriesGgWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesHhWarrants" xlink:to="CVM_GainLossSeriesHhWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesHhWarrants_2_lbl" xml:lang="en-US">GainLossSeriesHhWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesIiWarrants" xlink:to="CVM_GainLossSeriesIiWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesIiWarrants_2_lbl" xml:lang="en-US">GainLossSeriesIiWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesJjWarrants" xlink:to="CVM_GainLossSeriesJjWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesJjWarrants_2_lbl" xml:lang="en-US">GainLossSeriesJjWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesKkWarrants" xlink:to="CVM_GainLossSeriesKkWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesKkWarrants_2_lbl" xml:lang="en-US">GainLossSeriesKkWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CVM_GainLossSeriesLlWarrants" xlink:to="CVM_GainLossSeriesLlWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CVM_GainLossSeriesLlWarrants_2_lbl" xml:lang="en-US">GainLossSeriesLlWarrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_2_lbl" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Rolling after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cvm-20170630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: QXInteractive; Version: 4.20a -->
    <!-- Field: Doc-Info; Name: Source; Value: 173321 12312017 10Q1.xfr; Date: 2018%2D02%2D09T15:11:46Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:href="cvm-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheets" xlink:href="cvm-20170630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:href="cvm-20170630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfOperations" xlink:href="cvm-20170630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/StatementsOfCashFlows" xlink:href="cvm-20170630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="cvm-20170630.xsd#A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/B.OperationsAndFinancing" xlink:href="cvm-20170630.xsd#B.OperationsAndFinancing" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquity" xlink:href="cvm-20170630.xsd#C.StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurements" xlink:href="cvm-20170630.xsd#D.FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/E.RelatedPartyTransactions" xlink:href="cvm-20170630.xsd#E.RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/F.NotesPayable" xlink:href="cvm-20170630.xsd#F.NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingencies" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.Patents" xlink:href="cvm-20170630.xsd#H.Patents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShare" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/J.SubsequentEvents" xlink:href="cvm-20170630.xsd#J.SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cvm-20170630.xsd#A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityTables" xlink:href="cvm-20170630.xsd#C.StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurementsTables" xlink:href="cvm-20170630.xsd#D.FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesTables" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.PatentsTables" xlink:href="cvm-20170630.xsd#H.PatentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareTables" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails1" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails2" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails3" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetails4" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/C.StockholdersEquityDetailsNarrative" xlink:href="cvm-20170630.xsd#C.StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurementsDetails" xlink:href="cvm-20170630.xsd#D.FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/D.FairValueMeasurementsDetails1" xlink:href="cvm-20170630.xsd#D.FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/E.RelatedPartyLoanDetailsNarrative" xlink:href="cvm-20170630.xsd#E.RelatedPartyLoanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/F.NotesPayableDetailsNarrative" xlink:href="cvm-20170630.xsd#F.NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails1" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetailsNarrative" xlink:href="cvm-20170630.xsd#G.CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.PatentsDetails" xlink:href="cvm-20170630.xsd#H.PatentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/H.PatentsDetailsNarrative" xlink:href="cvm-20170630.xsd#H.PatentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails1" xlink:href="cvm-20170630.xsd#I.EarningsLossPerCommonShareDetails1" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_DocumentAndEntityInformationAbstract" xlink:label="loc_CVMDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheets" xlink:title="00000002 - Statement - BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToOfficersOrStockholdersCurrent" xlink:label="loc_us-gaapDueToOfficersOrStockholdersCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToOfficersOrStockholdersCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="loc_us-gaapNotesAndLoansPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesAndLoansPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_LeaseLiability" xlink:label="loc_CVMLeaseLiability" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_CVMLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherIncome" xlink:label="loc_us-gaapOtherIncome" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/StatementsOfCashFlows" xlink:title="00000005 - Statement - STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_CapitalizedLeaseInterest" xlink:label="loc_CVMCapitalizedLeaseInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CVMCapitalizedLeaseInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInDeposits" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders" xlink:label="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDueToOfficersAndStockholders" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingLiabilitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:label="loc_CVMLeasePaymentsIncludedInAccountsPayableAtYearEnd" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMLeasePaymentsIncludedInAccountsPayableAtYearEnd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsIncurred" xlink:label="loc_us-gaapCapitalLeaseObligationsIncurred" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCapitalLeaseObligationsIncurred" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_LiabilitiesAssumed" xlink:label="loc_CVMLiabilitiesAssumed" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMLiabilitiesAssumed" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IncreaseInDirectFinancingCosts" xlink:label="loc_CVMIncreaseInDirectFinancingCosts" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMIncreaseInDirectFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IncreaseInPrepaidServices" xlink:label="loc_CVMIncreaseInPrepaidServices" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CVMIncreaseInPrepaidServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:title="00000006 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/B.OperationsAndFinancing" xlink:title="00000007 - Disclosure - B. OPERATIONS AND FINANCING">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquity" xlink:title="00000008 - Disclosure - C. STOCKHOLDERS EQUITY">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_StockholdersEquityTextBlock" xlink:label="loc_CVMStockholdersEquityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_CVMStockholdersEquityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurements" xlink:title="00000009 - Disclosure - D. FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/E.RelatedPartyTransactions" xlink:title="00000010 - Disclosure - E. RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NotesToFinancialStatementsAbstract" xlink:label="loc_CVMNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/F.NotesPayable" xlink:title="00000011 - Disclosure - F. NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_F.NotesPayableAbstract" xlink:label="loc_CVMF.NotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMF.NotesPayableAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingencies" xlink:title="00000012 - Disclosure - G. COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.Patents" xlink:title="00000013 - Disclosure - H. PATENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShare" xlink:title="00000014 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/J.SubsequentEvents" xlink:title="00000015 - Disclosure - J. SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000016 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:label="loc_CVMOrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMOrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaapPropertyPlantAndEquipmentImpairment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMOrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentImpairment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMOrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMOrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMOrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaapDerivativesReportingOfDerivativeActivity" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMOrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapDerivativesReportingOfDerivativeActivity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMOrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMOrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMOrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMOrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityTables" xlink:title="00000017 - Disclosure - C. STOCKHOLDERS EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_StockholdersEquityTablesAbstract" xlink:label="loc_CVMStockholdersEquityTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" xlink:label="loc_CVMScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockholdersEquityTablesAbstract" xlink:to="loc_CVMScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockholdersEquityTablesAbstract" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" xlink:label="loc_CVMScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockholdersEquityTablesAbstract" xlink:to="loc_CVMScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ScheduleOfDerivativeLiabilitiesAtFairValue" xlink:label="loc_CVMScheduleOfDerivativeLiabilitiesAtFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockholdersEquityTablesAbstract" xlink:to="loc_CVMScheduleOfDerivativeLiabilitiesAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock" xlink:label="loc_CVMScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockholdersEquityTablesAbstract" xlink:to="loc_CVMScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurementsTables" xlink:title="00000018 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueMeasurementsTablesAbstract" xlink:label="loc_CVMFairValueMeasurementsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsTablesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsTablesAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesTables" xlink:title="00000019 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_F.CommitmentsAndContingenciesTablesAbstract" xlink:label="loc_CVMF.CommitmentsAndContingenciesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMF.CommitmentsAndContingenciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMF.CommitmentsAndContingenciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.PatentsTables" xlink:title="00000020 - Disclosure - H. PATENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PatentsTablesAbstract" xlink:label="loc_CVMPatentsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsTablesAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShareTables" xlink:title="00000021 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NetIncomeLossPerCommonShareTablesAbstract" xlink:label="loc_CVMNetIncomeLossPerCommonShareTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNetIncomeLossPerCommonShareTablesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMNetIncomeLossPerCommonShareTablesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails" xlink:title="00000022 - Disclosure - C. STOCKHOLDERS EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_C.StockholdersEquityDetailsAbstract" xlink:label="loc_CVMC.StockholdersEquityDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMC.StockholdersEquityDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IncentiveStockOptionPlansMember" xlink:label="loc_CVMIncentiveStockOptionPlansMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMIncentiveStockOptionPlansMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NonQualifiedStockOptionPlansMember" xlink:label="loc_CVMNonQualifiedStockOptionPlansMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMNonQualifiedStockOptionPlansMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_StockBonusPlansMember" xlink:label="loc_CVMStockBonusPlansMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMStockBonusPlansMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaapStockCompensationPlanMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockCompensationPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IncentiveStockBonusPlansMember" xlink:label="loc_CVMIncentiveStockBonusPlansMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CVMIncentiveStockBonusPlansMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails1" xlink:title="00000023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_C.StockholdersEquityDetails1Abstract" xlink:label="loc_CVMC.StockholdersEquityDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMC.StockholdersEquityDetails1Abstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMC.StockholdersEquityDetails1Abstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMC.StockholdersEquityDetails1Abstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails2" xlink:title="00000024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_StockholdersEquityDetails2Abstract" xlink:label="loc_CVMStockholdersEquityDetails2Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockholdersEquityDetails2Abstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_NonemployeesShareBasedCompensation" xlink:label="loc_CVMNonemployeesShareBasedCompensation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMStockholdersEquityDetails2Abstract" xlink:to="loc_CVMNonemployeesShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails3" xlink:title="00000025 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_DerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" xlink:label="loc_CVMDerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMDerivativesLiabilitiesWarrantsAndOtherOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesDdMember" xlink:label="loc_CVMSeriesDdMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesDdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesEeMember" xlink:label="loc_CVMSeriesEeMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesEeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesNMember" xlink:label="loc_CVMSeriesNMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesNMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesSMember" xlink:label="loc_CVMSeriesSMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesVMember" xlink:label="loc_CVMSeriesVMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesVMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesWMember" xlink:label="loc_CVMSeriesWMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesWMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesXMember" xlink:label="loc_CVMSeriesXMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesXMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesYMember" xlink:label="loc_CVMSeriesYMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesYMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesZzMember" xlink:label="loc_CVMSeriesZzMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZzMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesBbMember" xlink:label="loc_CVMSeriesBbMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesBbMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesZMember" xlink:label="loc_CVMSeriesZMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesZMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesFfMember" xlink:label="loc_CVMSeriesFfMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesFfMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesCcMember" xlink:label="loc_CVMSeriesCcMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesCcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesHhMember" xlink:label="loc_CVMSeriesHhMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesHhMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesAaMember" xlink:label="loc_CVMSeriesAaMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesAaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesJjMember" xlink:label="loc_CVMSeriesJjMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesJjMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesLlMember" xlink:label="loc_CVMSeriesLlMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesLlMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesMmMember" xlink:label="loc_CVMSeriesMmMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesMmMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesNnMember" xlink:label="loc_CVMSeriesNnMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesNnMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesOoMember" xlink:label="loc_CVMSeriesOoMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesOoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesQqMember" xlink:label="loc_CVMSeriesQqMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesQqMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesGgMember" xlink:label="loc_CVMSeriesGgMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesGgMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesIiMember" xlink:label="loc_CVMSeriesIiMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesIiMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesRrMember" xlink:label="loc_CVMSeriesRrMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesRrMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesKkMember" xlink:label="loc_CVMSeriesKkMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesKkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesSsMember" xlink:label="loc_CVMSeriesSsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesSsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SeriesPpMember" xlink:label="loc_CVMSeriesPpMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMSeriesPpMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ConsultantsMember" xlink:label="loc_CVMConsultantsMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CVMConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_IssueDate1" xlink:label="loc_CVMIssueDate1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMIssueDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_SharesIssuableUponExerciseOfwarrant" xlink:label="loc_CVMSharesIssuableUponExerciseOfwarrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMSharesIssuableUponExerciseOfwarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExercisePrice" xlink:label="loc_CVMExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExercisePriceMinimum" xlink:label="loc_CVMExercisePriceMinimum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExercisePriceMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExercisePriceMaximum" xlink:label="loc_CVMExercisePriceMaximum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExercisePriceMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ExpirationDate" xlink:label="loc_CVMExpirationDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_CVMExpirationDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetails4" xlink:title="00000026 - Disclosure - C. STOCKHOLDERS EQUITY (Details 4)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:label="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesSWarrants" xlink:label="loc_CVMFairValueOfSeriesSWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesSWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesUWarrants" xlink:label="loc_CVMFairValueOfSeriesUWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesUWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesVWarrants" xlink:label="loc_CVMFairValueOfSeriesVWarrants" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesVWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesWWarrants" xlink:label="loc_CVMFairValueOfSeriesWWarrants" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesWWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesZwarrants" xlink:label="loc_CVMFairValueOfSeriesZwarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesZwarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesZzWarrants" xlink:label="loc_CVMFairValueOfSeriesZzWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesZzWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesAaWarrants" xlink:label="loc_CVMFairValueOfSeriesAaWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesAaWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesBbWarrants" xlink:label="loc_CVMFairValueOfSeriesBbWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesBbWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesCcWarrants" xlink:label="loc_CVMFairValueOfSeriesCcWarrants" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesCcWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesDdWarrants" xlink:label="loc_CVMFairValueOfSeriesDdWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesDdWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesEeWarrants" xlink:label="loc_CVMFairValueOfSeriesEeWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesEeWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesFfWarrants" xlink:label="loc_CVMFairValueOfSeriesFfWarrants" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesFfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesGgWarrants" xlink:label="loc_CVMFairValueOfSeriesGgWarrants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesGgWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesHhWarrants" xlink:label="loc_CVMFairValueOfSeriesHhWarrants" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesHhWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesIiWarrants" xlink:label="loc_CVMFairValueOfSeriesIiWarrants" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesIiWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesJjWarrants" xlink:label="loc_CVMFairValueOfSeriesJjWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesJjWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesKkWarrants" xlink:label="loc_CVMFairValueOfSeriesKkWarrants" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesKkWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueOfSeriesLlWarrants" xlink:label="loc_CVMFairValueOfSeriesLlWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMFairValueOfSeriesLlWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_TotalFairValueOfDerivativeLiabilities" xlink:label="loc_CVMTotalFairValueOfDerivativeLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMTotalFairValueOfDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesSWarrant" xlink:label="loc_CVMGainLossSeriesSWarrant" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesSWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesVWarrants" xlink:label="loc_CVMGainLossSeriesVWarrants" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesVWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesWWarrants" xlink:label="loc_CVMGainLossSeriesWWarrants" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesWWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesZWarrants" xlink:label="loc_CVMGainLossSeriesZWarrants" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesZWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesZzWarrants" xlink:label="loc_CVMGainLossSeriesZzWarrants" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesZzWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesAaWarrants" xlink:label="loc_CVMGainLossSeriesAaWarrants" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesAaWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesBbWarrants" xlink:label="loc_CVMGainLossSeriesBbWarrants" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesBbWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesCcWarrants" xlink:label="loc_CVMGainLossSeriesCcWarrants" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesCcWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesDdWarrants" xlink:label="loc_CVMGainLossSeriesDdWarrants" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesDdWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesEeWarrants" xlink:label="loc_CVMGainLossSeriesEeWarrants" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesEeWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesFfWarrants" xlink:label="loc_CVMGainLossSeriesFfWarrants" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesFfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesGgWarrants" xlink:label="loc_CVMGainLossSeriesGgWarrants" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesGgWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesHhWarrants" xlink:label="loc_CVMGainLossSeriesHhWarrants" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesHhWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesIiWarrants" xlink:label="loc_CVMGainLossSeriesIiWarrants" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesIiWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesJjWarrants" xlink:label="loc_CVMGainLossSeriesJjWarrants" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesJjWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesKkWarrants" xlink:label="loc_CVMGainLossSeriesKkWarrants" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesKkWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_GainLossSeriesLlWarrants" xlink:label="loc_CVMGainLossSeriesLlWarrants" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_CVMGainLossSeriesLlWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/C.StockholdersEquityDetailsNarrative" xlink:title="00000027 - Disclosure - C. STOCKHOLDERS EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_C.StockholdersEquityDetailsNarrativeAbstract" xlink:label="loc_CVMC.StockholdersEquityDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMC.StockholdersEquityDetailsNarrativeAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMC.StockholdersEquityDetailsNarrativeAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurementsDetails" xlink:title="00000028 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueMeasurementsDetailsAbstract" xlink:label="loc_CVMFairValueMeasurementsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueMeasurementsAbstract" xlink:label="loc_CVMFairValueMeasurementsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CVMFairValueMeasurementsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaapDerivativeFairValueOfDerivativeLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsAbstract" xlink:to="loc_us-gaapDerivativeFairValueOfDerivativeLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/D.FairValueMeasurementsDetails1" xlink:title="00000029 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_FairValueMeasurementsDetails1Abstract" xlink:label="loc_CVMFairValueMeasurementsDetails1Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:label="loc_us-gaapFairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMFairValueMeasurementsDetails1Abstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/E.RelatedPartyLoanDetailsNarrative" xlink:title="00000030 - Disclosure - E. RELATED PARTY LOAN (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_E.LoansFromOfficerDetailsNarrativeAbstract" xlink:label="loc_CVME.LoansFromOfficerDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaapInterestExpenseRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVME.LoansFromOfficerDetailsNarrativeAbstract" xlink:to="loc_us-gaapInterestExpenseRelatedParty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/F.NotesPayableDetailsNarrative" xlink:title="00000031 - Disclosure - F. NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_F.NotesPayableDetailsNarrativeAbstract" xlink:label="loc_CVMF.NotesPayableDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentAmount1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMF.NotesPayableDetailsNarrativeAbstract" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMF.NotesPayableDetailsNarrativeAbstract" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails" xlink:title="00000032 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_CommitmentsAndContingenciesDetailsAbstract" xlink:label="loc_CVMCommitmentsAndContingenciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMCommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails1" xlink:title="00000033 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_F.CommitmentsAndContingenciesDetailsAbstract" xlink:label="loc_CVMF.CommitmentsAndContingenciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMF.CommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMF.CommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMF.CommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMF.CommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMF.CommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMF.CommitmentsAndContingenciesDetailsAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/G.CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000034 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_G.CommitmentsAndContingenciesDetailsNarrativeAbstract" xlink:label="loc_CVMG.CommitmentsAndContingenciesDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMG.CommitmentsAndContingenciesDetailsNarrativeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaapStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaapSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementGeographicalAxis" xlink:to="loc_us-gaapSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_ResearchAndDevelopmentLabMember" xlink:label="loc_CVMResearchAndDevelopmentLabMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_CVMResearchAndDevelopmentLabMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_HeadquartersMember" xlink:label="loc_CVMHeadquartersMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentGeographicalDomain" xlink:to="loc_CVMHeadquartersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRentCreditCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.PatentsDetails" xlink:title="00000035 - Disclosure - H. PATENTS (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PatentsDetailsAbstract" xlink:label="loc_CVMPatentsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/H.PatentsDetailsNarrative" xlink:title="00000036 - Disclosure - H. PATENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_PatentsDetailsNarrativeAbstract" xlink:label="loc_CVMPatentsDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsNarrativeAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMPatentsDetailsNarrativeAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails" xlink:title="00000037 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Details)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_I.EarningsPerShareDetailsAbstract" xlink:label="loc_CVMI.EarningsPerShareDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapIncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails1" xlink:title="00000038 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Details 1)">
      <link:loc xlink:type="locator" xlink:href="cvm-20170630.xsd#CVM_I.EarningsPerShareDetailsNarrativeAbstract" xlink:label="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CVMI.EarningsPerShareDetailsNarrativeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825775136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 04, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CEL SCI CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000725363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Is Entity a Well-known Seasoned Issuer?</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Is Entity a Voluntary Filer?</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Is Entity's Reporting Status Current?</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,993,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826252112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,142,734<span></span>
</td>
<td class="nump">$ 2,369,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">47,610<span></span>
</td>
<td class="nump">218,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">805,729<span></span>
</td>
<td class="nump">826,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits - current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory used for R&amp;D and manufacturing</a></td>
<td class="nump">644,749<span></span>
</td>
<td class="nump">672,522<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,640,822<span></span>
</td>
<td class="nump">4,236,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Plant, property and equipment, net</a></td>
<td class="nump">16,647,211<span></span>
</td>
<td class="nump">16,793,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patent costs, net</a></td>
<td class="nump">214,872<span></span>
</td>
<td class="nump">223,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">1,670,917<span></span>
</td>
<td class="nump">1,670,917<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">22,173,822<span></span>
</td>
<td class="nump">22,924,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,872,799<span></span>
</td>
<td class="nump">8,196,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">970,042<span></span>
</td>
<td class="nump">936,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOfficersOrStockholdersCurrent', window );">Due to employees</a></td>
<td class="nump">846,751<span></span>
</td>
<td class="nump">693,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayableCurrent', window );">Notes payable</a></td>
<td class="nump">874,593<span></span>
</td>
<td class="nump">994,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative instruments, current portion</a></td>
<td class="nump">19,724<span></span>
</td>
<td class="nump">10,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">11,815<span></span>
</td>
<td class="nump">12,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,595,724<span></span>
</td>
<td class="nump">10,844,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative instruments - net of current portion</a></td>
<td class="nump">2,991,908<span></span>
</td>
<td class="nump">2,042,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_LeaseLiability', window );">Lease Liability</a></td>
<td class="nump">13,255,468<span></span>
</td>
<td class="nump">13,211,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">126,550<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">38,212<span></span>
</td>
<td class="nump">37,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">27,007,862<span></span>
</td>
<td class="nump">26,261,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' DEFICIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value - 600,000,000 shares authorized; 13,258,051 and 11,903,133 shares issued and outstanding at December 31, 2017 and September 30, 2017, respectively</a></td>
<td class="nump">132,581<span></span>
</td>
<td class="nump">119,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">300,975,618<span></span>
</td>
<td class="nump">296,298,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(305,942,239)<span></span>
</td>
<td class="num">(299,754,409)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(4,834,040)<span></span>
</td>
<td class="num">(3,336,977)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT</a></td>
<td class="nump">$ 22,173,822<span></span>
</td>
<td class="nump">$ 22,924,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOfficersOrStockholdersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOfficersOrStockholdersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762127888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock Shares Par Value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Shares Authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock Shares Par Value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock Shares Authorized</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="nump">13,258,051<span></span>
</td>
<td class="nump">11,903,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock Shares Outstanding</a></td>
<td class="nump">13,258,051<span></span>
</td>
<td class="nump">11,903,133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826347152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Grant and other income</a></td>
<td class="nump">$ 113,897<span></span>
</td>
<td class="nump">$ 17,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">2,326,014<span></span>
</td>
<td class="nump">3,548,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General &amp; administrative</a></td>
<td class="nump">2,699,313<span></span>
</td>
<td class="nump">1,407,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,025,327<span></span>
</td>
<td class="nump">4,955,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(4,911,430)<span></span>
</td>
<td class="num">(4,938,008)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Loss) gain on derivative instruments</a></td>
<td class="num">(958,230)<span></span>
</td>
<td class="nump">8,928,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(318,170)<span></span>
</td>
<td class="num">(469,151)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (ioss) income available to common shareholders</a></td>
<td class="num">$ (6,187,830)<span></span>
</td>
<td class="nump">$ 3,521,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET (LOSS) INCOME PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">BASIC</a></td>
<td class="nump">11,636,730<span></span>
</td>
<td class="nump">5,994,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">DILUTED</a></td>
<td class="nump">11,636,730<span></span>
</td>
<td class="nump">6,084,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826932272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) Income</a></td>
<td class="num">$ (6,187,830)<span></span>
</td>
<td class="nump">$ 3,521,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) income to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">155,417<span></span>
</td>
<td class="nump">159,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based payments for services</a></td>
<td class="nump">42,342<span></span>
</td>
<td class="nump">78,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity based compensation</a></td>
<td class="nump">1,448,098<span></span>
</td>
<td class="nump">312,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Common stock contributed to 401(k) plan</a></td>
<td class="nump">35,880<span></span>
</td>
<td class="nump">38,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on retired equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss (gain) on derivative instruments</a></td>
<td class="nump">958,230<span></span>
</td>
<td class="num">(8,928,312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">611,717<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_CapitalizedLeaseInterest', window );">Capitalized lease interest</a></td>
<td class="nump">43,543<span></span>
</td>
<td class="nump">51,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>(Increase)/decrease in assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">195,871<span></span>
</td>
<td class="nump">85,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">3,765<span></span>
</td>
<td class="nump">96,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory used for R&amp;D and manufacturing</a></td>
<td class="nump">27,773<span></span>
</td>
<td class="nump">314,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeposits', window );">Deposits</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract', window );"><strong>Increase/(decrease) in liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(286,984)<span></span>
</td>
<td class="num">(75,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">33,344<span></span>
</td>
<td class="num">(59,196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">1,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders', window );">Due to employees</a></td>
<td class="nump">152,920<span></span>
</td>
<td class="nump">17,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent liability</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="num">(1,496)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,612,858)<span></span>
</td>
<td class="num">(4,239,206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Expenditures for patent costs</a></td>
<td class="num">(959)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(959)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="nump">2,389,395<span></span>
</td>
<td class="nump">3,709,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on obligations under capital lease</a></td>
<td class="num">(2,282)<span></span>
</td>
<td class="num">(2,048)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,387,113<span></span>
</td>
<td class="nump">3,707,883<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(226,704)<span></span>
</td>
<td class="num">(531,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD</a></td>
<td class="nump">2,369,438<span></span>
</td>
<td class="nump">2,917,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, END OF PERIOD</a></td>
<td class="nump">2,142,734<span></span>
</td>
<td class="nump">2,386,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease in receivable due under the litigation funding arrangement offset by the same amount payable to the legal firm providing the services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">305,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capitalizable patent costs included in accounts payable</a></td>
<td class="nump">6,967<span></span>
</td>
<td class="nump">6,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd', window );">Capital lease obligation included in accounts payable</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsIncurred', window );">Property and equipment acquired through capital lease</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_LiabilitiesAssumed', window );">Fair value of warrants issued in connection with public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,316,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncreaseInDirectFinancingCosts', window );">Financing costs included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">77,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IncreaseInPrepaidServices', window );">Prepaid consulting services paid with issuance of common stock</a></td>
<td class="num">(16,935)<span></span>
</td>
<td class="num">(18,183)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes payable converted into common shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest expense</a></td>
<td class="nump">$ 433,707<span></span>
</td>
<td class="nump">$ 469,366<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_CapitalizedLeaseInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_CapitalizedLeaseInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncreaseInDirectFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncreaseInDirectFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IncreaseInPrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IncreaseInPrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_LeasePaymentsIncludedInAccountsPayableAtYearEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_LiabilitiesAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_LiabilitiesAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase during the period in capital lease obligations due to entering into new capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a),(c),(d),(e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6477933&amp;loc=d3e60009-112784<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease), during an accounting period, in total obligations owed to the reporting entity's executives and owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToOfficersAndStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817239520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify; text-indent: 40pt"><u>Basis of Presentation</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">The accompanying condensed financial
statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included
in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of
America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of
the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim
condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s
annual report on Form 10-K for the year ended September 30, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">In the opinion of management, the
accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring
nature) necessary for a fair presentation of the Company&#8217;s financial position as of December 31, 2017 and the results of
its operations for the three months then ended. The condensed balance sheet as of September 30, 2017 is derived from the September
30, 2017 audited financial statements. Significant accounting policies have been consistently applied in the interim financial
statements and the annual financial statements. The results of operations for the three months ended December 31, 2017 and 2016
are not necessarily indicative of the results to be expected for the entire year.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">The financial statements have been
prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity
needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do
not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><u>Summary of Significant Accounting
Policies:</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><i>Research and Office Equipment
and Leasehold Improvements</i> - Research and office equipment is recorded at cost and depreciated using the straight-line method
over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful
life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when
incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><i>Patents</i> - Patent expenditures
are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of
the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate
adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted
cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset.
The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><i>Research and Development Costs</i>
- Research and development costs are expensed as incurred. Management accrues CRO expenses and clinical trial study expenses based
on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study.
Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated
expense in the period in which the facts that give rise to the revision become known.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><i>&#160;</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><i>Income Taxes</i> - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability
method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss
carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records
a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. &#160;A full
valuation allowance was recorded against the deferred tax assets as of December 31, 2017 and September 30, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">On December
22, 2017, the "Tax Cuts and Jobs Act" (the "Tax Act"), was signed into law by the President of the United States (U.S.). The
Tax Act includes significant changes to corporate taxation, including reduction of the U.S. corporate tax rate from 35% to
21%, effective January 1, 2018, limitation of the tax deduction for interest expense to 30% of earnings (execpt for
certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and
elimination of net operating loss carrybacks. The Company has accounted for certain income tax effects of the Act in applying
FASB ASC 740 to the current reporting period. Because the Company records a valuation allowance for its entire deferred
income tax asset, there was no impact to the amounts reported in the Companys&#8217; financial statements resulting from the
Tax Act.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><i>Derivative Instruments</i> &#8211;
The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative
features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &#8220;Accounting
for Derivative Instruments and Hedging Activities.&#8221; In accordance with accounting principles generally accepted in the United
States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance
sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the
nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments
based on available market data using appropriate valuation models giving consideration to all of the rights and obligations of
each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><i>Deferred Rent</i>&#8211; Certain
of the Company&#8217;s operating leases provide for minimum annual payments that adjust over the life of the lease.&#160; The aggregate
minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent
liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent
liability when the lease payments exceed the straight-line rent expense.&#160; For tenant improvement allowances and rent holidays,
the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><i>Leases &#8211;</i> Leases are
categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over
the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of
capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes
an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural
improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit
leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance.
If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on
the Company's balance sheet.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><i>Stock-Based Compensation</i> &#8211;
Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of
ASC 718 &#8220;Compensation &#8211; Stock Compensation.&#8221; The fair value of stock options is calculated using the Black-Scholes
option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option
life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service
or vesting period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">Equity instruments issued to non-employees
are accounted for in accordance with ASC 505-50, &#8220;Equity-Based Payments to Non Employees.&#8221; Accordingly, compensation
is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model
requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected
life of the options.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">The Company has Incentive Stock Option
Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some
cases, these Plans are collectively referred to as the &#34;Plans&#34;. All Plans have been approved by the stockholders.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">The Company&#8217;s stock options
are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess
of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility
on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption was based on the U.S.
Treasury rate at date of the grant with term equal to the expected life of the option. Forfeitures are accounted for when they
occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined
based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly,
stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">Vesting of restricted stock granted
under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity
awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria
is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance
criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><u>New Accounting Pronouncements</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">In May 2017, the FASB issued ASU
2017-09,&#160;<i>Compensation &#8211; Stock Compensation (Topic 718)</i>, which affects any entity that changes the terms or conditions
of a share-based payment award.&#160; This Update amends the definition of modification by qualifying that modification accounting
does not apply to changes to outstanding share-based payment awards that do not affect the total fair value, vesting requirements,
or equity/liability classification of the awards.&#160; The amendments in this Update are effective for all entities for annual
periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including
adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not
yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available
for issuance. The amendments in this Update should be applied prospectively to an award modified on or after the adoption date.
The Company is currently evaluating the impact the adoption of the standard will have on the Company&#8217;s financial position
or results of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">In July 2017, the FASB issued ASU
2017-11,&#160;<i>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivative and Hedging
(Topic 815)</i>. The amendments in Part I of this Update change the classification analysis of certain equity-linked financial
instruments (or embedded features) with down-round features. When determining whether certain financial instruments should be classified
as liabilities or equity instruments, a down-round feature no longer precludes equity classification when assessing whether the
instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified
instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be
accounted for as a derivative liability at fair value as a result of the existence of a down-round feature. For freestanding equity
classified financial instruments, the amendments require entities that present earnings per share (&#8220;EPS&#8221;) in accordance
with Topic 260 to recognize the effect of the down-round feature when it is triggered. That effect is treated as a dividend and
as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options
that have down-round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic
470-20,&#160;<i>Debt&#8212;Debt with Conversion and Other Options</i>), including related EPS guidance (in Topic 260). The amendments
in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as
pending content in the Accounting Standards Codification, to a scope exception. Those amendments do not have an accounting effect.
For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If
an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal
year that includes that interim period. The amendments in Part I of this Update should be applied either retrospectively to outstanding
financial instruments with a down-round feature by means of a cumulative-effect adjustment to the statement of financial position
as of the beginning of the first fiscal year and interim period(s) in which the pending content that links to this paragraph is
effective or retrospectively to outstanding financial instruments with a down-round feature for each prior reporting period presented
in accordance with the guidance on accounting changes in paragraphs 250-10-45-5 through 45-10. The amendments in Part II of this
Update do not require any transition guidance because those amendments do not have an accounting effect.&#160;The Company does
not expect the adoption of this standard to have a significant impact on its EPS calculations, as it does not have any free-standing
equity based financial instruments with down-round provisions.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">In August 2017, the FASB issued ASU
2017-12,&#160;<i>Derivatives and Hedging (Topic 850)</i>, the objective of which is to improve the financial reporting of hedging
relationships to better portray the economic results of an entity&#8217;s risk management activities in its financial statements.
In addition, the amendments in this Update make certain targeted improvements to simplify the application and disclosure of the
hedge accounting guidance in current general accepted accounting principles.&#160;&#160;For public business entities, the amendments
in&#160;this Update are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.
For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods beginning
after December 15, 2020. Early adoption is permitted in any period after issuance.&#160;&#160;For cash flow and net investment
hedges existing at the date of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate&#160;measurement
of ineffectiveness to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained
earnings as of the beginning of the fiscal year that an entity adopts the amendments in this Update. The amended presentation and
disclosure guidance is required only prospectively.&#160;&#160;The Company is currently evaluating the impact the adoption of the
standard will have on the Company&#8217;s financial position or results of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">In February
2016, the FASB issued ASU 2016-02,&#160;<i>Leases</i>, which will require most long-term leases to be recognized on the
balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease.
Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital
lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal
years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the
modified retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating
the effect of the new standard on its financial statements and related disclosures. The Company is currently evaluating the
impact the adoptin of the standard will have on the Company&#8217;s financial position or results of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">In March 2016, the FASB issued ASU
2016-09 <i>Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</i>. The
guidance simplified the accounting and financial reporting of the income tax impact of share-based compensation arrangements. This
guidance requires excess tax benefits to be recorded as a discrete item within income tax expense rather than additional paid-in-capital.
In addition, excess tax benefits are required to be classified as cash from operating activities rather than cash from financing
activities. The Company adopted the provisions of ASU 2016-09 effective October&#160;1, 2017. The Company elected to apply the
cash flow guidance of ASU 2016-09 retrospectively to all prior periods with no impact to historical periods. The Company also adopted
a change in accounting policy to recognize forfeitures of awards as they occur instead of estimating potential forfeitures with
no material impact on historical periods.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">The Company has considered all other
recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact
on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617671328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>B. OPERATIONS AND FINANCING<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">B. OPERATIONS AND FINANCING</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company has incurred significant
costs since its inception for the acquisition of certain patented and unpatented proprietary technology and know-how relating to
the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory
facilities, and clinical trials.&#160; The Company has funded such costs with proceeds from loans and the public and private sale
of its common stock.&#160; The Company will be required to raise additional capital or find additional long-term financing in order
to continue with its research efforts.&#160; To date, the Company has not generated any revenue from product sales. As a result,
the Company has been dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital requirements
and anticipates having to do so in the future.&#160; The ability of the Company to complete the necessary clinical trials and obtain
US Food &#38; Drug Administration (FDA) approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately,
the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues
to support its cost structure.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company is currently running
a large multi-national Phase 3 clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma.
During the three months ended December 31, 2017, the Company raised approximately $2.45 million net proceeds from a public offering.
To finance the study beyond the next twelve months, the Company plans to raise additional capital in the form of corporate partnerships,
debt and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so
consistently in the past and because Multikine is a product in the Phase 3 clinical trial stage. However, there can be no assurance
that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company
on acceptable terms or at all.&#160; If the Company does not raise the necessary amounts of money, it may have to curtail its operations
until such time as it is able to raise the required funding. The financial statements have been prepared assuming the Company will
continue as a going concern, but due to the Company&#8217;s negative working capital, stockholders&#8217; deficit, recurring losses
from operations and future liquidity needs, there is substantial doubt about the Company&#8217;s ability to continue as a going
concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">Since the Company launched its Phase
3 clinical trial for Multikine, the Company has incurred expenses of approximately $47.0 million as of December 31, 2017 on direct
costs for the Phase 3 clinical trial. the Company estimates it will incur additional expenses of approximately $12.2 million for
the remainder of the Phase 3 clinical trial. It should be noted that this estimate is based only on the information currently available
in the Company&#8217;s contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and
does not include other related costs, e.g., the manufacturing of the drug. This number may be affected by the rate of death accumulation
in the study, foreign currency exchange rates, and many other factors, some of which cannot be foreseen today. It is therefore
possible that the cost of the Phase 3 clinical trial will be higher than currently estimated.&#160;Nine hundred twenty-eight (928)
head and neck cancer patients have been enrolled and have completed treatment in the Phase 3 study. The study end point is a 10%
increase in overall survival of patients between the two main comparator groups in favor of the group receiving the Multikine treatment
regimen. The determination if the study end point is met will occur when there are a total of 298 deaths in those two groups.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company&#8217;s shareholders
approved a reverse split of the Company&#8217;s common stock which became effective on the NYSE American on June 15, 2017. On that
date, every twenty-five issued and outstanding shares of the Company&#8217;s common stock automatically converted into one outstanding
share of common stock. As a result of the reverse stock split, the number of outstanding shares of common stock decreased from
230,127,331 (pre-split) shares to 9,201,645 (post-split) shares. By reducing the number of outstanding shares, the Company&#8217;s
loss per share in all prior periods increased by a factor of twenty-five. The reverse stock split affected all stockholders of
the Company&#8217;s common stock uniformly, and did not affect any stockholder&#8217;s percentage of ownership interest. The par
value of the Company&#8217;s stock remained unchanged at $0.01 per share&#160;and the number of authorized shares of common stock
remained the same after the reverse stock split.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817162640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>C. STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockholdersEquityTextBlock', window );">C. STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">Stock options, stock bonuses and
compensation granted by the Company as of December 31, 2017 are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Name of Plan</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total Shares Reserved Under Plans</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Reserved for Outstanding Options</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Issued</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Remaining Options/Shares Under Plans</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 48%"><font style="font-size: 8pt">Incentive Stock Options Plans</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">138,400</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">124,758</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">454</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Non-Qualified Stock Option Plans</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,187,200</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,107,054</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">46,798</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Stock Bonus Plans</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">383,760</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">222,574</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">161,153</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Stock Compensation Plan</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">134,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">115,590</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">18,410</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Incentive Stock Bonus Plan</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">640,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">624,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">Stock options, stock bonuses and
compensation granted by the Company as of September 30, 2017 are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; border-bottom: black 0.75pt solid"><b>Name of Plan</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total Shares Reserved Under Plans</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Reserved for Outstanding Options</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Issued</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Remaining Options/Shares Under Plans</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 48%"><font style="font-size: 8pt">Incentive Stock Option Plans</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">138,400</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">124,758</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">454</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Non-Qualified Stock Option Plans</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,187,200</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,115,086</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">42,830</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Bonus Plans</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">383,760</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">206,390</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">177,337</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Stock Compensation Plan</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">134,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">115,590</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">18,410</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Incentive Stock Bonus Plan</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">640,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">624,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><u>Stock option activity</u>:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 8pt"><b>Three Months Ended December 31,</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 72%"><font style="font-size: 8pt">Granted</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">10,300</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Expired</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">17,523</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">15,081</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Forfeited</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">809</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><u>Stock-Based Compensation Expense</u></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Three months Ended December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 72%"><font style="font-size: 8pt">Employees</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">1,448,098</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">312,375</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Non-employees</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">42,342</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">78,553</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">Employee compensation expense includes the expense related to options issued or vested and restricted stock. The increase
in employee's expense in 2017 is primarily due to an increase of approximately $1.1 million in equity based compensation related
to the Company's shareholder approved 2014 Incentive Stock Bonus Plan. Non&#173;employee expense includes the expense related
to options and stock issued to consultants expensed over the period of their service contracts. Stock based compensation expense
is included in general and administrative expenses on the statements of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt"><u>Warrants and Non-employee Options</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The following chart presents the
outstanding warrants and non-employee options, listed by expiration date at December 31, 2017:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 15%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Warrant</b></font></td>
    <td style="width: 28%; border-bottom: black 1pt solid; padding-right: 18.75pt; text-align: center"><font style="font-size: 8pt"><b>Issue Date</b></font></td>
    <td style="width: 16%; border-bottom: black 1pt solid; padding-right: 7.5pt; text-align: center"><font style="font-size: 8pt"><b>Shares Issuable upon Exercise of Warrants</b></font></td>
    <td style="width: 13%; border-bottom: black 1pt solid; padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="width: 18%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Expiration Date</b></font></td>
    <td style="width: 10%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Reference</b></font></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td><font style="font-size: 8pt">Series DD</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1,360,960</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$4.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3/1/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series EE</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1,360,960</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$4.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3/1/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series N</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">8/18/2008</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">85,339</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/18/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series S</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">10/11/13- 10/24/14</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1,037,120</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$31.25</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/11/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series V</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">5/28/2015</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">810,127</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$19.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5/28/2020</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series W</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">10/28/2015</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">688,930</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$16.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/28/2020</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series X</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1/13/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">120,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$9.25</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1/13/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series Y</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">2/15/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">26,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$12.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/15/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series ZZ</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">5/23/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">20,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5/18/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series BB</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">8/26/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">16,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/22/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series Z</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">5/23/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">264,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">11/23/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series FF</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">68,048</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.91</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/1/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series CC</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">680,480</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$5.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/8/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series HH</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">2/23/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">20,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.13</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/16/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series AA</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">8/26/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">200,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series JJ</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">3/14/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">30,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.13</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3/8/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series LL</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">4/30/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">26,398</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.59</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">4/30/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series MM</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">6/22/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">893,491</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$1.86</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">6/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series NN</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">7/24/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">539,300</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.52</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">7/24/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series OO</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">7/31/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">60,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.52</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">7/31/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series QQ</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">8/22/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">87,500</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series GG</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">2/23/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">400,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/23/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series II</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">3/14/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">600,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">9/14/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series RR</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">10/30/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">583,057</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$1.65</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/30/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series KK</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">5/3/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">395,970</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.04</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">11/3/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series SS</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">12/19/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1,289,478</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.09</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/18/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series PP</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">8/28/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1,750,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.30</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/28/2023</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Consultants</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">3/30/15- 7/28/17</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">40,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.18- $25.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3/29/18- 7/27/27</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif">
<tr>
    <td style="vertical-align: top; width: 24px"><font style="font-size: 8pt">1.</font></td>
    <td style="padding: 0.75pt; text-align: justify"><font style="font-size: 8pt"><u>Derivative Liabilities</u></font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The table below presents the warrant
liabilities and their respective balances at the balance sheet dates:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>December 31, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>September 30, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Series S warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">19,705</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">32,773</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series V warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">171,225</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">72,912</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series W warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">213,221</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">83,754</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series Z warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">132,751</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">77,216</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series ZZ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">8,096</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,753</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series AA warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">112,447</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">65,087</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series BB warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">6,953</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,322</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series CC warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">591,041</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">394,220</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series DD warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">9</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,492</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series EE warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">9</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,492</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series FF warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">65,201</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">47,154</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series GG warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">457,305</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">342,173</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series HH warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">21,676</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">16,014</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series II warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">690,442</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">511,636</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series JJ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">32,745</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">24,203</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series KK warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">460,747</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">345,720</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series LL warrants</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">28,059</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">20,481</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total warrant liabilities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">3,011,632</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">2,053,402</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt">The table below presents the gains and (losses) on the
warrant liabilities for the three months ended December 31:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Series S Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">13,068</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">2,621,321</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series V warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(98,313</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,417,721</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series W warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(129,467</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,667,604</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series Z warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(55,535</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">868,787</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series ZZ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(3,343</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">63,884</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series AA warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(47,360</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">679,569</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series BB warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(2,631</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">52,672</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series CC warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(196,821</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">604,492</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series DD warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,483</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">370,919</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series EE warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,483</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">514,603</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series FF warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(18,047</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">66,740</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series GG warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(115,132</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series HH warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(5,662</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series II warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(178,806</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series JJ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(8,542</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series KK warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(115,027</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Series LL warrants</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(7,578</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Net (loss) gain on warrant liabilities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">(958,230</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">8,928,312</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: right; text-indent: -0.25in">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company reviews all outstanding
warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate
whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument&#8217;s
contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain
dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company&#8217;s stock because
future equity offerings or sales of the Company&#8217;s stock are not an input to the fair value of a &#8220;fixed-for-fixed&#8221;
option on equity shares, and equity classification is therefore precluded.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In accordance with ASC 815, derivative
liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration.
Any change in fair value between the respective reporting dates is recognized as a gain or loss.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">2. <u>Issuance of Equity Warrants</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Series SS Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">On December 19, 2017 the Company
received subscription agreements for the purchase of 1,289,478 shares of CEL-SCI common stock at a price of $1.90 in the principal
amount of $2.45 million.&#160; The purchasers of the common stock also received Series SS warrants which entitle the purchasers
to acquire up to 1,289,478 shares of the Company&#8217;s common stock.&#160;&#160;The warrants are exercisable at a fixed price
of $2.09 per share, are exercisable on June 20, 2018 and will expire on December 18, 2022. Shares issuable upon the exercise of
the warrants will be restricted securities unless registered. The Company allocated the proceeds received to the shares and the
Series SS warrants on a relative fair value basis. As a result of such allocation, the Company determined the initial carrying
value of the Series SS warrants to be approximately $1.0 million. The Series SS warrants qualify for equity treatment in accordance
with ASC 815.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Series RR Warrants</i>&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">On October 30, 2017, holders of convertible
notes in the principal amount of $1.1 million issued in June 2017 and holders of convertible notes in the principal amount of $1.2
million issued in July 2017 agreed to extend the maturity date of these notes to September 21, 2018.&#160;&#160;In consideration
for the extension of the maturity date of the convertible notes, the Company issued a total of 583,057 Series RR warrants to the
convertible note holders that agreed to the extension.&#160;&#160;Each Series RR warrant entitles the holder to purchase one share
of the Company&#8217;s common stock.&#160;&#160;The Series RR warrants may be exercised at any time on or before October 30, 2022
at an exercise price of $1.65 per share. The Series RR warrants were recorded at the fair value on the date of issuance of approximately
$0.7 million, as described in Note F.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Expiration of Warrants</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">On October 17, 2017, 17,821 Series
U warrants, with an exercise price of $43.75 expired. The fair value of the Series U warrants was $0 on the date of expiration.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">On December 6, 2016, 105,000 Series
R warrants, with an exercise price of $100.00, expired. The fair value of the Series R warrants was $0 on the date of expiration.<i>&#160;</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif">
<tr>
    <td style="vertical-align: top; width: 24px"><font style="font-size: 8pt">3.&#160;</font></td>
    <td style="padding: 0.75pt"><font style="font-size: 8pt"><u>Options and shares issued to Consultants</u></font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company typically enters into
consulting arrangements in exchange for common stock or stock options. During the three months ended December 31, 2017, the Company
issued 13,705 shares of common stock, of which 13,705 were restricted shares. During the three months ended December 31, 2016,
the Company issued 14,900 shares of common stock, of which 10,800 were restricted shares. The weighted average grant value of the
shares issued to consultants was $1.85 and $4.98 during the three months ended December 31, 2017 and 2016, respectively. The aggregate
values of the issuances of restricted common stock and common stock options are recorded as prepaid expenses and are charged to
general and administrative expenses over the periods of service.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">During the three months ended December
31, 2017 and 2016, the Company recorded total expense of approximately $42,000 and $79,000, respectively, relating to these consulting
agreements. At December 31, 2017 and September 30, 2017, approximately $28,000 and $45,000, respectively, are included in prepaid
expenses. As of December 31, 2017, the Company had 40,000 options outstanding, which were issued to consultants as payment for
services. All off these options were vested and all were issued from the Non-Qualified Stock Option plans.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Other Equity Transactions</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">On August 15, 2017, the Company entered
into a Securities Purchase Agreement with Ergomed plc, the Company&#8217;s Clinical Research Provider, to facilitate a partial
payment of the accounts payable balances due Ergomed. Under the Agreement, the Company issued Ergomed 480,000 shares, with a fair
market value of approximately $1.3 million, as a forbearance fee in exchange for Ergomed&#8217;s agreement to provisionally forbear
collection of the payables in an amount equal to the net proceeds from the resales of the shares issued to Ergomed. During the
year ended September 30, 2017, the Company recorded the full amount of the expense upon issuance, offset by amounts realized through
the resale of 64,792 shares and the corresponding reduction of the payables, for a net expense of $1.2 million. During the quarter
ended December 31, 2017, the Company realized approximately $0.7 million through the resale of the remaining 415,208 shares and
reduced the payables and interest expense by that amount.</p>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockholdersEquityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockholdersEquityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6636086128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>D. FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">D. FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In accordance with ASC 820-10, <i>&#8220;Fair
Value Measurements,&#8221;</i> the Company determines fair value as the price that would be received to sell an asset or paid to
transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies
the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present
amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">ASC 820-10 establishes a fair value
hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for
identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The
Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy
are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 60px; padding-left: 27pt; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">&#9679;&#160;</font></td>
    <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">Level 1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 60px; padding-left: 27pt; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">&#9679;&#160;</font></td>
    <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">Level 2 &#8211; Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="width: 100%">
<tr>
    <td style="vertical-align: top; width: 60px; padding-left: 27pt; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 8pt">&#9679;&#160;</font></td>
    <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 8pt">Level 3 &#8211; Unobservable inputs that reflect management&#8217;s assumptions</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">For disclosure purposes, assets and
liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant
to the overall fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value
measurement requires judgment and may affect the placement within the fair value hierarchy levels.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The table below sets forth the assets
and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2017:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Other Observable Inputs (Level 2)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Unobservable Inputs (Level 3)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Derivative instruments</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">19,705</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2,991,927</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">3,011,632</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The table below sets forth the assets
and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2017:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Other Observable Inputs (Level 2)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Unobservable Inputs (Level 3)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Derivative instruments</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">32,773</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2,020,629</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2,053,402</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The following sets forth the reconciliation
of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three
months ended December 31, 2017 and the year ended September 30, 2017:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>3 months ended</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>12 months ended</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>December 31, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>September 30, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Beginning balance</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">2,020,629</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">5,283,573</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Issuances</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,665,683</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Realized and unrealized losses and (gains)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">971,298</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(7,928,627</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Ending balance</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2,991,927</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2,020,629</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The fair values of the Company&#8217;s
derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such
as historical price and volatility of the Company&#8217;s stock, as well as U.S. Treasury Bill rates, are observable in active
markets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817183584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>E. RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">E. RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">On July 24, 2017, the Company issued
convertible notes (Series NN Notes) in the aggregate principal amount of $1.2 million to 12 individual investors. A trust in which
Geert Kersten, the Company&#8217;s Chief Executive Officer, holds a beneficial interest participated in the offering and purchased
a note in the principal amount of $250,000. Patricia B. Prichep, the Company&#8217;s Senior Vice President of Operations, participated
in the offering and purchased a note in the principal amount of $25,000. The terms of the trust&#8217;s note and Ms. Prichep&#8217;s
note were identical to the other participants. The number of shares of the Company&#8217;s common stock issued upon conversion
will be determined by dividing the principal amount to be converted by $2.29, which would result in the issuance of 109,170 shares
to the trust and 10,917 shares to Ms. Prichep upon conversion. Along with the other purchasers of the convertible notes, the trust
and Ms. Prichep also received Series NN warrants to purchase up to 109,170 and 10,917 shares, respectively, of the Company&#8217;s
common stock. The Series NN warrants are exercisable at a fixed price of $2.52 per share and expire on July 24, 2022. Shares issuable
upon the exercise of the notes and warrants were restricted securities unless registered. The shares were registered effective
September 1, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">On June 22, 2017, CEL-SCI issued
convertible notes (Series MM Notes) in the aggregate principal amount of $1.5 million to six individual investors. Geert Kersten,
the Company&#8217;s Chief Executive Officer, participated in the offering and purchased notes in the principal amount of $250,000.
The terms of Mr. Kersten&#8217;s note were identical to the other participants. The number of shares of the Company&#8217;s common
stock issued upon conversion will be determined by dividing the principal amount to be converted by $1.69, which would result in
the issuance of 147,929 shares to Mr. Kersten upon conversion. Along with the other purchasers of the convertible notes, Mr. Kersten
also received Series MM warrants to purchase up to 147,929 shares of the Company&#8217;s common stock. The Series MM warrants are
exercisable at a fixed price of $1.86 per share and expire on June 22, 2022. Shares issuable upon the exercise of the notes and
warrants were restricted securities unless registered. The shares were registered effective August 8, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">On October 30, 2017, the due date
of the Series NN and Series MM Notes was extended from December 22, 2017 to September 21, 2018 in exchange for Series RR warrants.
Mr. Kersten, the Trust and Ms. Prichep received 73,965, 54,585 and 5,459 Series RR warrants, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">Approximately $6,000 in accrued interest was due the officers at December 31, 2017. No interest payments were made to officers
during the three months ended December 31, 2017.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6630094064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>F. NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_F.NotesPayableAbstract', window );"><strong>F. Notes Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">F. NOTES PAYABLE</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">On October 30, 2017, the Company
extended the due dates of the Series MM and Series NN Notes (the &#8220;Notes&#8221;) from December 22, 2017 to September 2l, 20l8,
and issued the note holders an additional 583,057 of Series RR Warrants. The Series RR warrants expire on October 30, 2022 and
are priced at $ 1.65 per share, the closing price on October 27, 2017. These Series RR warrants are classified as equity warrants
and are recorded at approximately $0.7 million, the fair value on the date of issuance.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">Because the Company is experiencing
financial difficulties and the creditors granted the Company a concession they would not have otherwise considered in the form
of a lower effective interest rate, this modification was accounted for under ASC 470-60, &#8220;<i>Troubled Debt Restructuring.</i>&#8221;
The Company calculated the future cash flows of the restructured debt to be greater than the carrying value of the debt and accounted
for the change in debt prospectively, using the effective interest rate that equated the carrying amount to the future cash flows.
The carrying value of the debt on the date of restructuring was approximately $0.7 million, which was net of a discount of approximately
$1.6 million. The discount is being amortized to interest expense over the life of the Notes using the effective interest method.
The Company recorded approximately $0.6 million in interest expense, relating to the amortization of the debt discount. As of December
31, 2017, after conversions, the carrying value of the Notes is approximately $0.9 million, net of a discount of approximately
$1.3 million. The Notes bear interest at 4% and are convertible in shares of common stock. At the option of the note holders, the
Notes can be converted into shares of the Company&#8217;s common stock at a fixed conversion rate of $1.69 for the Series MM Notes
and $2.29 for the Series NN Notes.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">During the quarter ended December
31, 2017, a note holder converted a Series NN note, in the principal amount of $75,000, into 32,751 shares of common stock. The
unamortized debt discount relating to the converted Note was charged to interest expense.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Series MM and Series NN Notes
are secured by a first lien on all of the Company&#8217;s assets.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_F.NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_F.NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632576080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>G. COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">G. COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; color: #292929"><i>Clinical Research Agreements</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In March 2013, the Company entered
into an agreement with Aptiv Solutions, Inc. (which was subsequently acquired by ICON Inc.) to provide certain clinical research
services in accordance with a master service agreement. The Company will reimburse ICON for costs incurred. The agreement required
the Company to make $600,000 in advance payments which are being credited against future invoices in $150,000 annual increments
through December 2017. As of December 31, 2017, all advance payments have been expensed.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In April 2013, the Company entered
into a co-development and revenue sharing agreement with Ergomed. Under the agreement, Ergomed will contribute up to $10 million
towards the Company&#8217;s Phase 3 Clinical Trial in the form of offering discounted clinical services in exchange for a single
digit percentage of milestone and royalty payments, up to a specific maximum amount. In October 2015, the Company entered into
a second <font style="color: #292929">co-development and revenue sharing agreement with Ergomed</font> for an additional $2 million,
for a total of $12 million. The Company accounted for the co-development and revenue sharing agreement in accordance with ASC 808
&#8220;Collaborative Arrangements&#8221;. The Company determined the payments to Ergomed are within the scope of ASC 730 &#8220;Research
and Development.&#8221; Therefore, the Company records the discount on the clinical services as a credit to research and development
expense on its Statements of Operations. Since the Company entered into the co-development and revenue sharing agreement with Ergomed,
it has incurred research and development expenses of approximately $25.9 million related to Ergomed&#8217;s services. This amount
is net of Ergomed&#8217;s discount of approximately $8.6 million. During the three months ended December 31, 2017 and 2016, the
Company recorded, net of Ergomed&#8217;s discount, approximately $0.9 million and $1.3 million, respectively, as research and development
expense related to Ergomed&#8217;s services.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company is currently involved
in a pending arbitration proceeding, CEL-SCI Corporation v. inVentiv Health Clinical, LLC (f/k/a PharmaNet LLC) and PharmaNet GmbH
(f/k/a PharmaNet AG). The Company initiated the proceedings against inVentiv Health Clinical, LLC, or inVentiv, the former third-party
CRO, and is seeking payment for damages related to inVentiv&#8217;s prior involvement in the Phase 3 clinical trial of Multikine.
The arbitration claim, initiated under the Commercial Rules of the American Arbitration Association, alleges (i) breach of contract,
(ii) fraud in the inducement, and (iii) common law fraud. Currently, the Company is seeking at least $50 million in damages in
its amended statement of claim.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In an amended statement of claim,
the Company asserted the claims set forth above as well as an additional claim for professional malpractice.&#160;&#160;The arbitrator
subsequently granted inVentiv&#8217;s motion to dismiss the professional malpractice claim based on the &#8220;economic loss doctrine&#8221;
which, under New Jersey law, is a legal doctrine that, under certain circumstances, prohibits bringing a negligence-based claim
alongside a claim for breach of contract.&#160;&#160;The arbitrator denied the remainder of inVentiv&#8217;s motion, which had
sought to dismiss certain other aspects of the amended statement of claim.&#160;&#160;In particular, the arbitrator rejected inVentiv&#8217;s
argument that several aspects of the amended statement of claim were beyond the arbitrator&#8217;s jurisdiction.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In connection with the pending arbitration
proceedings, inVentiv has asserted counterclaims against the Company for (i) breach of contract, seeking at least $2 million in
damages for services allegedly performed by inVentiv; (ii) breach of contract, seeking at least $1 million in damages for the alleged
use of inVentiv&#8217;s name in connection with publications and promotions in violation of the parties&#8217; contract; (iii)
opportunistic breach, restitution and unjust enrichment, seeking at least $20 million in disgorgement of alleged unjust profits
allegedly made by the Company as a result of the purported breaches referenced in subsection (ii); and (iv) defamation, seeking
at least $1 million in damages for allegedly defamatory statements made about inVentiv. The Company believes inVentiv&#8217;s counterclaims
are meritless&#160;and has defended against them. However, if such defense is unsuccessful, and inVentiv successfully asserts any
of its counterclaims, such an adverse determination could have a material adverse effect on the Company&#8217;s business, results,
financial condition and liquidity.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In October 2015 the Company signed
an arbitration funding agreement with a company established by Lake Whillans Litigation Finance, LLC, a firm specializing in funding
litigation expenses. Pursuant to the agreement, an affiliate of Lake Whillans provided the Company with up to $5 million in funding
for litigation expenses to support its arbitration claims against inVentiv. The funding was available to the Company to fund the
expenses of the ongoing arbitration and will only be repaid if the Company receives proceeds from the arbitration. All related
legal fees are directly billed to and paid by Lake Whillans. As part of the agreement with Lake Whillans, the law firm agreed to
cap its fees and expenses for the arbitration at $5 million.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The hearing (the
&#8220;trial&#8221;) started on September 26, 2016. The last witness in the arbitration hearing testified on November 8,
2017, and no further witnesses or testimony are expected. With that final witness, the testimony phase of the arbitration
concluded. All that remained after November 8, 2017 at the trial level were closing statements and post&#173;trial
submissions.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Lease Agreements</i></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company leases a manufacturing
facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company&#8217;s specifications
so that it can be used by the Company to manufacture Multikine for the Company&#8217;s Phase 3 clinical trial and sales of the
drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%.
The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs
and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building
at the end of the 20-year lease. The Company contributed approximately $9.3 million towards the tenant-directed improvements, of
which $3.2 million is being refunded during years six through twenty through reduced rental payments. The landlord paid approximately
$11.9 million towards the purchase of the building, land and the tenant-directed improvements. The Company placed the building
in service in October 2008.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company was deemed to be the
owner of the building for accounting purpose under the build-to-suit guidance in ASC 840-40-55. In addition to tenant improvements
the Company incurred, the Company also recorded an asset for tenant-directed improvements and for the costs paid by the lessor
to purchase the building and to perform improvements, as well as a corresponding liability for the landlord costs. Upon completion
of the improvements, the Company did not meet the &#8220;sale-leaseback&#8221; criteria under ASC 840-40-25, Accounting for Lease,
Sale-Leaseback Transactions, and therefore, treated the lease as a financing obligation. Thus, the asset and corresponding liability
were not de-recognized. As of December 31, 2017 and September 30, 2017, the leased building asset has a net book value of approximately
$16.5 and $16.6 million, respectively, and the landlord liability has a balance of approximately $13.3 and $13.2 million, respectively.
The leased building is being depreciated using a straight line method over the 20 year lease term to a residual value. The landlord
liability is being amortized over the 20 years using the effective interest method. Lease payments allocated to the landlord liability
are accounted for as debt service payments on that liability using the finance method of accounting per ASC 840-40-55.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company was required to deposit
the equivalent of one year of base rent in accordance with the lease. When the Company meets the minimum cash balance required
by the lease, the deposit will be returned to the Company. The approximate $1.7 million deposit is included in non-current assets
at December 31, 2016 and September 30, 2016.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">Approximate future minimum
lease payments under the San Tomas lease as of December 31, 2017 are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">&#160;Nine months ending September 30, 2018&#160;&#160;&#160;</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">1,314,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;Year ending September 30,</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,808,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,872,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,937,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2,004,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2,073,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">11,685,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;Total future minimum lease obligation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">22,693,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;Less imputed interest on financing obligation</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(9,438,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;Net present value of lease financing obligation</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">13,255,000</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company subleases a portion of
its rental space on a month-to-month term lease, which requires a 30 day notice for termination. The Company receives approximately
$6,000 per month in rent for the sub-leased space.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company leases its research and
development laboratory under a 60 month lease which expires February 28, 2022. The operating lease includes escalating rental payments.
The Company is recognizing the related rent expense on a straight-line basis over the full 60 month term of the lease at the rate
of approximately $13,000 per month. As of December 31, 2017 and September 30, 2017, the Company has recorded a deferred rent liability
of approximately $8,000 and $5,000, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company leases its office headquarters
under a 60 month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing
the related rent expense on a straight line basis over the full 60 month term of the lease at the rate approximately $8,000 per
month. As of December 31, 2017 and September 30, 2017, the Company has recorded a deferred rent liability of approximately $17,000
and $18,000, respectively.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">As of December 31, 2017, material
contractual obligations, excluding the San Tomas lease, consisting of non-cancelable operating lease payments are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">Nine months ending September 30, 2018</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">189,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Year ending September 30,</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">258,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">238,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">163,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2022</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">69,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">917,000</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company leases office equipment
under a capital lease arrangement. The term of the capital lease is 60 months and expires on October 31, 2021. The monthly lease
payment is $505. The lease bears interest at approximately 6.25% per annum.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620030432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>H. PATENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">H. PATENTS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">During the three months ended December
31, 2017 and 2016, no patent impairment charges were recorded. For the three months ended December 31, 2017 and 2016, amortization
of patent costs totaled approximately $9,000. Approximate estimated future amortization expense is as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">Nine months ending September 30, 2018</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">27,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Year ending September 30,</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">35,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">32,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">29,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">25,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">15,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">52,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">215,000</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6600460640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>I. EARNINGS (LOSS) PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">I. LOSS PER COMMON SHARE</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
following table provides the details of the basic and diluted earnings (loss) per-share computations:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three
    Months Ended December 31, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Net
    loss</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted
    Average Shares</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>LPS</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Basic
    and diluted loss per share</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(6,187,830)</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">11,636,730</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(0.53</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three
    Months Ended December 31, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Net
    Income</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted
    Average Shares</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>EPS</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 58%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Basic
    earnings per share</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">3,521,153</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">5,994,431</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.59</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Gain
    on derivatives (1)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(1,556,754</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">90,277</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Dilutive
    earnings per share</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,964,399</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">6,084,708</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.32</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td colspan="2" style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;(1)
    Includes certain Series CC, DD, EE and FF warrants</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">The
gain on derivatives priced lower than the average market price during the period is excluded from the numerator and the related
shares are excluded from the denominator in calculating diluted loss per share.</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -20pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">In
accordance with the contingently issuable shares guidance of FASB ASC Topic 260, <i>Earnings Per Share</i>, the calculation of
diluted net earnings (loss) per share excludes the following securities because their inclusion would have been anti-dilutive
as of December 31:</font></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 74%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Options
    and Warrants</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">10,491,090</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">6,946,179</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Unvested
    Restricted Stock</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">332,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">604,000</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Convertible
    debt</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">1,133,355</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">-</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Total</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">11,956,945</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">7,550,179</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817190288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>J. SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">J. SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">As of January 1, 2018, the Company
was indebted to Ergomed, plc for services provided by Ergomed in connection with the Company&#8217;s Phase III clinical trial.
On January 1, 2018 the Company agreed to issue Ergomed 660,000 restricted shares of the Company&#8217;s common stock in partial
payment of the amount the Company owed Ergomed.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">On January 12, 2018, the exercise
price of the Company&#8217;s outstanding Series S warrants (CUSIP number 150837177), that are publicly traded under the symbol
&#8220;CVM WS&#8221; on the NYSE American, was changed to $3.00 per share for a three month period which will end on April 12,
2018. After this date, the exercise price will revert back to $31.25 per share of common stock. As a result of the reverse stock
split which became effective on the NYSE American on June 15, 2017, 25 Series S warrants are required to purchase one share of
common stock. The Series S warrants expire on October 11, 2018.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">On February 5, 2018, the Company
received subscription agreements/commitments for the purchase of 2,608,097 shares of common stock at the closing price on February
5, 2018 of $1.87 in the principal amount of $4,877,140 from 20 investors. The common stock is restricted unless registered. The
purchasers of the common stock also received warrants which entitle the purchasers to acquire up to 1,956,074 shares of the Company&#8217;s
common stock. The warrants are exercisable at a fixed price of $2.24 per share, will not be exercisable for 6 months and one day
and will expire on February 5, 2023. Shares issuable upon the exercise of the warrants are restricted securities unless registered.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767155568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract', window );"><strong>Dilutive EPS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -20pt; text-align: justify; text-indent: 0.25in"><u>Basis of Presentation</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The accompanying condensed financial
statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included
in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of
America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of
the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim
condensed financial statements should be read in conjunction with the financial statements and notes included in the Company&#8217;s
annual report on Form 10-K for the year ended September 30, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In the opinion of management, the
accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring
nature) necessary for a fair presentation of the Company&#8217;s financial position as of December 31, 2017 and the results of
its operations for the three months then ended. The condensed balance sheet as of September 30, 2017 is derived from the September
30, 2017 audited financial statements. Significant accounting policies have been consistently applied in the interim financial
statements and the annual financial statements. The results of operations for the three months ended December 31, 2017 and 2016
are not necessarily indicative of the results to be expected for the entire year.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The financial statements have been
prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations and future liquidity
needs, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do
not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Research and Office Equipment and Leasehold Improvements</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Research and Office Equipment
and Leasehold Improvements</i> - Research and office equipment is recorded at cost and depreciated using the straight-line method
over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful
life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when
incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Patents</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Patents</i> - Patent expenditures
are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of
the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate
adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted
cash flows expected to result from the use of the asset, and from its disposition, is less than the carrying value of the asset.
The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Research and Development Costs</i>
- Research and development costs are expensed as incurred. Management accrues CRO expenses and clinical trial study expenses based
on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study.
Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated
expense in the period in which the facts that give rise to the revision become known.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>&#160;</i></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt"><i>Income Taxes</i> - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability
method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the
financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss
carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in
the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records
a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. &#160;A full
valuation allowance was recorded against the deferred tax assets as of December 31, 2017 and September 30, 2017.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify; text-indent: 0pt">On December
22, 2017, the "Tax Cuts and Jobs Act" (the "Tax Act"), was signed into law by the President of the United States (U.S.). The
Tax Act includes significant changes to corporate taxation, including reduction of the U.S. corporate tax rate from 35% to
21%, effective January 1, 2018, limitation of the tax deduction for interest expense to 30% of earnings (execpt for
certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and
elimination of net operating loss carrybacks. The Company has accounted for certain income tax effects of the Act in applying
FASB ASC 740 to the current reporting period. Because the Company records a valuation allowance for its entire deferred
income tax asset, there was no impact to the amounts reported in the Companys&#8217; financial statements resulting from the
Tax Act.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Derivative Instruments</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Derivative Instruments</i> &#8211;
The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative
features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, &#8220;Accounting
for Derivative Instruments and Hedging Activities.&#8221; In accordance with accounting principles generally accepted in the United
States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance
sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the
nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments
based on available market data using appropriate valuation models giving consideration to all of the rights and obligations of
each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Rent</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Deferred Rent</i>&#8211; Certain
of the Company&#8217;s operating leases provide for minimum annual payments that adjust over the life of the lease.&#160; The aggregate
minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent
liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent
liability when the lease payments exceed the straight-line rent expense.&#160; For tenant improvement allowances and rent holidays,
the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Leases &#8211;</i> Leases are
categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over
the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of
capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes
an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural
improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit
leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance.
If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on
the Company's balance sheet.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><i>Stock-Based Compensation</i> &#8211;
Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of
ASC 718 &#8220;Compensation &#8211; Stock Compensation.&#8221; The fair value of stock options is calculated using the Black-Scholes
option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option
life. The stock-based compensation cost is recognized on the straight line allocation method as expense over the requisite service
or vesting period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">Equity instruments issued to non-employees
are accounted for in accordance with ASC 505-50, &#8220;Equity-Based Payments to Non Employees.&#8221; Accordingly, compensation
is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model
requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected
life of the options.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company has Incentive Stock Option
Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some
cases, these Plans are collectively referred to as the &#34;Plans&#34;. All Plans have been approved by the stockholders.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company&#8217;s stock options
are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess
of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility
on the variance of daily closing prices of the Company&#8217;s stock. The risk-free interest rate assumption was based on the U.S.
Treasury rate at date of the grant with term equal to the expected life of the option. Forfeitures are accounted for when they
occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined
based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly,
stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">Vesting of restricted stock granted
under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity
awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria
is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance
criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify"><u>New Accounting Pronouncements</u></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In May 2017, the FASB issued ASU
2017-09,&#160;<i>Compensation &#8211; Stock Compensation (Topic 718)</i>, which affects any entity that changes the terms or conditions
of a share-based payment award.&#160; This Update amends the definition of modification by qualifying that modification accounting
does not apply to changes to outstanding share-based payment awards that do not affect the total fair value, vesting requirements,
or equity/liability classification of the awards.&#160; The amendments in this Update are effective for all entities for annual
periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including
adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not
yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available
for issuance. The amendments in this Update should be applied prospectively to an award modified on or after the adoption date.
The Company is currently evaluating the impact the adoption of the standard will have on the Company&#8217;s financial position
or results of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In July 2017, the FASB issued ASU
2017-11,&#160;<i>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivative and Hedging
(Topic 815)</i>. The amendments in Part I of this Update change the classification analysis of certain equity-linked financial
instruments (or embedded features) with down-round features. When determining whether certain financial instruments should be classified
as liabilities or equity instruments, a down-round feature no longer precludes equity classification when assessing whether the
instrument is indexed to an entity&#8217;s own stock. The amendments also clarify existing disclosure requirements for equity-classified
instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be
accounted for as a derivative liability at fair value as a result of the existence of a down-round feature. For freestanding equity
classified financial instruments, the amendments require entities that present earnings per share (&#8220;EPS&#8221;) in accordance
with Topic 260 to recognize the effect of the down-round feature when it is triggered. That effect is treated as a dividend and
as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options
that have down-round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic
470-20,&#160;<i>Debt&#8212;Debt with Conversion and Other Options</i>), including related EPS guidance (in Topic 260). The amendments
in Part II of this Update re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as
pending content in the Accounting Standards Codification, to a scope exception. Those amendments do not have an accounting effect.
For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in an interim period. If
an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal
year that includes that interim period. The amendments in Part I of this Update should be applied either retrospectively to outstanding
financial instruments with a down-round feature by means of a cumulative-effect adjustment to the statement of financial position
as of the beginning of the first fiscal year and interim period(s) in which the pending content that links to this paragraph is
effective or retrospectively to outstanding financial instruments with a down-round feature for each prior reporting period presented
in accordance with the guidance on accounting changes in paragraphs 250-10-45-5 through 45-10. The amendments in Part II of this
Update do not require any transition guidance because those amendments do not have an accounting effect.&#160;The Company does
not expect the adoption of this standard to have a significant impact on its EPS calculations, as it does not have any free-standing
equity based financial instruments with down-round provisions.&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In August 2017, the FASB issued ASU
2017-12,&#160;<i>Derivatives and Hedging (Topic 850)</i>, the objective of which is to improve the financial reporting of hedging
relationships to better portray the economic results of an entity&#8217;s risk management activities in its financial statements.
In addition, the amendments in this Update make certain targeted improvements to simplify the application and disclosure of the
hedge accounting guidance in current general accepted accounting principles.&#160;&#160;For public business entities, the amendments
in&#160;this Update are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.
For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods beginning
after December 15, 2020. Early adoption is permitted in any period after issuance.&#160;&#160;For cash flow and net investment
hedges existing at the date of adoption, an entity should apply a cumulative-effect adjustment related to eliminating the separate&#160;measurement
of ineffectiveness to accumulated other comprehensive income with a corresponding adjustment to the opening balance of retained
earnings as of the beginning of the fiscal year that an entity adopts the amendments in this Update. The amended presentation and
disclosure guidance is required only prospectively.&#160;&#160;The Company is currently evaluating the impact the adoption of the
standard will have on the Company&#8217;s financial position or results of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In February 2016, the FASB issued
ASU 2016-02,&#160;<i>Leases</i>, which will require most long-term leases to be recognized on the balance sheet as an asset
and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed
using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current
standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after
December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified
retrospective method beginning with the earliest comparative period presented. The Company is currently evaluating the effect
of the new standard on its financial statements and related disclosures. The Company is currently evaluating the impact the
adoption of the standard will have on the Company&#8217;s financial position or results of operations.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">In March 2016, the FASB issued ASU
2016-09 <i>Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</i>. The
guidance simplified the accounting and financial reporting of the income tax impact of share-based compensation arrangements. This
guidance requires excess tax benefits to be recorded as a discrete item within income tax expense rather than additional paid-in-capital.
In addition, excess tax benefits are required to be classified as cash from operating activities rather than cash from financing
activities. The Company adopted the provisions of ASU 2016-09 effective October&#160;1, 2017. The Company elected to apply the
cash flow guidance of ASU 2016-09 retrospectively to all prior periods with no impact to historical periods. The Company also adopted
a change in accounting policy to recognize forfeitures of awards as they occur instead of estimating potential forfeitures with
no material impact on historical periods.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The Company has considered all other
recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact
on its financial statements.</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 -40pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_OrganizationAndSummaryOfSignificantAccountingPoliciesPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579240-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesReportingOfDerivativeActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6606184240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>C. STOCKHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockholdersEquityTablesAbstract', window );"><strong>C. Stockholders Equity Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany', window );">Stock options, stock bonuses and compensation granted by the Company</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify; text-indent: -20pt">Stock options, stock bonuses and
compensation granted by the Company as of December 31, 2017 are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt"><b>Name of Plan</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total Shares Reserved Under Plans</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Reserved for Outstanding Options</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Issued</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Remaining Options/Shares Under Plans</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 48%"><font style="font-size: 8pt">Incentive Stock Options Plans</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">138,400</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">124,758</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">454</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Non-Qualified Stock Option Plans</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,187,200</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,107,054</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">46,798</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Stock Bonus Plans</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">383,760</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">222,574</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">161,153</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Stock Compensation Plan</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">134,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">115,590</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">18,410</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Incentive Stock Bonus Plan</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">640,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">624,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 20pt; text-align: justify; text-indent: -20pt">Stock options, stock bonuses and
compensation granted by the Company as of September 30, 2017 are as follows:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; border-bottom: black 0.75pt solid"><b>Name of Plan</b></p></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total Shares Reserved Under Plans</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Reserved for Outstanding Options</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Shares Issued</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Remaining Options/Shares Under Plans</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 48%"><font style="font-size: 8pt">Incentive Stock Option Plans</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">138,400</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">124,758</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">454</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Non-Qualified Stock Option Plans</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,187,200</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,115,086</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">42,830</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Bonus Plans</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">383,760</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">206,390</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">177,337</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Stock Compensation Plan</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">134,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">115,590</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">18,410</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Incentive Stock Bonus Plan</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">640,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">N/A</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">624,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">16,000</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="6" style="text-align: center"><font style="font-size: 8pt"><b>Three Months Ended December 31,</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 72%"><font style="font-size: 8pt">Granted</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">10,300</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Expired</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">17,523</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">15,081</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Forfeited</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">809</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
</table>


<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of employees and non-employees stock compensation</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Three months Ended December 31,</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 72%"><font style="font-size: 8pt">Employees</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">1,448,098</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 0%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">312,375</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Non-employees</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">42,342</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">78,553</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions', window );">Derivative Liabilities, Warrants and Other Options</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 15%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Warrant</b></font></td>
    <td style="width: 28%; border-bottom: black 1pt solid; padding-right: 18.75pt; text-align: center"><font style="font-size: 8pt"><b>Issue Date</b></font></td>
    <td style="width: 16%; border-bottom: black 1pt solid; padding-right: 7.5pt; text-align: center"><font style="font-size: 8pt"><b>Shares Issuable upon Exercise of Warrants</b></font></td>
    <td style="width: 13%; border-bottom: black 1pt solid; padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt"><b>Exercise Price</b></font></td>
    <td style="width: 18%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Expiration Date</b></font></td>
    <td style="width: 10%; border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Reference</b></font></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td><font style="font-size: 8pt">Series DD</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1,360,960</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$4.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3/1/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series EE</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1,360,960</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$4.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3/1/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series N</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">8/18/2008</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">85,339</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/18/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series S</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">10/11/13- 10/24/14</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1,037,120</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$31.25</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/11/2018</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series V</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">5/28/2015</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">810,127</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$19.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5/28/2020</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series W</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">10/28/2015</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">688,930</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$16.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/28/2020</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series X</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1/13/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">120,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$9.25</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1/13/2021</font></td>
    <td style="text-align: center">-</td></tr>
<tr>
    <td><font style="font-size: 8pt">Series Y</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">2/15/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">26,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$12.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/15/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series ZZ</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">5/23/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">20,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">5/18/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series BB</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">8/26/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">16,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/22/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series Z</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">5/23/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">264,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">11/23/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series FF</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">68,048</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.91</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/1/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series CC</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">12/8/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">680,480</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$5.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/8/2021</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series HH</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">2/23/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">20,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.13</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/16/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series AA</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">8/26/2016</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">200,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$13.75</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series JJ</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">3/14/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">30,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.13</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3/8/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series LL</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">4/30/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">26,398</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.59</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">4/30/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series MM</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">6/22/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">893,491</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$1.86</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">6/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series NN</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">7/24/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">539,300</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.52</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">7/24/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series OO</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">7/31/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">60,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.52</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">7/31/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series QQ</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">8/22/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">87,500</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/22/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series GG</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">2/23/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">400,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">8/23/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series II</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">3/14/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">600,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.00</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">9/14/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series RR</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">10/30/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">583,057</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$1.65</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">10/30/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series KK</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">5/3/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">395,970</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$3.04</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">11/3/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">1</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series SS</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">12/19/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1,289,478</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.09</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">12/18/2022</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Series PP</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">8/28/2017</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">1,750,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.30</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">2/28/2023</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">-</font></td></tr>
<tr>
    <td><font style="font-size: 8pt">Consultants</font></td>
    <td style="padding-right: 18.75pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">3/30/15- 7/28/17</font></td>
    <td style="padding-right: 7.5pt; padding-left: 0.25in; text-align: right"><font style="font-size: 8pt">40,000</font></td>
    <td style="padding-right: -4.5pt; text-align: center"><font style="font-size: 8pt">$2.18- $25.50</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3/29/18- 7/27/27</font></td>
    <td style="text-align: center"><font style="font-size: 8pt">3</font></td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ScheduleOfDerivativeLiabilitiesAtFairValue', window );">Tabular disclosure of derivative liabilities at fair value</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>December 31, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>September 30, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Series S warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">19,705</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">32,773</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series V warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">171,225</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">72,912</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series W warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">213,221</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">83,754</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series Z warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">132,751</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">77,216</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series ZZ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">8,096</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,753</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series AA warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">112,447</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">65,087</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series BB warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">6,953</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,322</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series CC warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">591,041</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">394,220</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series DD warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">9</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,492</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series EE warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">9</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,492</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series FF warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">65,201</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">47,154</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series GG warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">457,305</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">342,173</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series HH warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">21,676</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">16,014</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series II warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">690,442</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">511,636</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series JJ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">32,745</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">24,203</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series KK warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">460,747</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">345,720</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series LL warrants</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">28,059</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">20,481</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total warrant liabilities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">3,011,632</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">2,053,402</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock', window );">Schedule Of Gains and (Losses) on Derivative Liabilities</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Series S Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">13,068</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">2,621,321</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series V warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(98,313</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,417,721</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series W warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(129,467</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,667,604</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series Z warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(55,535</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">868,787</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series ZZ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(3,343</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">63,884</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series AA warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(47,360</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">679,569</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series BB warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(2,631</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">52,672</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series CC warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(196,821</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">604,492</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series DD warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,483</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">370,919</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series EE warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">5,483</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">514,603</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series FF warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(18,047</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">66,740</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series GG warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(115,132</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series HH warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(5,662</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series II warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(178,806</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series JJ warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(8,542</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Series KK warrants</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(115,027</font></td>
    <td><font style="font-size: 8pt">)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Series LL warrants</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(7,578</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><font style="font-size: 8pt">Net (loss) gain on warrant liabilities</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">(958,230</font></td>
    <td style="padding-bottom: 3pt"><font style="font-size: 8pt">)</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">8,928,312</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ScheduleOfDerivativeLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ScheduleOfDerivativeLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ScheduleOfDerivativeLiabilitiesWarrantsAndOtherOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ScheduleOfGainsAndLossesOnDerivativeLiabilitiesTableTextblock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ScheduleStockOptionsStockBonusesAndCompensationGrantedByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockholdersEquityTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockholdersEquityTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762275984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>D. FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueMeasurementsTablesAbstract', window );"><strong>D. Fair Value Measurements Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The table below sets forth the assets
and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at December 31, 2017:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Other Observable Inputs (Level 2)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Unobservable Inputs (Level 3)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Derivative instruments</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">19,705</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2,991,927</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">3,011,632</font></td>
    <td>&#160;</td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0pt; text-align: justify">The table below sets forth the assets
and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2017:</p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Other Observable Inputs (Level 2)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Significant Unobservable Inputs (Level 3)</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>Total</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 48%"><font style="font-size: 8pt">Derivative instruments</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">32,773</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">2,020,629</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">2,053,402</font></td>
    <td style="width: 1%">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>3 months ended</b></font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 8pt"><b>12 months ended</b></font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>December 31, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>September 30, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Beginning balance</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">2,020,629</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">5,283,573</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Issuances</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">-</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">4,665,683</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Realized and unrealized losses and (gains)</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">971,298</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">(7,928,627</font></td>
    <td><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Ending balance</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2,991,927</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">2,020,629</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueMeasurementsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueMeasurementsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6638135872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>G. COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_F.CommitmentsAndContingenciesTablesAbstract', window );"><strong>G. Commitments And Contingencies Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Future minimum lease payments under the San Tomas lease</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">&#160;Nine months ending September 30, 2018&#160;&#160;&#160;</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">1,314,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;Year ending September 30,</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,808,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,872,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">1,937,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2,004,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">2,073,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">11,685,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;Total future minimum lease obligation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">22,693,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;Less imputed interest on financing obligation</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">(9,438,000</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 8pt">)</font></td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">&#160;Net present value of lease financing obligation</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">13,255,000</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum payments under operating leases</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">Nine months ending September 30, 2018</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">189,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Year ending September 30,</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">258,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">238,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">163,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2022</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">69,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total</font></td>
    <td style="padding-bottom: 3pt">&#160;</td>
    <td style="border-bottom: black 1pt double"><font style="font-size: 8pt">$</font></td>
    <td style="border-bottom: black 1pt double; text-align: right"><font style="font-size: 8pt">917,000</font></td>
    <td style="padding-bottom: 3pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_F.CommitmentsAndContingenciesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_F.CommitmentsAndContingenciesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817269232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>H. PATENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_PatentsTablesAbstract', window );"><strong>H. Patents Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of total estimated future amortization</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 87%"><font style="font-size: 8pt">Nine months ending September 30, 2018</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 8pt">$</font></td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">27,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Year ending September 30,</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2019</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">35,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">32,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">29,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">25,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">15,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">52,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 8pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 8pt">215,000</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_PatentsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_PatentsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6641710000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>I. EARNINGS (LOSS) PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NetIncomeLossPerCommonShareTablesAbstract', window );"><strong>I. Earnings Loss Per Common Share Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of dilutive net loss per share</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three
    Months Ended December 31, 2017</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Net
    loss</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted
    Average Shares</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>LPS</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Basic
    and diluted loss per share</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(6,187,830)</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">11,636,730</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><font style="font: 8pt Times New Roman, Times, Serif">(0.53</font></td>
    <td style="padding-bottom: 3pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p>

<table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="10" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Three
    Months Ended December 31, 2016</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Net
    Income</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>Weighted
    Average Shares</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="border-bottom: black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: center"><font style="font: 8pt Times New Roman, Times, Serif"><b>EPS</b></font></td>
    <td style="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td colspan="2" style="text-align: center; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="width: 58%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Basic
    earnings per share</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">3,521,153</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">5,994,431</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 1%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="width: 0%; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 10%; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.59</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Gain
    on derivatives (1)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">(1,556,754</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">)</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">90,277</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif">
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">Dilutive
    earnings per share</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">1,964,399</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">6,084,708</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">0.32</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif">
    <td colspan="2" style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;(1)
    Includes certain Series CC, DD, EE and FF warrants</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; text-align: right; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="vertical-align: bottom; font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td>
    <td style="font: 8pt Times New Roman, Times, Serif"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></td></tr>
</table>
<p style="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><font style="font: 8pt Times New Roman, Times, Serif">&#160;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Antidilutive securities</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2017</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><font style="font-size: 8pt"><b>2016</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 74%"><font style="font-size: 8pt">Options and Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">10,491,090</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right"><font style="font-size: 8pt">6,946,179</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Unvested Restricted Stock</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">332,000</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">604,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Convertible debt</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">1,133,355</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1pt solid">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: right"><font style="font-size: 8pt">-</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><font style="font-size: 8pt">Total</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">11,956,945</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 8pt">7,550,179</font></td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NetIncomeLossPerCommonShareTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NetIncomeLossPerCommonShareTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827337808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>C. STOCKHOLDERS EQUITY (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CVM_IncentiveStockOptionPlansMember', window );">Incentive Stock Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total Shares Reserved Under Plans</a></td>
<td class="nump">138,400<span></span>
</td>
<td class="nump">138,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares Reserved for Outstanding Options</a></td>
<td class="nump">124,758<span></span>
</td>
<td class="nump">124,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/Shares Under Plans</a></td>
<td class="nump">454<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CVM_NonQualifiedStockOptionPlansMember', window );">Non Qualified Stock Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total Shares Reserved Under Plans</a></td>
<td class="nump">1,187,200<span></span>
</td>
<td class="nump">1,187,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares Reserved for Outstanding Options</a></td>
<td class="nump">1,107,054<span></span>
</td>
<td class="nump">1,115,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/Shares Under Plans</a></td>
<td class="nump">46,798<span></span>
</td>
<td class="nump">42,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CVM_StockBonusPlansMember', window );">Stock Bonus Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total Shares Reserved Under Plans</a></td>
<td class="nump">383,760<span></span>
</td>
<td class="nump">383,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares Reserved for Outstanding Options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares Issued</a></td>
<td class="nump">222,574<span></span>
</td>
<td class="nump">206,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/Shares Under Plans</a></td>
<td class="nump">161,153<span></span>
</td>
<td class="nump">177,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total Shares Reserved Under Plans</a></td>
<td class="nump">134,000<span></span>
</td>
<td class="nump">134,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares Reserved for Outstanding Options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares Issued</a></td>
<td class="nump">115,590<span></span>
</td>
<td class="nump">115,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/Shares Under Plans</a></td>
<td class="nump">18,410<span></span>
</td>
<td class="nump">18,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CVM_IncentiveStockBonusPlansMember', window );">Incentive Stock Bonus Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total Shares Reserved Under Plans</a></td>
<td class="nump">640,000<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Shares Reserved for Outstanding Options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares Issued</a></td>
<td class="nump">624,000<span></span>
</td>
<td class="nump">624,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Remaining Options/Shares Under Plans</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CVM_IncentiveStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CVM_IncentiveStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CVM_NonQualifiedStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CVM_NonQualifiedStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CVM_StockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CVM_StockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CVM_IncentiveStockBonusPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CVM_IncentiveStockBonusPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6749703200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>C. STOCKHOLDERS EQUITY (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_C.StockholdersEquityDetails1Abstract', window );"><strong>C. Stockholders Equity Details 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">10,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired</a></td>
<td class="nump">17,523<span></span>
</td>
<td class="nump">15,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited</a></td>
<td class="nump">809<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_C.StockholdersEquityDetails1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_C.StockholdersEquityDetails1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817248672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>C. STOCKHOLDERS EQUITY (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_StockholdersEquityDetails2Abstract', window );"><strong>C. Stockholders Equity Details 2</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Employees</a></td>
<td class="nump">$ 1,448,098<span></span>
</td>
<td class="nump">$ 312,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_NonemployeesShareBasedCompensation', window );">Non-employees</a></td>
<td class="nump">$ 42,342<span></span>
</td>
<td class="nump">$ 78,553<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_NonemployeesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_NonemployeesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_StockholdersEquityDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_StockholdersEquityDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6829197904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>C. STOCKHOLDERS EQUITY (Details 3)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesDdMember', window );">Series DD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">12/8/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">1,360,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">3/1/2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesEeMember', window );">Series EE [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">12/8/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">1,360,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 4.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">3/1/2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember', window );">Series N [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">8/18/2008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">85,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/18/2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember', window );">Series S [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">10/11/13- 10/24/14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">1,037,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 31.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">10/11/2018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember', window );">Series V [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">5/28/2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">810,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 19.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">5/28/2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember', window );">Series W [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">10/28/2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">688,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 16.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">10/28/2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesXMember', window );">Series X [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">1/13/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">1/13/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesYMember', window );">Series Y [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">2/15/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">2/15/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZzMember', window );">Series ZZ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">5/23/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">5/18/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBbMember', window );">Series BB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">8/26/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/22/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember', window );">Series Z [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">5/23/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">264,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">11/23/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesFfMember', window );">Series FF [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">12/8/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">68,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">12/1/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesCcMember', window );">Series CC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">12/8/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">680,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">12/8/2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesHhMember', window );">Series HH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">2/23/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">2/16/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAaMember', window );">Series AA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">8/26/2016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">2/22/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesJjMember', window );">Series JJ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">3/14/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">3/8/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesLlMember', window );">Series LL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">4/30/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">26,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">4/30/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesMmMember', window );">Series MM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">6/22/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">893,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">6/22/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNnMember', window );">Series NN [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/24/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">539,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/24/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesOoMember', window );">Series OO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">7/31/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">7/31/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesQqMember', window );">Series QQ [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">8/22/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">87,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/22/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesGgMember', window );">Series GG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">2/23/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">8/23/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesIiMember', window );">Series II [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">3/14/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">9/14/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRrMember', window );">Series RR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">10/30/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">583,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 1.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">10/30/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesKkMember', window );">Series KK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">5/3/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">395,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">11/3/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSsMember', window );">Series SS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">12/19/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">1,289,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">12/18/2022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesPpMember', window );">Series PP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">8/28/2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">1,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 2.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">2/28/2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_ConsultantsMember', window );">Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_IssueDate1', window );">Issue Date</a></td>
<td class="text">3/30/15- 7/28/17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_SharesIssuableUponExerciseOfwarrant', window );">Shares Issuable upon Exercise of Warrant | shares</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePriceMinimum', window );">Exercise Price Minimum</a></td>
<td class="nump">$ 2.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExercisePriceMaximum', window );">Exercise Price Maximum</a></td>
<td class="nump">$ 25.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_ExpirationDate', window );">Expiration Date</a></td>
<td class="text">3/29/18- 7/27/27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExercisePriceMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExercisePriceMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExercisePriceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExercisePriceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_ExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_ExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_IssueDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_IssueDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_SharesIssuableUponExerciseOfwarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issuable Upon Exercise Of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_SharesIssuableUponExerciseOfwarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesDdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesDdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesEeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesEeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesWMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesBbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesFfMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesFfMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesCcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesCcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesHhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesHhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesAaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesJjMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesJjMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesLlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesLlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesMmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesMmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesNnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesOoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesOoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesQqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesQqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesGgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesGgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesRrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesKkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesKkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesSsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesPpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_SeriesPpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CVM_ConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CVM_ConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825760544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>C. STOCKHOLDERS EQUITY (Details 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract', window );"><strong>C. Stockholders Equity Details 4</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesSWarrants', window );">Series S warrants</a></td>
<td class="nump">$ 19,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesVWarrants', window );">Series V warrants</a></td>
<td class="nump">171,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,912<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesWWarrants', window );">Series W warrants</a></td>
<td class="nump">213,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesZwarrants', window );">Series Z warrants</a></td>
<td class="nump">132,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesZzWarrants', window );">Series ZZ warrants</a></td>
<td class="nump">8,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesAaWarrants', window );">Series AA warrants</a></td>
<td class="nump">112,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesBbWarrants', window );">Series BB warrants</a></td>
<td class="nump">6,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesCcWarrants', window );">Series CC warrants</a></td>
<td class="nump">591,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">394,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesDdWarrants', window );">Series DD warrants</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesEeWarrants', window );">Series EE warrants</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesFfWarrants', window );">Series FF warrants</a></td>
<td class="nump">65,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesGgWarrants', window );">Series GG warrants</a></td>
<td class="nump">457,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesHhWarrants', window );">Series HH warrants</a></td>
<td class="nump">21,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesIiWarrants', window );">Series II warrants</a></td>
<td class="nump">690,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesJjWarrants', window );">Series JJ warrants</a></td>
<td class="nump">32,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesKkWarrants', window );">Series KK warrants</a></td>
<td class="nump">460,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueOfSeriesLlWarrants', window );">Series LL warrants</a></td>
<td class="nump">28,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_TotalFairValueOfDerivativeLiabilities', window );">Total warrant liabilities</a></td>
<td class="nump">3,011,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,053,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesSWarrant', window );">Series S warrants</a></td>
<td class="nump">13,068<span></span>
</td>
<td class="nump">$ 2,621,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesVWarrants', window );">Series V warrants</a></td>
<td class="num">(98,313)<span></span>
</td>
<td class="nump">1,417,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesWWarrants', window );">Series W warrants</a></td>
<td class="num">(129,467)<span></span>
</td>
<td class="nump">1,667,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesZWarrants', window );">Series Z warrants</a></td>
<td class="num">(55,535)<span></span>
</td>
<td class="nump">868,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesZzWarrants', window );">Series ZZ warrants</a></td>
<td class="num">(3,343)<span></span>
</td>
<td class="nump">63,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesAaWarrants', window );">Series AA warrants</a></td>
<td class="num">(47,360)<span></span>
</td>
<td class="nump">679,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesBbWarrants', window );">Series BB warrants</a></td>
<td class="num">(2,631)<span></span>
</td>
<td class="nump">52,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesCcWarrants', window );">Series CC warrants</a></td>
<td class="num">(196,821)<span></span>
</td>
<td class="nump">604,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesDdWarrants', window );">Series DD warrants</a></td>
<td class="nump">5,483<span></span>
</td>
<td class="nump">370,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesEeWarrants', window );">Series EE warrants</a></td>
<td class="nump">5,483<span></span>
</td>
<td class="nump">514,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesFfWarrants', window );">Series FF warrants</a></td>
<td class="num">(18,047)<span></span>
</td>
<td class="nump">66,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesGgWarrants', window );">Series GG warrants</a></td>
<td class="num">(115,132)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesHhWarrants', window );">Series HH warrants</a></td>
<td class="num">(5,662)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesIiWarrants', window );">Series II warrants</a></td>
<td class="num">(178,806)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesJjWarrants', window );">Series JJ warrants</a></td>
<td class="num">(8,542)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesKkWarrants', window );">Series KK warrants</a></td>
<td class="num">(115,027)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_GainLossSeriesLlWarrants', window );">Series LL warrants</a></td>
<td class="num">(7,578)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Net (loss) gain on warrant liabilities</a></td>
<td class="num">$ (958,230)<span></span>
</td>
<td class="nump">$ 8,928,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesAaWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesAaWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesBbWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesBbWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesCcWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesCcWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesDdWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesDdWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesEeWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesEeWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesFfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesFfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesGgWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesGgWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesHhWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesHhWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesIiWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesIiWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesJjWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesJjWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesKkWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesKkWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesLlWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesLlWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesSWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesSWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesVWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesVWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesWWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesWWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesZwarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesZwarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueOfSeriesZzWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueOfSeriesZzWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairvalueofDerivativesLiabilitiesWarrantsAndOtherOptionsDetails1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesAaWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesAaWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesBbWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesBbWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesCcWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesCcWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesDdWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesDdWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesEeWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesEeWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesFfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesFfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesGgWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesGgWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesHhWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesHhWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesIiWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesIiWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesJjWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesJjWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesKkWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesKkWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesLlWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesLlWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesSWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesSWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesVWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesVWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesWWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesWWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesZWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesZWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_GainLossSeriesZzWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_GainLossSeriesZzWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_TotalFairValueOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_TotalFairValueOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6631491072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>C. STOCKHOLDERS EQUITY (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_C.StockholdersEquityDetailsNarrativeAbstract', window );"><strong>C. Stockholders Equity Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for consulting agreement</a></td>
<td class="nump">13,705<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_C.StockholdersEquityDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_C.StockholdersEquityDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765004160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>D. FAIR VALUE MEASUREMENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">$ 3,011,632<span></span>
</td>
<td class="nump">$ 2,053,402<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">19,705<span></span>
</td>
<td class="nump">32,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative instruments</a></td>
<td class="nump">$ 2,991,927<span></span>
</td>
<td class="nump">$ 2,020,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=82924980&amp;loc=SL51823488-111719<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5624163-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817253968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>D. FAIR VALUE MEASUREMENTS (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_FairValueMeasurementsDetails1Abstract', window );"><strong>D. Fair Value Measurements Details 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 2,020,629<span></span>
</td>
<td class="nump">$ 5,283,573<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,665,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings', window );">Realized and unrealized gains</a></td>
<td class="nump">971,298<span></span>
</td>
<td class="num">(7,928,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 2,991,927<span></span>
</td>
<td class="nump">$ 2,020,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_FairValueMeasurementsDetails1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_FairValueMeasurementsDetails1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) included in earnings, which have arisen from the use of significant unobservable inputs (level 3) to measure fair value of assets, liabilities, and financial instruments classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasuredOnRecurringBasisGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6631589024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>E. RELATED PARTY LOAN (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_E.LoansFromOfficerDetailsNarrativeAbstract', window );"><strong>E. Related Party Loan Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense paid to officers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_E.LoansFromOfficerDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_E.LoansFromOfficerDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6635100064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>F. NOTES PAYABLE (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_F.NotesPayableDetailsNarrativeAbstract', window );"><strong>F. Notes Payable Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Notes payable converted into common shares</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Common shares issued for notes payable</a></td>
<td class="nump">32,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_F.NotesPayableDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_F.NotesPayableDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823987136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>G. COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_CommitmentsAndContingenciesDetailsAbstract', window );"><strong>Commitments And Contingencies Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">Nine months ending September 30, 2018</a></td>
<td class="nump">$ 1,314,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths', window );">2019</a></td>
<td class="nump">1,808,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo', window );">2020</a></td>
<td class="nump">1,872,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree', window );">2021</a></td>
<td class="nump">1,937,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour', window );">2022</a></td>
<td class="nump">2,004,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive', window );">2023</a></td>
<td class="nump">2,073,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">11,685,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Total future minimum lease obligation</a></td>
<td class="nump">22,693,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less imputed interest on financing obligation</a></td>
<td class="num">(9,438,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Net present value of lease financing obligation</a></td>
<td class="nump">$ 13,255,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_CommitmentsAndContingenciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Custom Element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_CommitmentsAndContingenciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases due in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817256032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>G. COMMITMENTS AND CONTINGENCIES (Details 1)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_F.CommitmentsAndContingenciesDetailsAbstract', window );"><strong>G. Commitments And Contingencies Details 1</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">Nine months ending September 30, 2018</a></td>
<td class="nump">$ 189,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Year ending September 30, 2019</a></td>
<td class="nump">258,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Year ending September 30, 2020</a></td>
<td class="nump">238,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Year ending September 30, 2021</a></td>
<td class="nump">163,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Year ending September 30, 2022</a></td>
<td class="nump">69,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 917,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_F.CommitmentsAndContingenciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_F.CommitmentsAndContingenciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6631754960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>G. COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=CVM_ResearchAndDevelopmentLabMember', window );">Research and Development Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent liability</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=CVM_HeadquartersMember', window );">Headquarters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent liability</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=CVM_ResearchAndDevelopmentLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=CVM_ResearchAndDevelopmentLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=CVM_HeadquartersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=CVM_HeadquartersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763374624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>H. PATENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_PatentsDetailsAbstract', window );"><strong>H. Patents Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Nine months ending September 30, 2018</a></td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Year ending September 30, 2019</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Year ending September 30, 2020</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Year ending September 30, 2021</a></td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Year ending September 30, 2022</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Year ending September 30, 2023</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 214,872<span></span>
</td>
<td class="nump">$ 223,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_PatentsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_PatentsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6632444912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>H. PATENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_PatentsDetailsNarrativeAbstract', window );"><strong>H. Patents Details Narrative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Patent impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of patent costs</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_PatentsDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_PatentsDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6640849872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>I. EARNINGS (LOSS) PER COMMON SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CVM_I.EarningsPerShareDetailsAbstract', window );"><strong>I. Earnings Loss Per Common Share Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (6,187,830)<span></span>
</td>
<td class="nump">$ 3,521,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted Average Shares - Basic and Diluted</a></td>
<td class="nump">11,636,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and dilutive loss per share</a></td>
<td class="num">$ (.53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,521,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Gain on derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,556,754)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net Income, Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,964,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares - Basic</a></td>
<td class="nump">11,636,730<span></span>
</td>
<td class="nump">5,994,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Gain on derivatives, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Shares - Diluted</a></td>
<td class="nump">11,636,730<span></span>
</td>
<td class="nump">6,084,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Dilutive earnings per share</a></td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CVM_I.EarningsPerShareDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CVM_I.EarningsPerShareDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CVM_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1757-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817162640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>I. EARNINGS (LOSS) PER COMMON SHARE (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">11,956,945<span></span>
</td>
<td class="nump">7,550,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember', window );">Options and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">10,491,090<span></span>
</td>
<td class="nump">6,946,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">332,000<span></span>
</td>
<td class="nump">604,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">1,133,355<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W$7;!V)W]Q\9G0=G!K[N07U!+ P04    " "OB4Q,F5R<(Q &  "<)P
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MCSUW7$C63^^)8'[4%'\ 4$L#!!0    ( *^)3$RR+6Q!4@0  ,03   8
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MMP7*VK4?^!\3K^6ED'H";?*&7. GR%_-GJL1&J*<R@IJ4;+:XW!>^Y^"U2[
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M1KJQG 5&5,2M*!* TH2$ I5 6G'<"HAZH@LH9J2BNP@10^ZM@B>58[> TI-
M)8JZ*@ OII6B,P4S.O* I!G/S9"<5>0L<2]2Y@"A,*U 1RA8@:RS"?.V!)UY
MX$1&Q#$Q:]X,K=SG'GA*4A><L57!D Y1D!0ES@J0?"1?.6Y'JF+E3&E*Z!0%
MB5$2LU,2$KWWHL>EC, "E3I,1RE(EA)?-D&!J3/YCSOZJ>ZM(YVF$.4@+*R;
MJ",0)0(M'X0H^7:!H8J!]<9:$WIGL&1)1R%*%/*%L4:)."*RPI!"PKR:Q\*\
M0)V#*#GH^.X")=_R]H+WNJ(J=#CJ%$1)08ZW&B7>P&%$84;1>8"2(1V#*+>2
MP =[/8O88*^X'ZFZ %OL*QVJ**$*1@QH2<L+K "#XUL>39DW:KDQ2[9TM&(E
M)BJ8PFJ,.@Y1XA",Z'L)NHOH(L]*JDJ]KI,0)0G!<#:C1)SF1:I*7G0&HF0@
MF,*>E'0(DH0@\.%9DX0;4HC$MVEK14C>Q$BE(YZ.09(8!,-W/*0 #C'P<X0J
M,[:P_)&.09(8!,/7/Y*$RZV4L<*79$686\F'4-B&4>$D+($()G)3DG2YE2K/
MA^Q:$SH"PI(I'8JD0!$X%$GB#JF*EF\IUIHPGTACB8RDDY$4,@(G(TG>(5CT
M?..UUH04JJIT4":=BZ1PL71*(9V+I'"1C[::WB/>G)&R1S2.;&G6ZF0DA8S
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MP19#0>/C\3:<[31FD^&QGW\06[YQ^1M02P,$%     @ KXE,3"\7UZZS 0
MT@,  !@   !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q]4]MNW" 0_17$!X1=
MO$FCE6TIFZAJI%9:I6KSS-KCBP*, WB=_GT!>QTGM?H"S##GS)EA2 <T+[8!
M<.1-26TSVCC7[1FS10-*V"OL0/N;"HT2SINF9K8S(,H(4I+QS>:&*=%JFJ?1
M=S1YBKV3K8:C(;972I@_!Y X9'1++XZGMFY<<+ \[40-/\']ZH[&6VQF*5L%
MVK:HB8$JHW?;_6$7XF/ [Q8&NSB34,D)\248CV5&-T$02"A<8!!^.\,]2!F(
MO(S7B9/.*0-P>;ZP?XVU^UI.PL(]RN>V=$U&;RDIH1*]=$\X?(.IGFM*IN*_
MPQFD#P]*?(X"I8TK*7KK4$TL7HH2;^/>ZK@/XTUR@:T#^ 3@,^ V MB8*"I_
M$$[DJ<&!F+'WG0A/O-USWYLB.&,KXIT7;[WWG&_Y=<K.@6B*.8PQ?!DS1S#/
M/J?@:RD._!\X7X<GJPJ3"$\^*$S6"7:K!+M(L/MOB6LQ-Y^2L$5/%9@Z3I,E
M!?8Z3O+".P_L'8]O\AX^3OL/8>I66W)"YU\V]K]"=."E;*[\"#7^@\V&A,J%
MXQ=_-N.8C8;#;OI!;/[&^5]02P,$%     @ KXE,3"=[Q9NU 0  T@,  !@
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M>'S9V/_&& \H);G!$>KP@RV&A,:'XWL\VVG,)L.;?OY!;/G&Y1]02P,$%
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M 8?O,-5S3<E4_ ^X@/3A08G/4:"T<25%;QVJB<5+4>)EW%L=]V&\V>TGV#J
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M;/9R:OW)T**?IQI91FO^%U!+ P04    " "OB4Q,Y <WBL$!   W!   &0
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M)UQRK90%9R6Y<EY:U\7+0D!M_?2+F^OI+4\+J_JY3<GRKRC^ 5!+ P04
M" "OB4Q,]</H [<!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6QM4V%OVR 0_2N('U 2QVO3R+;4=*HV:9.B3ML^$_MLHP+G H[;?U_ KN=V
M_@+<<>_=N^/(!C1/M@5PY$5);7/:.M<=&+-E"XK;*^Q ^YL:C>+.FZ9AMC/
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M    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;'U4VXZ;,!#]%<0'K(FY)(T
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M=U:6!9='[(8<)H\#?G*-'F='*H+:ZG= Y?O-E;"3 "$!.X6V0V:@4)#S>N,
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M7$G<5*!*6X-; +B) ND#;@V$*3N8V8**;<UL <P.66;,6%G*#&:UH$);LUH
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MTMCF\4]<2VG !AD]V/A:._3S@4%MW'9G]RJT?C@8V4]33>9?2_$74$L#!!0
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M]]#IE8H+1I0.18UE+X"4MHA1'/K^/6:D[;P\M;F3R%,^*-IV<!)(#HP1\><
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M#^BZ;Y\YQ$$AXZ'%>$VP<\C##T(&#W(EG@UT,PS9)T,M\4Y9]?TSQ:0AE2+
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M_$N-_G,=H:C"%_!'I7F@S"$(**(-H"?FMHF04W6*,V-2#!?5";6P/Q36%W5
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MR-SE:N 274]1VN9L3'GCEF.6&%REJOGV3.% 807;E!L^7[%GXLUB)Z\:X:A
M SL"JMTEY1T9'=7<*B7C-&DL18D58QP3@8\%W]$\:2>(N7,@-QGR>%W2P9XL
MX8)XW-H('CP+"T+K-=5T(I[Q-9.H AVNSCO(MRN'#*-HH=U:1*W4: "WFU%Y
M>Q,,_K76=8;U<'1%]09^IV^\5T!;\OW]DF[;_0[]V5(CE"H%UCV';9$8GE)_
M)/[.<.'$NA@XPCLHH PD_(&<]9*NUAS$PWZC_5HZ,Z>+<B/B:N2&M2**<T,8
MF<B5FM^QRC$;+CC=#.)1J:KZDVW1DIZE%+LOY7.;>#-;+6OD['V7NG%/[[C+
M-G65O:9.EY.KIC:7Y]@><6<J;9^KU UJ\V:<G.T^SN:"-O7PAK$):[?KED>'
M(BVL8'AQGFX ?=U9COD=I%Q/U_.N>R+"6<*5&>'R2^T\U8H50#L%,-#H4QU9
M )Q$5='6M=I4O64=E]*4UX/UQ%%.T,4.]"H;RD5OTVQUO\<:0[0$CJ.3UJQ4
M*U%%8*F-JFJ;I9@TU67RC4K@I<JK7VA-AD,2&!"G[E.J:4"D!2\06?5VJK E
MJ!6YVMN;0%)JI0\?E;7@<LS*,6_8#)'AUC A:M%879-5CTYJ1U T\1BN[O+%
M\P=(=>QJQYPJPD6M\4J3_M(8>&.'O20F[$7%N.A^>]P-7:3B-X&.-'=V.3>G
M:+I[JEB>1O([KBU?KL&K-2Q%3U*KFKF-7B5I+L$B\(^@%B^RQVQ7*;$%BT-]
M<"U),_ESL@0NIV#MR39@"I#/D)8#S@"#VZ]TZ,/4XJN^2GRJP)YC0A.D2SE%
M]OW.(V@O$(WXM_S"UK#$W:2J@_1]I@IM2Z@.190U]<3]TH5)/E,A%/=#"E!X
MTH?AN9>7Y^[)P]FO9XD4B<8\0/B1@PW,3^]7]Q^<VL#Q^]-*;6O*8JAD6E!"
ME[I6!Y?BL6N<1W@:0P@WL^VB@TKPLW-^>^VI[EM%FE)%6RM,#D2/5?)8]G:H
M.4TY-BHG)\!M*NY8J4B):KLJJ\CJO'T$(%!E*\_:O6D@<VXJF=_NK?@I79%P
M;,TS+HI\GDFR")"(%+=QDIVZ]UO5M575BO&<DRQ#V3;96SU$,<Q'F@F@@R+#
M(<+%L>DAC0:NI["K:@/7X$QVU((;!-#8M\OS*-"".D_=GU8LG^C2,K1"! :G
MPJT/C"C'$2.+WBJ\H>>XF)WXNMB[83D1RH(XC:>C!XQ[8 $0?EXERPV"2K>P
M4D>&H90V[U/"9 U+5OE.C$U E[ ULD+KQH_(.DKN?I'[D#SD*R R5-QPD<\!
MJ]:I2D D7N0)TF /FA^PSAX6&?[J<2E1;OZNWJ-P 35>L^5L.]^O,+ATCD8/
M6.13=H^'=(]TASOSK-/'988"2ZK:+^&*G01-*R@/(Q?1L*SC7!6*( *NLU2U
M[K6J_K8 4EF&GI*%4R"[W-F@51MARTY">K.^+B]@F@EF8)2VUKA-_\+%'JN+
M H'RD5-\*?JB2+]P,/6Q'V8EVZI,;SZJ]_T7D.B+13;G?(EIO44]X5.=J#L6
MZ?0,S:3^ENJF,)_<RF51]-6^5'B*+=2CX::'UD5WU$5_*+4_)(JT@!LC79I8
M7%3+^]XEDG3<UX(FLJ*#J/A#SIX-6#5T6F-!OJP.36XF8%4G!S RZI'P\"7+
METDYKG.+^J6J?*[6^SU33B>GA@Y[#*N'J\O[(I/.+MOM=ZK=T7Z-^=980AAP
MFXEO W#+9#0K'O.M;JRN]JNF0@*3H2:NX4VFG'KYPFI)6(IF8F,L+9:8H%2W
M(BY!9(\!AF?UO;")+Z=8]3U9">>1Y3M'G)99HDR 73.L2F.T<"[XKDZQI75"
M[9!+^$W:'[+,'5DF58,[ZKBSL*1V@,+*:FV021*FZLQ#A=U-\P(1(]3U,@^6
MBB/AIYY-LQMK19Z$(I)N0751RV65YV1[J/944F/9O*"X1%5H5MUV/=5>V[,L
M([J3G$2-2N']FL!:0A9N?^S@:BUY0WH45(72A M/<WEX":&EFWZ):M7/3X *
M6 OR$E;QR!.]XXX=(L21:KYBR1K#)J1UCWS-69KW3$+%#:A]^V1M.MP:1007
M_?! 42Y$#LJK$/6T; JB;8BB$MNXJ];P0%&/M76XE3XN-2&O+LA*JMI>U;XK
M6CM94-C-7K*+[:KZ9.5=<T\'^XLZF9I*WU/V,^4$9>66%V*9+AJ"]JW9.&E$
MU3%D@>(AE0A''9IZGU$9=#(H /G$KU7/G;1:I)R:19:QIS28V3')GH@2.M?4
MF2<;;BN6BGU/ T0S 1L2.^L<)?PZ984*[;Z.B%DDJVN[+^ NT4)XWS+T2J(B
M3[),J&?@#B^;]D):WU4?V2'-)X-ICHF;7WBN(9?T]*30(1SNEF07F3#E=B=4
MKCY'@FTU[>RZ/S/[QXBY;$TU[W=\Y<D\KU_:J%H&E:51,PRI.H$'*S&P4KV9
MBS9;"Y7XJYTXU9&.< @J"3'*H&P1;CK^'*,DL$@FO8%",TIJG,%(??5L2Y5-
MU9?<="\IMS50#<NP24BR==\FV,8I1ZOVQV3[O"1>1(9^*K.[@JM$\XB.>;_/
MEOJ.P4XQ<(FY6E,MF5H@DJCYTM&ER%W5JT<:W^REFGC-DJ0V8!?65SC:9NVH
M-X0HE3-QL+$#->^M=!=^=S$6Q.2F <)D=:M8+F].\7.%F!<D+%=,4BC6NUO)
M"4H+6 (231+(*.@.MAQ]RPJLI?;9/=HV"15,H'04HO\2' ,B7T$:#S;* L[X
MC*W*4Y).I5T0ILFMLCVR1D3#7<I=G-3%]IA\B4F/W S[G81BVINF5NDE8Y+G
M)DR.4TEF\BII^OPB'<I7.-ATW:'-ZI3'<H+ZSD(FIUQ#!?\,?7Z;)BT+*\8*
M5LO2&9ET+M>VAQ$4=ATFL(BN5J=(##9AY0_+ %KR=R%&21#>N&.?>.[XW#'P
M02<",4*H?ZI$'\0 /"JQ=BEBMUXLX:(P6:^DJ@=!=]2X ;N>B@TYC^;3KIE#
M^RP#D8+$%^530-%4[,.9+<7XPXJ5F&2^=)6JKL=XF:B8?G5Y?'&L3ID<Z&]9
M9FAD9Y=WBCU0@4>0H@A=,908<XAZ?@?^$\=LR1!C W%TVFEI@^64:+%5EXTK
M*O! 7&IK210AG#T .NZQ)-2&;>&**3/B%T5.[1 ;L9M/)U?J6@7Y;'M*)0-.
M)Z_H;VODH45TW4\<GT%-4B3VF$Q0I2_8 %!]$JC7H64:0;K8H;MVG\Q_56E<
MNO6O<:7)B82Q9W=0Q?41*_*<&<YTJ68J9:WJCNM<LLGCBB>I33TX!5-W9<M!
M['T4P>GN:2^;X4/C).Y&>#G$3W&?B[1CBB2U>@):<Y;UPA;6:=+7R0A *8CW
M>?YK2WZI@]5[)0,>_NH;=VTETUE14'6\YN3Y.RJ N2&!-0*2QQ^PB%<EY,&Y
M:]B'IF\+['@^%Y.I=(]&SQEU\%DBHUVENZ?<*J$->K0ASLP6R8I/ :7( *T$
M/;4GQ^Q)?]FX,:M3JQ!XX@IU)S O2(D_VG5CE1C*6P#JU/O#$S6[WYD^U&JZ
MG)O26*=A%J6Z(RK0/)3(7/FRQ'&=?MK,'@X )+\=T2_\&: G)@ETG!"D,:E
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M= >8%F48I:4.+<X-Y]4<Z.$B(Q+YM80L^,R3!V_S-6R?1K.2LZY]TPPAI:L
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M$F0Y+'I*2*:=.18EHM0DX<<-%$WU\K6D1Z"[7/!1Y?G;)$"):RQ8?7433O9
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MZL%2?8N3Z2$C;"TQTF\#UVI[9*=:]+$!=.#V@.&8K<.=T@-Z,8AE & 0 +S
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ KXE,3%WZ-9[N    *P(  !$
M             ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MKXE,3)E<G",0!@  G"<  !,              ( !M@(  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "OB4Q,5[33]GP"  #@"   &
M    @ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MKXE,3+(M;$%2!   Q!,  !@              ( !J0L  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *^)3$Q'W%J7/ (  *P'   8
M          "  3$0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " "OB4Q,=X]:>1$#  !P"P  &               @ &C$@  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ KXE,3*VL'K\\!0  J1D
M !@              ( !ZA4  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+
M 0(4 Q0    ( *^)3$P?<.3VLP$  -(#   8              "  5P;  !X
M;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "OB4Q,+Q?7KK,!
M  #2 P  &               @ %%'0  >&PO=V]R:W-H965T<R]S:&5E=#<N
M>&UL4$L! A0#%     @ KXE,3"=[Q9NU 0  T@,  !@              ( !
M+A\  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( *^)3$Q0
M&<?4L@$  -(#   8              "  1DA  !X;"]W;W)K<VAE971S+W-H
M965T.2YX;6Q02P$"% ,4    " "OB4Q,E4;\T+(!  #2 P  &0
M    @ $!(P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M *^)3$RF-,XHM $  -(#   9              "  >HD  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ KXE,3'3OUL6U 0  T@,  !D
M             ( !U28  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " "OB4Q,(YWKR[,!  #2 P  &0              @ '!*   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *^)3$SRC:DYM@$
M -(#   9              "  :LJ  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ KXE,3%9ROV2T 0  T@,  !D              ( !
MF"P  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "OB4Q,
M7AIW8RP"  !L!P  &0              @ &#+@  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( *^)3$Q@<%$P[0$  &8%   9
M      "  >8P  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ KXE,3.0'-XK! 0  -P0  !D              ( !"C,  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "OB4Q,G@PP=<0!   W!
M&0              @ $"-0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( *^)3$SUP^@#MP$  -(#   9              "  ?TV  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ KXE,3)1^%]#$
M 0  -P0  !D              ( !ZS@  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " "OB4Q,.!66UR\#  !\#P  &0
M@ 'F.@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( *^)
M3$S;Y@IH"P(  '8%   9              "  4P^  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ KXE,3%'LRROZ 0  ]@0  !D
M         ( !CD   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " "OB4Q,R[Q(.=H(  #/0   &0              @ &_0@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *^)3$RI 2 %!04  '\8
M   9              "  =!+  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ KXE,3(43B-/< 0  9@0  !D              ( !#%$
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "OB4Q,'/J_
M)P@"  #]!0  &0              @ $?4P  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( *^)3$PP(4=%, (  ",&   9
M  "  5Y5  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MKXE,3&"]VU38 0  7@0  !D              ( !Q5<  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " "OB4Q,F9Y@)? !  #)!   &0
M            @ '460  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( *^)3$PU<$Z>-0(  "('   9              "  ?M;  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ KXE,3*6^D:/N 0
M9 4  !D              ( !9UX  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " "OB4Q, S0^L,P!  "@!   &0              @ &,
M8   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( *^)3$Q;
M8'X=)0(  *P&   9              "  8]B  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ KXE,3&[H]!'N 0  Z00  !D
M     ( !ZV0  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M" "OB4Q,[VLL=Z\"   M"0  &0              @ $09P  >&PO=V]R:W-H
M965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( *^)3$QQ,1_%-P(  )D&   9
M              "  ?9I  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L!
M A0#%     @ KXE,3&-7W'WB30  $10! !0              ( !9&P  'AL
M+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ KXE,3.VAJ6,O @  ? D
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;72YX;6Q02P4&     "\ +P"[#   \<,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>90</ContextCount>
  <ElementCount>216</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/BalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StatementsOfOperations</Role>
      <ShortName>STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/StatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - B. OPERATIONS AND FINANCING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/B.OperationsAndFinancing</Role>
      <ShortName>B. OPERATIONS AND FINANCING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - C. STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/C.StockholdersEquity</Role>
      <ShortName>C. STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - D. FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/D.FairValueMeasurements</Role>
      <ShortName>D. FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - E. RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/E.RelatedPartyTransactions</Role>
      <ShortName>E. RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - F. NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cel-sci.com/role/F.NotesPayable</Role>
      <ShortName>F. NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - G. COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/G.CommitmentsAndContingencies</Role>
      <ShortName>G. COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - H. PATENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/H.Patents</Role>
      <ShortName>H. PATENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/I.EarningsLossPerCommonShare</Role>
      <ShortName>I. EARNINGS (LOSS) PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - J. SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/J.SubsequentEvents</Role>
      <ShortName>J. SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - C. STOCKHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/C.StockholdersEquityTables</Role>
      <ShortName>C. STOCKHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/C.StockholdersEquity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/D.FairValueMeasurementsTables</Role>
      <ShortName>D. FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/D.FairValueMeasurements</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/G.CommitmentsAndContingenciesTables</Role>
      <ShortName>G. COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/G.CommitmentsAndContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - H. PATENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/H.PatentsTables</Role>
      <ShortName>H. PATENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/H.Patents</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/I.EarningsLossPerCommonShareTables</Role>
      <ShortName>I. EARNINGS (LOSS) PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cel-sci.com/role/I.EarningsLossPerCommonShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - C. STOCKHOLDERS EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/C.StockholdersEquityDetails</Role>
      <ShortName>C. STOCKHOLDERS EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/C.StockholdersEquityTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/C.StockholdersEquityDetails1</Role>
      <ShortName>C. STOCKHOLDERS EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/C.StockholdersEquityTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/C.StockholdersEquityDetails2</Role>
      <ShortName>C. STOCKHOLDERS EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/C.StockholdersEquityTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/C.StockholdersEquityDetails3</Role>
      <ShortName>C. STOCKHOLDERS EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/C.StockholdersEquityTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - C. STOCKHOLDERS EQUITY (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/C.StockholdersEquityDetails4</Role>
      <ShortName>C. STOCKHOLDERS EQUITY (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/C.StockholdersEquityTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - C. STOCKHOLDERS EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/C.StockholdersEquityDetailsNarrative</Role>
      <ShortName>C. STOCKHOLDERS EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/C.StockholdersEquityTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/D.FairValueMeasurementsDetails</Role>
      <ShortName>D. FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/D.FairValueMeasurementsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/D.FairValueMeasurementsDetails1</Role>
      <ShortName>D. FAIR VALUE MEASUREMENTS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/D.FairValueMeasurementsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - E. RELATED PARTY LOAN (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/E.RelatedPartyLoanDetailsNarrative</Role>
      <ShortName>E. RELATED PARTY LOAN (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/E.RelatedPartyTransactions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - F. NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://cel-sci.com/role/F.NotesPayableDetailsNarrative</Role>
      <ShortName>F. NOTES PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/F.NotesPayable</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails</Role>
      <ShortName>G. COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/G.CommitmentsAndContingenciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/G.CommitmentsAndContingenciesDetails1</Role>
      <ShortName>G. COMMITMENTS AND CONTINGENCIES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/G.CommitmentsAndContingenciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - G. COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/G.CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>G. COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/G.CommitmentsAndContingenciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - H. PATENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/H.PatentsDetails</Role>
      <ShortName>H. PATENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/H.PatentsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - H. PATENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/H.PatentsDetailsNarrative</Role>
      <ShortName>H. PATENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/H.PatentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails</Role>
      <ShortName>I. EARNINGS (LOSS) PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/I.EarningsLossPerCommonShareTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cvm-20170630.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - I. EARNINGS (LOSS) PER COMMON SHARE (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cel-sci.com/role/I.EarningsLossPerCommonShareDetails1</Role>
      <ShortName>I. EARNINGS (LOSS) PER COMMON SHARE (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cel-sci.com/role/I.EarningsLossPerCommonShareTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cvm-20170630.xml</File>
    <File>cvm-20170630.xsd</File>
    <File>cvm-20170630_cal.xml</File>
    <File>cvm-20170630_def.xml</File>
    <File>cvm-20170630_lab.xml</File>
    <File>cvm-20170630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001654954-18-001366-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001654954-18-001366-xbrl.zip
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M(G".@UKTUM[<Z'_^#.MX\?CRAC9:[+VV!A7':IAL0!1N310+J*B)(FC71+&
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M4:1W/DFG,^@;Y[A^E5W 5.7<VX":N\+T.8[ H4]O/@?@/IV$DW=_9C[EYK?
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MO?""$#CS$W3YFM8?ESY(:SAR[X)VIT P$ T0!+ZX@K>DEUY*;S;1.&=VP!.
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MB!/%=Y^JCU>"QV8DR'W@%=1C9!,#9"@1^.M(E8KSP_ =JA:I!6%%V-*U%T\
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M)0'X[\18E6_K^CB\T8?-^,&-&N7EA?H-9<.&FHZ>-83OYOEU)3/&Y1X(B.*
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MGP>J,/_^]X,GLDZO!51V]*'^=J=K]P\U0O;APUU+XW93\+J^/'7'K]NFL\S
M;FW<<'0O:H(/#=$XB^*N+34/O&QX1R+K$2#:!\@?5GY^C5(O4++3"A9N -V=
M=-N[Y.U)E(T"<5\EL[<LNTT=+?B@Z"!L>@%\%\BL#Z1,*H/V:]N=UOT>2 D'
M[\_5R1U<?&/!L>Z.VX7GAWRC[7D0)8E(7EA1B-\0&"72QII&,?TRO8R%L&8
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M++ P?N'HS_VDV,^X1YVT>4AES//\I#^#IXJT(#4-JJ&DM#=)$\C =(-N.!A
MK#;S)@+/7KV HP>;3<HH]:TW<)<7/6T0A3.?Y\"?A)/32,Z9'P-A[(6S/8Z"
M*'YE_9<[Q/_H*!@U#UYNS*Y;IC] O_Q]-O[.0KS#! B!,VG?UBC?&) LNSS/
M@?^M\RC(I(-\%HZ;UG-I(7@)35<6?V;P ^QPS!.&R98X._WTD9Y^H1O!3[#
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M@!8X5^N?E7 ;4\.6!K2XW>901U:,HO>R,2SYD"::'L ,R) D-!T$7E_VN_P
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M9/ S.7UK%5*69Y%Z2<(19%;8\ R>0RHO=7'%@U%04#2OZ'GB &"^J4AX6!@
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M[B$F5 \YC>IN%!7;(XP?;NJT=XA!Z0W2I4\SPMR[BU[>[T01I8?N-6CY1$+
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M)TP:15F=F((^"P.1X"<7?@(\!=+84G=-U*YBK0>*^PB2R-+HTD3'7 'H\=-
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M:<L(!R6HDL-G1DX84EC!<909A^U4?4FWA?B/RVM[$%$FBWPG8#U=U%<W;OR
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MN8,SW/?&'-8IU=;PQAE6'[-:(+QR6IWH_N"QV3CI.$B27&>BC4=LKF>24FR
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M;\>7:>NR953-U7>,R?[H/9.I:%J,@V<RRY*UREV:76.R_G,97@[9'/L=7^0
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MQ'KFB@!L"][?JL)KJXJJ6?N ]Q(TXV(:HS]6N<Z>A0A[QNWGRG&?HENJMG^
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M<*\GKV"0>P=/C7GG.3?>E"X07+,3L[YG75%54^<14*696@*-SL%9"YJF&/I
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M=&C86O:&[[I (SW$.VLS3QMBE7M*95-L"D9M/%F&:">O#TI) JI-C!0GH>J
M41LC>.>6J"FO#TQ))JI-G!2GH^J 41LGMB'24O5!*4E(M8F1XJ14'3#J<XEE
MVXJY*3 EF:DV<5*<GJH#1FV<&*99R"550"E)4+6)D>(D51TP-M$EJEZ(DRK
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M<!/TE_ 0O,V*X)PI?X<8]2(&.W4#^H"-YDRGS*E!S&S>L%4B!$-%LS(E70U
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M -A*>&EI1J9O*#-ZS8EK'PVAZO;0JC2S*.3Z$ER,P"4/W6WL 69R2D_.UPJ
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MD8;([7X4^F;@P_WO^;>;<.K]B/\/'_\_4$L#!!0    ( *^)3$Q=W*,E60\
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M&LKTE.V:H[ BZ2KO25<1WSP3S-. %*&(7OH0WBBZ'OXUP-"_!SJ:ZT9PK(W
M@YD_7:H;!MD'_'#D.3Z93<A[04YAEM%M;1;,A>%X]6+1/#S(#O.A@S4=BL,9
M,Q1". 6QCO/8][!):@-'?^["W.03ACW']E>QJ@XJ#/1MM-(]9.@_L!9 #EY
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M<T(N.?06=XPH+IS9J2BGM/:^:<70 .:[$-Z(/@1H"OL&'X5I,"![GQF=B:[
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M,N>C]VPZ%?#.YF/ED^C3-#F.*J%8&6ZY[MNEQA[9GC7"3[K"S_\!4$L#!!0
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MQ0RYH>I.-#?$X8J2Y<\BK 1_5-FCCZ:7-7LYJU.':'YH-^D#?X*(AJLY\>X
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M !3*:>"I=%Y$HUT;WRR;T&_W5H#()_\#4$L#!!0    ( *^)3$P23ZK$F@X
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MR9@?Q^E%3@SK<2K6OJ1<"8/1Y#,_K#E5-#&EWJ&19[BZ::.P$OXAM:#?*,-
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MZ)[X(5KD"C"X-,6IYX=X6;[+UULLLG46>"E>#O#*7_BR&9Z)HMTWRTP+TGS
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M@[)SKWUK>\.T;)WJ]BS7<M"3ZHH@Z$!E*LZIV0VGX(2&)0]C9S#;9&"$@"P
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MCZ*79Q04I%ZB78"?U &(*@_=EV01_*=X7HXYI%_XS*3N%;(-9CW*'_R392@
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MQ[WA,T>B8.]I:R>OR^VUE&=8A1]3>;ROT+(8P+\,R\+3X0K98?Q\E;NLU<X
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M              "  0    !C=FTM,C Q-S V,S N>&UL4$L! A0#%     @
MKXE,3%W<HR59#P  D;L  !               ( !#;   &-V;2TR,#$W,#8S
M,"YX<V102P$"% ,4    " "OB4Q,VGQ)P!L-  #UG   %
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52P4&      8 !@"$ 0  ?48!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
